Cancer evidence library
Kidney Cancer
PubMed-indexed evidence for renal cell carcinoma and other kidney malignancies.
PubMed only
Research ranked
Conflicts shown
Data downloadable
Living evidence synopsis
What the current PubMed collection shows.
Alexandria currently organizes 587 non-retracted PubMed-indexed records for Kidney Cancer. The structured collection includes 13 guideline or consensus records, 90 evidence syntheses/systematic reviews/meta-analyses, and 73 randomized or phase III studies. 116 records were identified by the configured last-24-month search. Conflict-of-interest statements are available in the PubMed record for 425 of 587 included records.
Evidence data
Research landscape
Charts are generated from Alexandria’s structured PubMed records, not copied from journal figures.
Publication activity
Latest 12 represented yearsRecords by publication year
1
2015
1
2017
3
2018
4
2020
9
2021
14
2022
17
2023
25
2024
48
2025
465
2026
Evidence composition
Study designs
Transparency
Conflict-of-interest reporting
Absence of a conflict-of-interest statement in PubMed does not establish that no conflict existed.
Abstract result signals
Extracted result direction
Reported outcomes
Numerical results extracted from PubMed abstracts
Each value remains attached to its original PMID. Alexandria does not pool these results or imply that unlike populations and endpoints are directly comparable.
Non-pooled ratio measures
Reference = 1.0
Hazard, risk, and odds ratios reported in abstracts
0.250.51.02.04.0
View extracted numerical results 60
| Publication | Outcome | Measure | Reported value | Source |
|---|---|---|---|---|
| FeNO as a Treatable Trait in Chronic Cough: Insights from the PROCOUGH Study.Lung · 2026 | not_reported | Odds Ratio | 1.03 95% CI 1.0–1.05 | PMID 42458103 |
| Clinical outcomes of metastatic non-clear cell renal cell carcinoma: a real-world single-centre experience.Annals of medicine · 2026 | not_reported | Hazard Ratio | 2.027 p = 0.023 | PMID 41578672 |
| Clinical outcomes of metastatic non-clear cell renal cell carcinoma: a real-world single-centre experience.Annals of medicine · 2026 | not_reported | Hazard Ratio | 2.285 p = 0.023 | PMID 41578672 |
| Clinical outcomes of metastatic non-clear cell renal cell carcinoma: a real-world single-centre experience.Annals of medicine · 2026 | not_reported | Hazard Ratio | 2.638 p = 0.007 | PMID 41578672 |
| Oncologic and Functional Outcomes of Active Surveillance and Ablative Therapy for Small Renal Masses: A Systematic Review and Meta-Analysis.Journal of vascular and interventional radiology : JVIR · 2026 | not_reported | Percentage Comparison | 84.8percent vs 74.0percent | PMID 41679379 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Odds Ratio | 240.0 | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Odds Ratio | 480.0 | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Percentage Comparison | 31.4percent vs 19.5percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Percentage Comparison | 30.2percent vs 18.7percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Percentage Comparison | 35.3percent vs 21.8percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | progression-free survival | Percentage Comparison | 22.7percent vs 9.0percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | progression-free survival | Percentage Comparison | 25.4percent vs 8.5percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | progression-free survival | Percentage Comparison | 12.5percent vs 11.3percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | response | Percentage Comparison | 48.0percent vs 19.0percent | PMID 41786248 |
| Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | response | Percentage Comparison | 50.0percent vs 23.0percent | PMID 41786248 |
| Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Percentage Comparison | 13.6percent vs 3.6percent | PMID 40998092 |
| Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Hazard Ratio | 0.79 95% CI 0.65–0.96 | PMID 40998092 |
| Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | not_reported | Percentage Comparison | 40.9percent vs 35.4percent | PMID 40998092 |
| Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | response | Percentage Comparison | 55.7percent vs 27.4percent | PMID 40998092 |
| Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | response | Percentage Comparison | 13.9percent vs 4.6percent | PMID 40998092 |
| Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trial.Annals of oncology : official journal of the European Society for Medical Oncology · 2026 | response | Percentage Comparison | 22.0percent vs 10.0percent | PMID 40998092 |
| Using flow ratio of peritumoral artery/renal aorta from DSA imaging to predict high-risk clear cell renal cell carcinoma.World journal of urology · 2026 | not_reported | Odds Ratio | 9.809 95% CI 1.928–49.895 P = 0.006 | PMID 41879872 |
| Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma.Urologic oncology · 2026 | recurrence | Hazard Ratio | 2.38 P = 0.03 | PMID 41266180 |
| Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma.Urologic oncology · 2026 | recurrence | Hazard Ratio | 2.92 P = 0.03 | PMID 41266180 |
| Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma.Urologic oncology · 2026 | recurrence | Hazard Ratio | 3.68 P = 0.03 | PMID 41266180 |
| Prognostic and Clinical Significance of Circulating Cystatin C Levels in Cancer Patients: A Meta-Analysis.Asian Pacific journal of cancer prevention : APJCP · 2026 | overall survival | Hazard Ratio | 1.6 95% CI 1.22–2.1 p = 0.0006 | PMID 42345173 |
| Robot-Assisted versus Laparoscopic Radical Nephrectomy for High-Complexity Renal Tumors: A Multidisciplinary Systematic Review and Meta-Analysis.La Clinica terapeutica · 2026 | not_reported | Odds Ratio | 0.54 95% CI 0.35–0.84 | PMID 42340793 |
| Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.The Lancet. Oncology · 2026 | not_reported | Odds Ratio | 42.0 | PMID 42144018 |
| Evaluating the Feasibility of Standard Ultrasound in the Bosniak Classification of Cystic Renal Masses Compared with Computed Tomography/Magnetic Resonance Imaging: A Multicenter Study.Ultrasound in medicine & biology · 2026 | not_reported | Percentage Comparison | 77.0percent vs 86.0percent p = 0.17 | PMID 41238458 |
| Evaluating the Feasibility of Standard Ultrasound in the Bosniak Classification of Cystic Renal Masses Compared with Computed Tomography/Magnetic Resonance Imaging: A Multicenter Study.Ultrasound in medicine & biology · 2026 | not_reported | Percentage Comparison | 79.0percent vs 78.0percent p = 0.17 | PMID 41238458 |
| Dose-response association of dietary inflammatory potential with risk of cancer: systematic review and meta-analysis of prospective cohort studies.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 | not_reported | Risk Ratio | 1.03 95% CI 1.02–1.04 | PMID 40536070 |
| Dose-response association of dietary inflammatory potential with risk of cancer: systematic review and meta-analysis of prospective cohort studies.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 | not_reported | Risk Ratio | 1.03 95% CI 1.02–1.05 | PMID 40536070 |
| Dose-response association of dietary inflammatory potential with risk of cancer: systematic review and meta-analysis of prospective cohort studies.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 | not_reported | Risk Ratio | 1.07 95% CI 1.03–1.12 | PMID 40536070 |
| Dose-response association of dietary inflammatory potential with risk of cancer: systematic review and meta-analysis of prospective cohort studies.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 | not_reported | Risk Ratio | 1.01 95% CI 1.0–1.02 | PMID 40536070 |
| Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma.Anticancer research · 2026 | not_reported | Hazard Ratio | 0.38 95% CI 0.23–0.62 | PMID 42373289 |
| Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma.Anticancer research · 2026 | not_reported | Hazard Ratio | 0.49 95% CI 0.37–0.64 | PMID 42373289 |
| Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma.Anticancer research · 2026 | not_reported | Hazard Ratio | 0.71 95% CI 0.3–1.71 | PMID 42373289 |
| Bayesian Analysis to Refine East Asian Subgroup Estimates in the CLEAR Trial (Lenvatinib Plus Pembrolizumab vs. Sunitinib) for Advanced Renal Cell Carcinoma.Anticancer research · 2026 | not_reported | Hazard Ratio | 0.78 95% CI 0.57–1.05 | PMID 42373289 |
| Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT.International journal of cancer · 2026 | survival | Hazard Ratio | 1.25 | PMID 41159297 |
| Performance of 99mTc-Sestamibi Single-Photon Emission Computed Tomography/Computed Tomography for Characterizing Renal Masses: Combined Results From a Prospective Scan-and-Resect Trial and Clinical Experience.The Journal of urology · 2026 | not_reported | Percentage Comparison | 52.0percent vs 48.0percent | PMID 41433425 |
Research transparency
Funding and conflicts of interest
Conflict and funding fields reproduce what is available in PubMed records. Missing disclosure data does not establish that no conflict or funding existed.
NCI NIH HHS122
National Natural Science Foundation of China47
NCATS NIH HHS9
National High Level Hospital Clinical Research Funding8
Cancer Research UK8
National Cancer Institute (NCI)6
Beijing Natural Science Foundation5
Japan Society for the Promotion of Science4
View records with declared financial or industry relationships 12
Geospatial correlation of industrial plastics emissions with bladder and kidney cancer burden in Ohio.
Declaration of competing interest LB: Research support: J&J, Valar labs, Artera, Natera, Droplet. Scientific advisor/consultant- Immunity Bio, Pfizer, J&J, Valar Labs, Artera, Natera. Honoraria: Pfizer, enGene, J&J. Travel: Pfizer, J&J. Editorial Boards: European Urology, Urology Times. Shilpa Gupta Consulting or advisory role. Company: Pfizer, Merck Foundation Medicine, Bristol-Myers Squibb/Medarex, Natera, Astellas Pharma, Johnson & Johnson/Janssen. Dr. Nizam has reported receiving honoraria from Aptitude Health, ASCO, Cleveland Clinic, Doximity, IntegrityCE, Mashup Media (GU Oncology Now), MECC Global Meetings, and Targeted Oncology; consulting or advisory roles with Astellas Pharma, AVEO, EMD Serono/Merck, Mashup Media (GU Oncology Now), Medscape, and Pfizer/Seagen; and travel, accommodations, and expenses from ASCO, Mashup Media, and MECC Global Meetings.
PMID 42320109 · 2026Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
Declaration of interests RJM, RM, SHP, MB, RI, EV, CS, ME, HJC, CP, RMK, SR, GdV, BPV, AAA, UDG, MP, PT, RF, HMW, AG, AN, FAS, BBMS, JBAGH, DYCH, and MS received funding to their institutions from Merck Sharp & Dohme, a subsidiary of Merck & Co ([MSD] Rahway, NJ, USA) to support the study. RJM reports consulting fees to self for Merck, AstraZeneca, Exelixis, EMD Serono, and Eisai for advisory board participation; consulting fees to Incyte for data safety and monitoring committee participation; and research funding to employer (Memorial Sloan Kettering Cancer Center) for clinical trial support from Merck, Bristol Myers Squibb, Eisai, Exelixis and Pfizer. RM reports honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Janssen, Astellas, Bristol Myers Squibb, MSD, and Ipsen; and travel support from Novartis, Pfizer, and Bayer. MB reports honoraria for speakers bureaus from MSD, Bristol Myers Squibb, and Roche. RI reports consulting fees from Astellas, Bristol Myers Squibb, Genenta, Ipsen, Johnson & Johnson, Merck, MSD, Pfizer, Bayer, and Eisai; and honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Astellas, Bristol Myers Squibb, Genenta, Ipsen, Johnson & Johnson, Merck, MSD, Pfizer, Bayer, and Eisai; and travel support from MSD, Pfizer, Ipsen, and Johnson & Johnson. EV reports payment for presentations from Eisai, MSD, Astellas, Bristol Myers Squibb, Johnson & Johnson, Novartis, Ipsen, and Pfizer; and participation on advisory boards for Eisai, MSD, Astellas, Bristol Myers Squibb, Johnson & Johnson, Novartis, Ipsen, and Pfizer. CS reports research funding from Ipsen, Bristol Myers Squibb, MSD, Pfizer, and Roche; consulting fees from Astellas, AstraZeneca, Bristol Myers Squibb, Ipsen, MSD, Sanofi, Roche, and Recordati; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Astellas, AstraZeneca, Bristol Myers Squibb, Ipsen, MSD; and travel support from Bristol Myers Squibb, Pfizer, Roche, and Recordati. ME reports honoraria from lectures from Astellas Pharma, AstraZeneca, Bayer Yakuhin, Bristol Myers Squibb, Eisai, Janssen Pharmaceutical, Merck Biopharma, Novartis, MSD, Ono Pharmaceutical, Pfizer, and Takeda Pharmaceutical. HJC reports research funding from Bristol Myers Squibb, AstraZeneca, Janssen, Bayer, MSD Oncology, Pfizer, Eli Lilly, and Protara Therapeutics; consulting fees from Bristol Myers Squibb, AstraZeneca, Janssen, Bayer, MSD Oncology, Pfizer, Astellas; honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bristol Myers Squibb, AstraZeneca, Janssen, Bayer, MSD Oncology, Pfizer, and Astellas; payment for expert testimony from Bristol Myers Squibb, AstraZeneca, Janssen, Bayer, MSD Oncology, Pfizer, and Astellas; travel support from Bristol Myers Squibb, AstraZeneca, Janssen, Bayer, MSD Oncology, Pfizer, Roche, Astellas, and Amgen; participation on a data safety monitoring board or advisory board from Bristol Myers Squibb, AstraZeneca, Janssen, Bayer, MSD Oncology, Pfizer, Astellas; and receipt of equipment, materials, drugs, medical writing, gifts, or other services from Bristol Myers Squibb. CP reports consulting fees from Angelini Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Exelixis, Genenta, GenMab, Ipsen, Merck Serono, and MSD; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Angelini Pharma, AstraZeneca, Bristol Myers Squibb, Eisai, Genenta, Ipsen, Lilly, and MSD; travel support from Ipsen and MSD; and participation on a data safety monitoring board or advisory board from Genenta. RMK reports research funding from MSD and AstraZeneca; consulting fees from AstraZeneca, AbbVie, Amgen, Astellas, Bayer, Bristol Myers Squibb, Eli Lilly, Ipsen, Jannsen, MSD, Merck Serono, Novartis, Pfizer, Roche, and Tenconfarma; honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, AbbVie, Amgen, Astellas, Bayer, Bristol Myers Squibb, Eli Lilly, Ipsen, Jannsen, MSD, Merck Serono, Novartis, Pfizer, Roche, and Tenconfarma; travel support from AstraZeneca, Pfizer, MSD, Ipsen, and Janssen; participation on a data safety monitoring board or advisory board from AstraZeneca, AbbVie, Astellas, Bayer, Eli Lilly, Jannsen, MSD, Merck Serono, Novartis, Pfizer, Roche, Tenconfarma; and medical writing support from AstraZeneca and MSD. SR reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events (to institution) from Ipsen, AstraZeneca, Bristol Myers Squibb, and MSD; travel support (for institution) from MSD and Ipsen; and participation on a data safety monitoring board or advisory board (for institution) from Ipsen, Janssen, MSD, and Pfizer. GdV reports consulting fees from Pfizer, Bristol Myers Squibb, MSD, Ipsen, Genmab, Jannsen, Roche, and Eisai; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer, Bristol Myers Squibb, MSD, Ipsen, Bayer, AstraZeneca, Astellas, Recordati, Adium Pharma, and Pierre Fabre; and travel support from Ipsen and MSD. BPV reports consulting fees from Astellas Pharma, Roche, Novartis AAA, AstraZeneca, Bayer, Bristol Myers Squibb, Recordati, Ipsen, Merck, Pfizer, MSD, and Janssen; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Novartis AAA, Almirall Pharma, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Merck, MSD, Roche, Pfizer and Janssen; travel support from Bristol Myers Squibb, Pfizer, Roche, Astellas Pharma, MSD, and Merck; and participation on a data safety monitoring board or advisory board for MSD and Astellas Pharma. AAA reports investigator grants from Astellas, Merck Serono, and AstraZeneca; and institutional grants from Bristol Myers Squibb, AstraZeneca, Aptevo Therapeutics, GlaxoSmithKline, Pfizer, MedImmune, Astellas, SYNthorx, Bionomics, Sanofi Aventis, Novartis, Ipsen, Exelixis, MSD, Janssen, Lilly, Gilead Sciences, Merck Serono, and Hinova; consulting fees from Astellas, Janssen, Novartis, and Aculeus Therapeutics; honoraria from Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix, Merck Serono, Janssen, Bristol Myers Squibb, Ipsen, Bayer, MSD, Amgen, Noxopharm, Aculeus Therapeutics, and Daiichi Sankyo; travel support and accommodation from Astellas, Merck Serono, Amgen, Novartis, Janssen, Tolmar, Pfizer, Bayer, and Hinova; participation on a data safety monitoring board or advisory board, Astellas, Novartis, Sanofi, AstraZeneca, Tolmar, Pfizer, Telix, Merck Serono, Janssen, BMS, Ipsen, Bayer, MSD, Amgen, Noxopharm, Daiichi Sankyo, and Arvinas; a leadership role at Clinical Oncology Society of Australia, ANZUP Cancer Trials Group, and ANZUP Cancer Trials Group; and medical writing support from Astellas, Exelixis, and Pfizer. UDG reports consulting fees from Amgen, Astellas Pharma, AstraZeneca, Bayer, Bristol Myers Squibb, Eisai, Ipsen, Janssen, Merck, MSD, Novartis, and Pfizer; travel support from Pfizer, Ipsen, and AstraZeneca; and institutional researching funding from AstraZeneca, Roche, and Sanofi. MP reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GSK, Janssen, Sanofi, Novartis, Merck, and Pfizer; and participation on a data safety monitoring board or advisory board from Novartis, Merck, Bristol Myers Squibb, Sanofi, Astra Zeneca, GSK, and Janssen. RF reports consulting fees from Tempus; honoraria from Oncology News Central for presentations and podcasts; and a leadership role and stock options at 4D Medical (Australia). AG reports payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Astellas, Eisai, Ipsen, and Johnson & Johnson; travel support from Johnson & Johnson and Ipsen; and participation on a data safety monitoring board or advisory board for MSD. AN reports institutional grants from AstraZeneca, Bristol Myers Squibb, Merck, and Gilead; consulting fees for advisory board participation for AstraZeneca, Johnson & Johnson, Bristol Myers Squibb, Samsung Bioepis, Merck, Daiichi Sankyo, Pfizer, Catalym, and Gilead; and travel support or accommodations from Gilead, Merck, and Johnson & Johnson. FAS reports consulting fees from Bristol Myers Squibb, MSD, Ipsen, Exelixis, Pfizer, Adium, Astellas, Bayer, and Novartis; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Bristol Myers Squibb, MSD, Ipsen, Exelixis, Pfizer, Astellas, Bayer, and Novartis; travel support from Johnson & Johnson, MSD, Ipsen, Merck Serono, and Astellas; and participation on a data safety monitoring board or advisory board for Bristol Myers Squibb, MSD, Ipsen, Exelixis, Pfizer, and Astellas. JBAGH reports institutional grants from AstraZeneca, Bristol Myers Squibb, BioNTech, Instil Bio, and Sāstra; and stock options from Neogene Ther and Sāstra. SSY is an employee of MSD and may own stock options in Merck & Co. RFP is an employee of MSD and may own stock options in Merck & Co. DW was an employee of MSD at the time the study was conducted and may own stock options in Merck & Co. DYCH reports consulting fees and honoraria from Merck, Ipsen, Eisai, Bristol Myers Squibb, Arcus, and AstraZeneca. MS reports consulting fees, honoraria, and participation on a data safety monitoring board or advisory board from MSD, Bristol Myers Squibb, Ipsen, Exelixis, and Eisai; and travel support from MSD and Ipsen.
PMID 42586114 · 2026Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Rana R. McKay . Consulting or Advisory Role: Janssen, Novartis, Tempus, Pfizer, Astellas Medivation, Dendreon, Bayer, Sanofi, Vividion Therapeutics, Calithera Biosciences, Caris Life Sciences, Sorrento Therapeutics, AVEO, Seagen, Telix Pharmaceuticals, Lilly, Blue Earth Diagnostics, Ambrx, Sumitomo Pharma Oncology, Esiai, NeoMorph, Arcus Biosciences, Daiichi Sankyo, Exelixis, Bristol Myers Squibb, Merck, AstraZeneca, Myovant Sciences, Precede Bio. Research Funding: Bayer (Inst), Tempus (Inst), AstraZeneca (Inst), Exelixis (Inst), Bristol Myers Squibb (Inst), Oncternal Therapeutics (Inst), Artera (Inst). Karla V. Ballman . This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Consulting or Advisory Role: GlaxoSmithKline. Expert Testimony: Janssen. Archana Ajmera . Honoraria: NCCN. Consulting or Advisory Role: Janssen Biotech. Tareq Al Baghdadi . Stock and Other Ownership Interests: Bristol Myers Squibb. Honoraria: Cardinal Health. Consulting or Advisory Role: Bristol Myers Squibb, AstraZeneca, Cardinal Health, Genentech/Roche. Brian C. Baumann . Stock and Other Ownership Interests: Myovant Sciences. Honoraria: Mevion Medical Systems, Varian Medical Systems, Boston Scientific. Consulting or Advisory Role: Sanofi/Regeneron, Sanofi/Regeneron (I), Galera Therapeutics, Boston Scientific, Varian Medical Systems, Myovant Sciences, Blue Earth Diagnostics, Novartis. Speakers' Bureau: Boston Scientific. Research Funding: Varian Medical Systems (Inst). Himisha Beltran . Consulting or Advisory Role: AstraZeneca, Pfizer, Daiichi Sankyo, Bayer, Sanofi, Merck, Novartis. Research Funding: Bristol Myers Squibb Foundation (Inst), Daiichi Sankyo (Inst), Novartis (Inst), Circle Pharma (Inst). Travel, Accommodations, Expenses: Janssen Oncology. Stephanie Berg . Honoraria: Aptitude Health, Curio Science. Consulting or Advisory Role: Eisai, Exelixis, Zencor, J&J, AstraZeneca, Daiichi Sankyo/AstraZeneca. Research Funding: Pfizer (Inst). Ronald C. Chen . Employment: University of Kansas Medical Center. Consulting or Advisory Role: Medivation/Astellas, Accuray, Bayer, Blue Earth Diagnostics, Accuray, AbbVie, Myovant Sciences, Genentech, Pfizer, Astellas Pharma, Janssen, VIR Biotechnology. Research Funding: Accuray. Travel, Accommodations, Expenses: Telix Pharmaceuticals, RefleXion Medical. Atish D. Choudhury . Employment: LeMaitre Vascular (I). Honoraria: Targeted Oncology, Aptitude Health, Pfizer, Lantheus Medical Imaging, Wiley, Color Genomics, Physicians' Education Resource, Outcomes4Me, DAVA Oncology, Medscape, MDoutlook, Conexiant, Oncology Learning Network, MECC Global Meetings, Curio Science, Total Health, Bayer. Consulting or Advisory Role: Pfizer, Astellas Pharma, Bayer, Pfizer, Daiichi Sankyo, Boundless Bio, Johnson & Johnson/Janssen, Tolmar, Novartis, Bayer. Research Funding: Pfizer (Inst), Lilly (Inst), Sumitomo Pharma Oncology (Inst), Bayer (Inst), Pfizer (Inst), Merck (Inst). Travel, Accommodations, Expenses: Astellas Pharma, Bayer, Novartis, MECC Global Meetings, Oncology Learning Network. Open Payments Link: https://openpaymentsdata.cms.gov/physician/145387. Suzanne Cole . Research Funding: Merck (Inst). Heather A. Jacene . Consulting or Advisory Role: Luminance Biosciences. Research Funding: Blue Earth Diagnostics (Inst), Lantheus Medical Imaging (Inst), Boston Scientific (I). Travel, Accommodations, Expenses: Abbott Laboratories (I), Abiomed (I), Medtronic (I), Biotronik International (I). Open Payments Link: https://openpaymentsdata.cms.gov/physician/1095124. Joshua M. Lang . Leadership: Eolas Diagnostics, INC. Stock and Other Ownership Interests: Eolas Diagnostics, INC. Consulting or Advisory Role: Sanofi, Janssen, Pfizer/Astellas, Gilead Sciences, Arvinas, Pfizer/Myovant, 4D Pharma, AstraZeneca, Pfizer, MacroGenics, Foundation Medicine, Daiichi Sankyo/AstraZeneca, Bayer. Research Funding: Medivation (Inst), Agensys (Inst), GlaxoSmithKline (Inst), Immunomedics (Inst), Bristol Myers Squibb (Inst), Janssen (Inst), Gilead Sciences (Inst), Arvinas (Inst). Patents, Royalties, Other Intellectual Property: I am listed on the patent on a technology for rare cell capture and analysis. This technology has been licensed by Salus Discovery, LLC, although no commercial products are available. Deepak Kilari . Honoraria: Exelixis. Consulting or Advisory Role: Exelixis, Pfizer, Eisai, Janssen Oncology, Foundation Medicine, Aptitude Health, MJH Life Sciences, Cardinal Health, IntegraConnect, Curio Science. Speakers' Bureau: Janssen, Exelixis, Astellas Pharma, AVEO, Eisai, MJH Life Sciences. Research Funding: Astellas Pharma (Inst), Exelixis (Inst), Genentech (Inst). Travel, Accommodations, Expenses: Exelixis, Janssen, Astellas Pharma, AVEO. Bradley McGregor . Consulting or Advisory Role: Exelixis, Astellas Pharma, Pfizer, Eisai, Bristol Myers Squibb, Gilead Sciences, Arcus Biosciences, Loxo/Lilly, Daiichi Sankyo/AstraZeneca, Genmab, AVEO, Hexagon, AstraZeneca, Merck. Research Funding: Bristol Myers Squibb (Inst), Exelixis (Inst), Seattle Genetics/Astellas (Inst), Pfizer (Inst), Gilead Sciences (Inst), AVEO (Inst). Michael J. Morris . Employment: Memorial Sloan-Kettering Cancer Center. Stock and Other Ownership Interests: Doximity. Consulting or Advisory Role: Flare Therapeutics, Transtherabio, Mashup Media, Amgen, Molecular Partners, Wren Laboratories, Isotopia, Actinium Pharmaceuticals, Sofinnova, ARTbio, Bristol Myers Squibb, AbbVie, GlaxoSmithKline, AdvanCell. Research Funding: Janssen (Inst), Novartis (Inst), Astellas Pharma (Inst), AstraZeneca (Inst), Bayer (Inst). Patents, Royalties, Other Intellectual Property: Telix Pharmaceuticals (Inst). Travel, Accommodations, Expenses: APCCC, Memorial Sloan-Kettering Cancer Center, AbbVie, Amgen. Uncompensated Relationships: Bayer, Janssen Oncology, Novartis, Amgen, Halda Therapeutics. Mamta Parikh . Consulting or Advisory Role: Pfizer, Exelixis, Bicycle Therapeutics, Lilly, AstraZeneca. Research Funding: Karyopharm Therapeutics (Inst), Gilead Sciences, Lilly (Inst). Umang Swami . This author is a member of the Journal of Clinical Oncology Editorial Board. Journal policy recused the author from having any role in the peer review of this manuscript. Consulting or Advisory Role: Astellas Pharma, Exelixis, AstraZeneca, Pfizer, Gilead Sciences, Adaptimmune, Janssen Scientific Affairs, Flatiron Health, Kairos Therapeutics, Merck. Research Funding: Janssen (Inst), Seattle Genetics/Astellas (Inst), Exelixis (Inst), Merck (Inst), Loxo/Lilly (Inst), LAVA Therapeutics (Inst), ORIC Pharmaceuticals (Inst), Seagen (Inst), Pfizer/Astellas (Inst), AstraZeneca (Inst). Alan Tan . Employment: Tempus. Leadership: Tempus. Honoraria: Exelixis, Aveo. Speakers' Bureau: Exelixis, AVEO. Yuanquan A. Yang . Stock and Other Ownership Interests: Pfizer. Consulting or Advisory Role: The WhiteOak Group, Exelixis, Xencor, Cardinal Health. Speakers' Bureau: AstraZeneca. Research Funding: Incyte (Inst), Novartis (Inst), Amgen (Inst), Recordati (Inst), Xencor (Inst). Tian Zhang . Leadership: Capio BioSciences (I), Archimmune Therapeutics (I). Stock and Other Ownership Interests: Capio Biosciences (I), Archimmune Therapeutics (I). Honoraria: MJH Life Sciences, Aptitude Health, Curio Science, PeerView, Clinical Care Options, Mashup Media, Dava Oncology. Consulting or Advisory Role: Exelixis, Pfizer, Bristol Myers Squibb, Eisai, Bayer, Lilly, AVEO, Merck, Novartis, Gilead Sciences, EMD Serono, AstraZeneca, Loxo/Lilly, Xencor, Johnson & Johnson/Janssen, Dendreon, Summit Therapeutics, Arcus Biosciences. Research Funding: Loxo/Lilly (Inst), Tempus (Inst), Pfizer (Inst), ALX Oncology (Inst), Exelixis (Inst), OncoC4, Astellas Pharma (Inst), Janssen (Inst), Janux Therapeutics (Inst), Bayer (Inst), Kura Oncology (Inst), Merck (Inst), Daiichi Sankyo/AstraZeneca (Inst). Patents, Royalties, Other Intellectual Property: Circulating tumor cell novel capture by c-MET technology (Inst), Prochelators as Targeted Prodrugs for Prostate Cancer (Inst). Travel, Accommodations, Expenses: Janux Therapeutics, Johnson & Johnson/Janssen, Kura Oncology. Other Relationship: ASCO, Kidney Cancer Association, KidneyCan, Myrovlytis Trust, Winn Foundation. Matthew Galsky . Consulting or Advisory Role: Janssen, Merck, Bristol Myers Squibb, Pfizer, EMD Serono, Gilead Sciences, AbbVie. Research Funding: Janssen Oncology (Inst), Dendreon (Inst), Novartis (Inst), Bristol Myers Squibb (Inst), Merck (Inst), AstraZeneca (Inst), Genentech/Roche (Inst). Patents, Royalties, Other Intellectual Property: METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792. Jonathan Rosenberg . Honoraria: Astellas Pharma, Merck. Consulting or Advisory Role: Lilly, Merck, Roche/Genentech, Bristol Myers Squibb, Seagen, Bayer, Astellas Pharma, Boehringer Ingelheim, Tyra Biosciences, Gilead Sciences, AstraZeneca, EMD Serono, Pfizer, Generate Biomedicines, Aktis Oncology, Samsung Bioepis, Johnson & Johnson/Janssen, Domain Therapeutics, Summit Therapeutics. Research Funding: Astellas Pharma (Inst), Acrivon Therapeutics, Lilly, Pfizer, Bristol Myers Squibb. Patents, Royalties, Other Intellectual Property: Predictor of platinum sensitivity (Inst), Amplification of chromosome 1q23 to predict cancer outcomes (Inst). Travel, Accommodations, Expenses: Astellas Pharma, Merck. Uncompensated Relationships: Alliance for Clinical Trials in Oncology, KaliVir Immunotherapeutics. Daniel George . Leadership: Capio BioSciences. Stock and Other Ownership Interests: Pfizer, BMS. Honoraria: Bayer, OncLive, Pfizer, UroToday, Axess Oncology, Janssen Oncology, Millennium Medical Publishing, Novartis, AstraZeneca, Eisai, IDEOlogy Health, Merck, Astellas Pharma, Sumitomo, Candel Therapeutics. Consulting or Advisory Role: Bayer, Pfizer, Astellas Pharma, Janssen, Merck Sharp & Dohme, AstraZeneca, Michael J. Hennessy Associates, Physicians' Education Resource, Novartis, Candel Therapeutics. Research Funding: Exelixis (Inst), Janssen Oncology (Inst), Novartis (Inst), Pfizer (Inst), Astellas Pharma (Inst), Bristol Myers Squibb (Inst), Bayer (Inst), Merck (Inst), Corvus Pharmaceuticals (Inst), Bayer (Inst), AstraZeneca (Inst), Convergent Therapeutics (Inst). Expert Testimony: Exelixis. Travel, Accommodations, Expenses: Exelixis, Pfizer, Novartis, Bayer, Merck. Toni K. Choueiri . Leadership: ASCO. Stock and Other Ownership Interests: Precede Bio, Osel, Tempest Therapeutics, Pionyr, Curesponse, Inndura, Primium, Abalytics Oncology, Bicycle Therapeutics, Faron Pharmaceuticals. Honoraria: HiberCell, Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck, Bristol Myers Squibb, Roche/Genentech, Eisai, Foundation Medicine, AstraZeneca, Exelixis, Prometheus, Ipsen, Sanofi/Aventis, Peloton Therapeutics, UpToDate, NCCN, Michael J. Hennessy Associates, Analysis Group, Clinical Care Options, PlatformQ Health, Navinata Health, Harborside Press, ASCO, The New England Journal of Medicine, Lancet Oncology, EMD Serono, Lilly, Tempest Therapeutics, Arcus Biosciences, Alkermes, Gilead Sciences, Scholar Rock, Janssen Oncology, Precede Bio, Aravive, Infinity Pharmaceuticals, ESMO, NiKang Therapeutics, Kanaph Therapeutics, Gilead Sciences, MashupMD. Consulting or Advisory Role: Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck, Bristol Myers Squibb, Roche/Genentech, Eisai, Foundation Medicine, AstraZeneca, Exelixis, Prometheus, Ipsen, Sanofi/Aventis, Peloton Therapeutics, UpToDate, NCCN, Michael J. Hennessy Associates, Analysis Group, Clinical Care Options, PlatformQ Health, Navinata Health, Harborside Press, ASCO, The New England Journal of Medicine, Lancet Oncology, EMD Serono, Lilly, Tempest Therapeutics, alkermes, Gilead Sciences, Scholar Rock, Janssen Oncology, Precede Bio, Aravive, Infinity Pharmaceuticals, ESMO, NiKang Therapeutics, Kanaph Therapeutics, Gilead Sciences, Neomorph, Arcus Biosciences, Curesponse, Bicycle Therapeutics, Caris Life Sciences. Research Funding: Pfizer (Inst), Novartis (Inst), Merck (Inst), Exelixis (Inst), TRACON Pharma (Inst), GlaxoSmithKline (Inst), Bristol Myers Squibb (Inst), AstraZeneca (Inst), Peloton Therapeutics (Inst), Roche/Genentech (Inst), Agensys (Inst), Eisai (Inst), Takeda (Inst), Ipsen (Inst), Seattle Genetics/Astellas (Inst), Bayer (Inst), Roche (Inst), Calithera Biosciences (Inst), NiKang Therapeutics (Inst), Arcus Biosciences (Inst), AVEO (Inst). Patents, Royalties, Other Intellectual Property: International Patent Application No. PCT/US2018/058430, titled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst),” International Patent Application No. PCT/US2018/12209, titled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst),” ctDNA Technologies. Travel, Accommodations, Expenses: Pfizer, Bayer, Novartis, GlaxoSmithKline, Merck, Bristol Myers Squibb, Roche/Genentech, Eisai, Foundation Medicine, Cerulean Pharma, AstraZeneca, Exelixis, Prometheus, alligent, Ipsen, Corvus Pharmaceuticals, Lpath, Alexion Pharmaceuticals, Sanofi/Aventis, UpToDate, Peloton Therapeutics, NCCN, Michael J. Hennessy Associates, Analysis Group, Kidney Cancer Association, Clinical Care Options, PlatformQ Health, Harborside Press, Navinata Health, The New England Journal of Medicine, Lancet Oncology, EMD Serono, HERON, Lilly, ESMO. Other Relationship: Other Medical Communication Companies. Uncompensated Relationships: AACR Scientific Advisory Council. No other potential conflicts of interest were reported.
PMID 42507969 · 2026Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Samer A. Srour . Consulting or Advisory Role: Novartis. Travel, Accommodations, Expenses: Allogene Therapeutics. Jad Chahoud . Consulting or Advisory Role: AVEO, DAVA Pharmaceuticals, Pfizer, Exelixis, Eisai, Merck. Research Funding: Pfizer (Inst), Exelixis (Inst), Allogene Therapeutics (Inst), Merck (Inst), AB Science (Inst), Xilio Therapeutics (Inst). Alexandra Drakaki . Employment: Athos Therapeutics (I), Attica Sciences (I), Dyania Health (I). Leadership: Athos Therapeutics (I), Attica Sciences (I). Stock and Other Ownership Interests: Urogen Pharma (I), Kynan Therapeutics (I), Athos Therapeutics (I), Attica Sciences, Dyania Health (I), Moderna Therapeutics (I), Proteas Bioanalytics (I). Honoraria: AstraZeneca. Consulting or Advisory Role: Bristol Myers Squibb, AstraZeneca, Radmetrix, Seagen, Janssen, PACT Pharma, Merck, Roche/Genentech, Exelixis, Dyania Health, Aveo, EMD Serono, Loxo/Lilly, Infinity Pharmaceuticals, Daiichi Sankyo. Research Funding: Kite/Gilead, AstraZeneca (Inst), Genentech/Roche (Inst), BMS (Inst), Merck Sharp & Dohme (Inst), Jounce Therapeutics (Inst), Infinity Pharmaceuticals (Inst), Seattle Genetics/Astellas (Inst), Immunomedics/Gilead (Inst), Pfizer (Inst). Patents, Royalties, Other Intellectual Property: My significant other has several patents with UCLA, Harvard Medical School, Athos Therapeutics, Proteas Bioanalytics and ATTICA Sciences (I). Travel, Accommodations, Expenses: Lilly, AstraZeneca, Seagen. Brendan D. Curti . Consulting or Advisory Role: Merck, AstraZeneca, Iovance Biotherapeutics. Research Funding: Bristol Myers Squibb (Inst), Ankyra Therapeutics (Inst), AstraZeneca (Inst). Patents, Royalties, Other Intellectual Property: Biomarkers for OX40 response (Inst). Geoffrey T. Gibney . Consulting or Advisory Role: Merck, Iovance Biotherapeutics, HUYA Bioscience International, Immunocore, Replimune. Speakers' Bureau: Immunocore. Research Funding: Exelixis (Inst). Lily Tang . Employment: Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics. Yizhou Jiang . Employment: Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics. Sara Charmsaz . Employment: Sonoma Biotherapeutics, Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics, Sonoma Biotherapeutics. Paul B. Robbins . Employment: Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics. Jeffrey McLeroy . Employment: Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics. Travel, Accommodations, Expenses: Allogene Therapeutics. Christopher J. Severyn . Employment: Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics. John B. Le Gall . Employment: Instil Bio, Allogene Therapeutics. Stock and Other Ownership Interests: Johnson & Johnson/Janssen, Allogene Therapeutics. Patents, Royalties, Other Intellectual Property: TIL patents pending. Uncompensated Relationships: CRM Nepal. Zachary J. Roberts . Employment: Allogene Therapeutics. Leadership: Allogene Therapeutics. Stock and Other Ownership Interests: Allogene Therapeutics. Travel, Accommodations, Expenses: Allogene Therapeutics. Nizar M. Tannir . Stock and Other Ownership Interests: Amgen, Johnson & Johnson/Janssen, Vanguard Health Care, SPDR S&P Pharmaceuticals ETF, AbbVie, Gilead Sciences, Pfizer, Coherus BioSciences, ImmunityBio, ABSCI, Allogene Therapeutics, Cabaletta Bio, Moderna Therapeutics, Arcus Biosciences, Summit Therapeutics. Honoraria: Bristol Myers Squibb, Eisai, Merck Sharp & Dohme, Oncorena, Ipsen, Nektar, Exelixis. Research Funding: Bristol Myers Squibb (Inst), Nektar (Inst), Novartis (Inst), Calithera Biosciences (Inst), Arrowhead Pharmaceuticals Inc (Inst), Oncorena (Inst), Pfizer (Inst). Sumanta Pal . Speakers' Bureau: MJH Life Sciences, IntrinsiQ, PeerView. Research Funding: Exelixis (Inst), Merck (Inst), Osel (Inst), Genentech (Inst), CRISPR therapeutics (Inst), Adicet Bio (Inst), ArsenalBio (Inst), Xencor (Inst), MIYARISAN pharmaceutical (Inst). Travel, Accommodations, Expenses: CRISPR Therapeutics, Ipsen, Exelixis. Open Payments Link: https://openpaymentsdata.cms.gov/physician/259259. Ritesh R. Kotecha . Consulting or Advisory Role: Eisai, Eisai, Guidepoint Inc, Merck. Research Funding: Pfizer (Inst), Takeda (Inst), Novartis (Inst), Allogene Therapeutics (Inst), Exelixis (Inst), Xencor (Inst), ArsenalBio (Inst). No other potential conflicts of interest were reported.
PMID 42447427 · 2026Percutaneous thermal ablation for renal cell carcinoma: a comprehensive review of current evidence and future directions.
Declarations. Conflict of interest: Maya Honda receives grants from Midtown Clinic Medical Corporation. Rintaro Ito is affiliated with the Department of Innovative BioMedical Visualization, Nagoya University Graduate School of Medicine, which is financially supported by Canon Medical Systems, Inc. Mami Iima is affiliated with the Department of Fundamental Development for Advanced Low Invasive Diagnostic Imaging, Nagoya University Graduate School of Medicine, which is financially supported by HiMedic, Inc. Other authors have no relevant financial or non-financial interests to disclose. Ethical approval: This is a review article and does not require ethical approval. Generative AI and AI-assisted technologies: During the preparation of this work, the author used Chat-GPT and Gemini in order to improve readability and language. After using these tools, the authors reviewed and edited the content as needed and took full responsibility for the content of the publication.
PMID 42613495 · 2026Projected lives saved and economic value of mRNA cancer immunotherapies in the United States.
M.C.F declares receiving consulting fees for Sanofi Pasteur for participation on Global Payer's Panel and Pfizer for expert input on vaccine modeling. S.M.M. declares receiving consulting fees from Janssen Canada and Sanofi for evaluating their vaccine products.
PMID 42604060 · 2026Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.
Competing interests: P.J.N. had research funding from Roche Genentech, B.M.S., M.S.D., CRISPR Therapeutics and Beigene. S.S. had research funding from M.S.D., Varian, Bayer Pharmaceuticals and speaker honoraria from Accuray.
PMID 42420295 · 2026IL-2 based cancer immunotherapies: an evolving paradigm.
SR, AD, and MO are currently employed at Synthekine, JE is a former employee of Synthekine.
PMID 39114660 · 2024Ureteric aspergillosis with obstructing fungal ball following partial nephrectomy for renal cell carcinoma in an immunocompetent patient: A case report.
The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:Has patent pending to. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
PMID 42667080 · 2026Generation of Automated Nephrometry Scores Through Direct Prediction of Each Component.
Declaration of Competing Interest The authors declare the following financial interests/personal relationships, which may be considered as potential competing interests: Dr. Vinay Duddalwarr is a consultant to Radmetrix, Roche, and Deeptek. The remaining authors have no competing financial interests or personal relationships to disclose.
PMID 41856377 · 2026Immune checkpoint inhibitors and other immunotherapies in the treatment of spinal column tumors: A systematic review and Meta-analysis of efficacy, and safety.
Declarations. Conflict of interest: All authors certify that they have no affiliations with or involvement in any organization or entity with any financial interest (such as honoraria, educational grants, participation in speakers’ bureaus, membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. Consent for publication: All authors consent to submitting this article to European Spine Journal.
PMID 40835773 · 2026Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.
L. Kinget reports grants from Kom op tegen Kanker (Stand Up To Cancer) during the conduct of the study. E.S. McTaggart reports personal fees from Pfizer Inc. outside the submitted work. A. Verbiest reports grants from Research Foundation Flanders during the conduct of the study as well as nonfinancial support from Ipsen and MSD outside the submitted work. B. Beuselinck reports grants from Fonds voor wetenschappelijk onderzoek Vlaanderen during the conduct of the study as well as other from MSD, Ipsen, Bristol Myers Squibb, and Pfizer outside the submitted work. No disclosures were reported by the other authors.
PMID 42008739 · 202601
Current Standard-of-Care Sources
Alexandria uses this label only for PubMed-indexed guidelines or consensus documents. These are source publications, not individualized recommendations.
International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma Treated With Stereotactic Ablative Radiation Therapy.
International journal of radiation oncology, biology, physics · 2026
PMID 41580163Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium.
The Lancet. Oncology · 2025
PMID 41038202What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.
World journal of urology · 2026
PMID 42373875Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.
Journal for immunotherapy of cancer · 2026
PMID 41871874SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
PMID 41067863Updated 2025 French guidelines for renal cell carcinoma.
The French journal of urology · 2025
PMID 41109639Kidney transplantation from donors with cancer or history of cancer: Transplantation and cancerology committee of Association Française d'Urologie guidelines (CTAFU/CCAFU).
The French journal of urology · 2025
PMID 41271370Role of radiotherapy in the management of primary renal cell carcinoma: Recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology).
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025
PMID 40934605Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025
PMID 40763792Salvage therapies for local recurrence of renal cell carcinoma: a systematic review and meta-analysis.
World journal of urology · 2026
PMID 42604476Immune checkpoint inhibitors and other immunotherapies in the treatment of spinal column tumors: A systematic review and Meta-analysis of efficacy, and safety.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026
PMID 40835773Thermal Ablation Modalities That Best Compete with Partial Nephrectomy for T1A and T1B Renal Cell Carcinoma: A Network Meta-Analysis.
Journal of vascular and interventional radiology : JVIR · 2025
PMID 4061747702
Highest-Priority Research
International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma Treated With Stereotactic Ablative Radiation Therapy.
International journal of radiation oncology, biology, physics · 2026
PURPOSE: Stereotactic ablative body radiation therapy (SABR) is an emerging indication for localized renal cell carcinoma (RCC), yet there is a need for standardizing contouring practices, as accurate target delineation is essential to ensure optimal outcomes. Our objective was to develop consensus guidelines for target volume contouring for RCC SABR. METHODS AND MATERIALS: An international panel of RCC SABR experts affiliated with IROCK was convened. All were asked to contour target volumes for 4 relevant clinical scenarios: a large tumor (>10 cm) with inferior vena cava tumor thrombus; a central tumor abutting the renal hilum; a local recurrence following nephrectomy; and an ablation cavit…
PMID 41580163Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium.
The Lancet. Oncology · 2025
Pathological response is a surrogate marker of efficacy of neoadjuvant therapy in various tumour types, but there is no consensus on reporting pathological response for renal cell carcinoma. We aimed to assess the status of pathological response reporting in renal cell carcinoma and develop a recommendation on tissue preparation and response reporting for neoadjuvant treatment. We conducted a systematic review of publications on the PubMed and Web of Science databases to identify manuscripts reporting response to pre-surgical therapy in renal cell carcinoma. 119 eligible papers were identified. Only five (4%) studies included details of how pathological response had been assessed. Qualitativ…
PMID 41038202Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review.
Targeted oncology · 2026
BACKGROUND: Immune checkpoint inhibitor (ICI)-based regimens are the standard first-line therapy for advanced renal cell carcinoma (RCC). However, their comparative effectiveness and safety in routine clinical practice remain incompletely characterised. OBJECTIVE: The aim of this study was to systematically synthesise comparative real-world evidence on the efficacy and safety of ICI-based regimens in patients with advanced RCC. METHODS: A systematic search of MEDLINE, Embase, and Scopus was conducted from database inception to 21 January 2026, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Observational cohort studies evaluating…
PMID 42218357What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.
World journal of urology · 2026
BACKGROUND AND OBJECTIVE: Renal cell carcinoma (RCC) is a common manifestation in Von-Hippel Lindau (VHL) syndrome, accounting for almost 30% of the patients. However, since VHL syndrome is relatively rare, there are no clear guidelines regarding the approach to VHL patients with RCC. This article aims to provide evidence-based insights for diagnosis, treatment, and surveillance in VHL patients with RCC. METHODS: The articles indexed between 1977 and 2025 in PubMed was searched. Only articles in English were included. RESULTS: Renal cysts are quite common in VHL patients and these cysts predispose for RCC. VHL patients are characterized with early-onset, multifocal and/or bilateral, recurren…
PMID 42373875Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.
Journal for immunotherapy of cancer · 2026
Immunotherapy has been a pillar of the renal cell carcinoma (RCC) treatment landscape for over three decades. Some of the earliest cancer immunotherapies available, such as interleukin 2 and interferon-alpha, have resulted in complete responses, but only in a small number of patients. Immune checkpoint inhibitors (ICIs), however, have demonstrated improved response rates and prolonged survival for a greater number of patients, fully transforming the standard of care in first-line and subsequent-line settings. More recently, ICIs are also being used in the adjuvant setting for high-risk patients. However, treatment with ICIs requires a nuanced understanding of topics such as patient selection…
PMID 41871874The impact of social determinants of health on access to partial nephrectomy, minimally invasive surgery, and robotic-assisted approaches for renal cell carcinoma.
World journal of urology · 2026
PURPOSE: Social determinants of health (SDOH), including race/ethnicity, socioeconomic status (SES), insurance coverage, and geographic location, are established drivers of disparities in surgical access and outcomes. Robotic-assisted partial nephrectomy (RAPN) has become the preferred minimally invasive approach for localized renal cell carcinoma (RCC), yet the extent to which SDOH influence access to partial nephrectomy, minimally invasive surgery, and RAPN specifically, as well as postoperative outcomes has not been comprehensively characterized. METHODS: A systematic review was conducted following PRISMA guidelines. PubMed/MEDLINE, Google Scholar, ScienceDirect, Embase, Web of Science, a…
PMID 42611330SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025
Anatomic imaging of renal masses provides limited information on the histology or likely aggressiveness of the tumor, leading to the use of invasive procedures such as renal mass biopsy or empiric partial or radical nephrectomy. Molecular imaging can assist in risk stratification of indeterminate renal masses, potentially contributing to optimal patient decision-making. Two primary approaches have been explored for renal mass molecular imaging. The first is the use of agents that target carbonic anhydrase IX (CAIX), a cell-surface protein that is over-expressed on clear cell renal cell carcinoma (ccRCC) and generally not expressed on other renal tumors. A recent phase III trial (ZIRCON) is w…
PMID 41067863Updated 2025 French guidelines for renal cell carcinoma.
The French journal of urology · 2025
The 2025 update of the French guidelines for localized renal cell carcinoma highlights several major advances. Renal biopsy reaffirms its central role in guiding therapeutic decisions and reducing overtreatment, with growing evidence supporting a broader "biopsy-all" strategy. Active surveillance is now established as a safe and effective option for small renal masses, including selected complex cystic lesions, providing oncological outcomes comparable to immediate intervention. Among alternative approaches, stereotactic body radiotherapy has emerged as a credible and well-tolerated treatment for medically inoperable patients. In hereditary syndromes, progress includes improved characterizat…
PMID 41109639Kidney transplantation from donors with cancer or history of cancer: Transplantation and cancerology committee of Association Française d'Urologie guidelines (CTAFU/CCAFU).
The French journal of urology · 2025
INTRODUCTION: Potential donors for transplantation are screened for malignancies that can be transmitted on to the recipient. The discovery of cancer or a history of cancer often leads to contraindications for organ donation, while in some cases the cancer transmission risk is very low. The current context of organ shortage leads us to reconsider the use of organs from donors with cancer or a history of cancer when the risk of transmission is minimal or less than the risk of death on the waiting list. The Transplantation Committee (CTAFU) in partnership with the Cancer Committee (CCAFU) of the Association Française d'Urology (AFU) were asked to publish guidelines for clinical practice concer…
PMID 41271370Role of radiotherapy in the management of primary renal cell carcinoma: Recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology).
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025
Renal cell carcinoma represents the 14th most frequent tumour worldwide, but its incidence is increasing partly due to incidental diagnoses. As a result, these tumours are diagnosed in patients at an increasingly advanced age, often frail and with comorbidities. Most renal cell carcinoma cases are clear cell carcinoma (80 %), with papillary tumours being the second most frequent histological subtype. The standard of care for localized RCC is surgery, with partial nephrectomy or radical nephrectomy being recommended for T1 and T2 tumours, respectively. Thermoablative strategies have been developed over the past decade for patients who are not amenable to surgery and/or with impaired renal fun…
PMID 40934605Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025
The NCCN Clinical Practice Guidelines (NCCN Guidelines) for Wilms Tumor (WT; nephroblastoma) cover strategies for the screening, diagnosis, and treatment of WT, which is the most frequent primary kidney tumor in children. WT can generally be separated into 2 histology types: favorable histology WT and anaplastic WT. Five-year survival is high for children with favorable histology WT who receive appropriate treatment; however, survival rates are much lower for patients who present with higher stage diffuse anaplastic WT. Treatment of WT can range from surgery alone to surgery plus intensive chemotherapy and radiation depending on whether the tumor is unilateral or bilateral, histology, and lo…
PMID 40763792Comparative outcomes of robot-assisted and open radical nephrectomy with inferior vena cava thrombectomy for renal cell carcinoma: a systematic review and meta-analysis.
Journal of robotic surgery · 2026
For patients with renal cell carcinoma (RCC) complicated by inferior vena cava (IVC) tumor thrombus, radical nephrectomy combined with thrombectomy remains a key surgical option. Open radical nephrectomy with IVC thrombectomy (O-RNTT) has long been regarded as the traditional operative strategy, whereas robot-assisted radical nephrectomy with IVC thrombectomy (R-RNTT) is now being used more frequently in high-experience centers. Direct comparative data, however, remain limited. This study aimed to compare perioperative outcomes and available short-term pathological and oncologic findings between R-RNTT and O-RNTT in patients with RCC and IVC tumor thrombus. A PRISMA-guided systematic review …
PMID 4262496603
Latest Research — Last 24 Months
2026
2026
Single-port versus multi-port robot-assisted partial nephrectomy for predominantly low-complexity renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · PMID 42634038
2026
Elevated C-reactive protein to albumin ratio is a promising predictive biomarker for prognosis in patients with renal cell carcinoma.
Annals of medicine · PMID 41566198
2026
Belzutifan in Von Hippel-Lindau-associated Hemangioblastomas: A Systematic Review and Meta-analysis.
Journal of neurological surgery. Part B, Skull base · PMID 42626756
2026
Antibiotic exposure and cancer risk: an umbrella review elucidating the direction of risk across 14 malignancies.
Journal of public health (Oxford, England) · PMID 42361054
2026
Ultrasound Radiomics for Differential Diagnosis of Renal Masses: A Systematic Review and Meta-Analysis.
Technology in cancer research & treatment · PMID 42640784
2026
Environmental Nonessential Element Exposure and Urologic Cancer: A Systematic Review and Meta-Analysis.
JAMA network open · PMID 42172026
2026
Molecular mechanisms and therapeutic targets of traditional Chinese Medicine compounds in renal cell carcinoma: A comprehensive narrative review.
Journal of ethnopharmacology · PMID 42276388
2026
2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · PMID 42149133
2026
Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study.
International journal of urology : official journal of the Japanese Urological Association · PMID 42179010
2026
2026
2026
2026
MRI-based habitat radiomics for assessing synchronous metastatic risk in renal cell carcinoma: a multicenter study.
Abdominal radiology (New York) · PMID 41711878
04
Treatment Options Studied in the PubMed Collection
These are interventions detected in PubMed metadata and abstracts. Inclusion does not establish approval, effectiveness, suitability, or standard-of-care status.
preliminary evidence
partial nephrectomy
41 linked PMIDs981974 reported cumulative sample signal
- Research status
- mostly neutral
- Outcomes represented
- reported clinical outcomes, renal function, quality of life, recurrence, recurrence-free survival, overall survival, mortality, adverse events
- Populations represented
- general population; localized; locally advanced; advanced; metastatic; papillary renal cell carcinoma; stage I; stage II; localized; advanced
- Mechanism
- Limitations include modest cohort size, retrospective design, and predominant ultrasound guidance potentially affecting targeting accuracy
preliminary evidence
Biomarkers, Tumor
33 linked PMIDs18950 reported cumulative sample signal
- Research status
- harm signal
- Outcomes represented
- reported clinical outcomes, overall survival, recurrence, disease-free survival, progression-free survival, objective response rate, response rate
- Populations represented
- general population; clear cell renal cell carcinoma; metastatic; first-line; localized; metastatic; clear cell renal cell carcinoma; PD-L1; localized; metastatic; first-line
- Mechanism
- Considering that the circulating proteome represents a primary source of candidate biomarkers and therapeutic targets, we conducted a large-scale Mendelian randomization (MR) study to identify plasma proteins potentially involved in the pathogenesis and treatment of common urological cancers (UCs), including bladder cancer (BC), prostate cancer (PC), renal cell carcinoma (RCC), and testicular cancer (TC) This study aimed to identify key prognostic biomarkers and potential therapeutic targets for KIRC via multi-omics integrative analysis and preliminary experimental validation
preliminary evidence
Immune Checkpoint Inhibitors
24 linked PMIDs40206 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, progression-free survival, response rate, objective response rate, reported clinical outcomes, quality of life, adverse events, disease-free survival
- Populations represented
- metastatic; first-line; metastatic; clear cell renal cell carcinoma; advanced; general population; metastatic; second-line
- Mechanism
- BACKGROUND: Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastatic clear cell RCC (ccRCC) Mechanistically, this sequence aligns vascular reprogramming, antigen-specific priming, and checkpoint release, converting an immune-excluded tumor into a T-cell-dominated, cytotoxic niche
preliminary evidence
radical nephrectomy
23 linked PMIDs43032 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, renal function, mortality, recurrence, adverse events, overall survival
- Populations represented
- general population; localized; advanced; clear cell renal cell carcinoma; CAIX; stage III; locally advanced; advanced; metastatic
- Mechanism
- Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may confer renal-protective and anti-inflammatory effects while reducing perinephric adiposity
preliminary evidence
pembrolizumab
16 linked PMIDs4210 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, objective response rate, response rate, disease-free survival, progression-free survival, adverse events, recurrence, reported clinical outcomes
- Populations represented
- metastatic; first-line; advanced; advanced; metastatic; first-line; clear cell renal cell carcinoma; localized; advanced; metastatic; localized; metastatic; first-line
- Mechanism
- BACKGROUND: Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastatic clear cell RCC (ccRCC)
moderate-confidence evidence
cabozantinib
14 linked PMIDs3059 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, adverse events, objective response rate, response rate, reported clinical outcomes, progression-free survival, quality of life
- Populations represented
- metastatic; first-line; advanced; advanced; first-line; locally advanced; advanced; metastatic; stage IV; first-line; second-line; previously treated; PD-L1; metastatic; metastatic; first-line; second-line
- Mechanism
- BACKGROUND: Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastatic clear cell RCC (ccRCC)
preliminary evidence
Nivolumab
11 linked PMIDs2495 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- progression-free survival, objective response rate, response rate, overall survival, reported clinical outcomes, adverse events, quality of life
- Populations represented
- metastatic; first-line; advanced; first-line; metastatic; second-line; advanced; metastatic; stage III; metastatic; first-line; second-line
- Mechanism
- BACKGROUND: Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastatic clear cell RCC (ccRCC)
preliminary evidence
Protein Kinase Inhibitors
7 linked PMIDs9177 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, adverse events, overall survival, disease-free survival, progression-free survival, objective response rate, response rate, quality of life
- Populations represented
- general population; advanced; advanced; metastatic; metastatic
- Mechanism
- Our goal was to repurpose known fluorescent ligands, originally developed for other targets, to study EGFR expression at the kidney cell membrane in healthy and diseased conditions, providing a potential tool for disease detection and staging Inhibition of ALOX5 inhibited the growth of subcutaneous tumors and lung metastases in 786O-R cell
moderate-confidence evidence
lenvatinib
7 linked PMIDs2489 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, progression-free survival, adverse events, objective response rate, response rate, reported clinical outcomes
- Populations represented
- metastatic; first-line; advanced; metastatic; first-line; locally advanced; advanced; metastatic; stage IV; first-line; second-line; previously treated; PD-L1
- Mechanism
- BACKGROUND: Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastatic clear cell RCC (ccRCC)
moderate-confidence evidence
Pyridines
6 linked PMIDs948 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, objective response rate, response rate, overall survival, progression-free survival, quality of life
- Populations represented
- advanced; metastatic; first-line; second-line; locally advanced; advanced; metastatic; stage IV; first-line; second-line; previously treated; PD-L1; metastatic
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
moderate-confidence evidence
Anilides
6 linked PMIDs948 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, objective response rate, response rate, overall survival, progression-free survival, quality of life
- Populations represented
- advanced; locally advanced; advanced; metastatic; stage IV; first-line; second-line; previously treated; PD-L1; metastatic; first-line; second-line; metastatic
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
Antibodies, Monoclonal, Humanized
6 linked PMIDs352 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, progression-free survival, objective response rate, response rate, adverse events, reported clinical outcomes, recurrence
- Populations represented
- advanced; metastatic; first-line; metastatic; first-line; second-line; advanced; first-line; localized; advanced; metastatic; clear cell renal cell carcinoma; localized
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preliminary evidence
axitinib
6 linked PMIDs334 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, response rate, progression-free survival, adverse events, reported clinical outcomes
- Populations represented
- metastatic; first-line; metastatic; first-line; second-line; advanced; first-line; clear cell renal cell carcinoma
- Mechanism
- BACKGROUND: Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastatic clear cell RCC (ccRCC) Mechanistically, P4HA3 inhibited ferroptosis by stabilizing the cystine transporter SLC7A11, thereby maintaining redox homeostasis and suppressing lipid peroxidation
preliminary evidence
ipilimumab
5 linked PMIDs1823 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- overall survival, reported clinical outcomes
- Populations represented
- metastatic; first-line; advanced; first-line
- Mechanism
- BACKGROUND: Sitravatinib, an oral multi-kinase inhibitor targeting VEGFR, TAM, and MET, has been shown to resensitize the tumor microenvironment to immune checkpoint inhibitors (ICI) by reducing immune-suppressive myeloid cells in metastatic clear cell RCC (ccRCC)
preliminary evidence
Contrast Media
5 linked PMIDs1067 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, recurrence-free survival, recurrence
- Populations represented
- general population; metastatic; clear cell renal cell carcinoma
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
moderate-confidence evidence
belzutifan
5 linked PMIDs541 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- adverse events, reported clinical outcomes, objective response rate, response rate, overall survival, progression-free survival, recurrence
- Populations represented
- VHL; locally advanced; advanced; metastatic; stage IV; first-line; second-line; previously treated; PD-L1; localized; metastatic; first-line
- Mechanism
- Not explicitly reported in the retrieved PubMed metadata or abstracts.
preclinical evidence only
Antineoplastic Agents
5 linked PMIDs— reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes
- Populations represented
- general population
- Mechanism
- The aim of this review is to systematically synthesize current knowledge on the role of mitochondrial dysfunction in RCC pathogenesis and to explore emerging therapeutic strategies targeting mitochondrial vulnerabilities Inhibition of ALOX5 inhibited the growth of subcutaneous tumors and lung metastases in 786O-R cell
moderate-confidence evidence
Biomarkers
4 linked PMIDs2375 reported cumulative sample signal
- Research status
- insufficiently reported
- Outcomes represented
- reported clinical outcomes, overall survival, recurrence
- Populations represented
- general population; clear cell renal cell carcinoma
- Mechanism
- PURPOSE: Type 2 (T2) inflammatory biomarkers are established therapeutic targets in asthma and non-asthmatic eosinophilic bronchitis (NAEB), but their relevance in chronic cough remains unclear Patients with CCAst/EB received inhaled corticosteroid/long-acting β₂-agonist (ICS/LABA) therapy, while those without evidence of T2 inflammation or who had failed ICS/LABA were treated with neuromodulators
05
Conflicting Research
higher-confidence evidence
38 studiespartial nephrectomy · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 26null: 9harm: 2mixed: 1
higher-confidence evidence
23 studiesBiomarkers, Tumor · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 19harm: 3mixed: 1
higher-confidence evidence
19 studiesradical nephrectomy · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: general population. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
harm: 1null: 5unknown: 13
higher-confidence evidence
9 studiesnivolumab · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 7benefit: 1null: 1
higher-confidence evidence
8 studiespembrolizumab · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 6benefit: 1null: 1
moderate-confidence evidence
7 studieslenvatinib · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 5benefit: 1null: 1
higher-confidence evidence
7 studiesipilimumab · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 5benefit: 1null: 1
moderate-confidence evidence
6 studiescabozantinib · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
unknown: 4benefit: 1null: 1
moderate-confidence evidence
3 studiescabozantinib · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
null: 1unknown: 1benefit: 1
moderate-confidence evidence
3 studiespembrolizumab · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: clear cell renal cell carcinoma. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
mixed: 1unknown: 2
moderate-confidence evidence
3 studiesnivolumab · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: metastatic. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
benefit: 2null: 1
moderate-confidence evidence
2 studiesPyridines · multiple reported outcomes
Status: apparently conflicting; different clinical questions. Population: clear cell renal cell carcinoma; advanced; first-line. Comparator: multiple or inconsistently reported comparators.
- The records use different or inconsistently reported comparators.
- The records report different endpoints or outcome definitions.
- The evidence combines different study designs.
- Some abstracts do not state whether the primary endpoint was met.
mixed: 1unknown: 1
06
Failed or Negative Trials
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
randomized controlled trial · 2024 · PMID 39255440
The long-term impact of single intraoperative instillation of pirarubicin after radical nephroureterectomy on local and systemic cancer control: a prospective, multicenter, randomized trial.
randomized controlled trial · 2025 · PMID 40080123
Suitability of the MP1000 system for robot-assisted partial nephrectomy: a multicenter randomized controlled noninferiority trial.
randomized controlled trial · 2024 · PMID 38349210
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
randomized controlled trial · 2026 · PMID 42507969
Robot-assisted radical nephroureterectomy using the KangDuo Surgical Robot-01 System versus the da Vinci System: a multicenter prospective randomized controlled trial.
randomized controlled trial · 2024 · PMID 39133792
Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy.
randomized controlled trial · 2026 · PMID 41360001
Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy.
randomized controlled trial · 2024 · PMID 37684178
Randomized controlled trial of the effect of general anesthetics on postoperative recovery after minimally invasive nephrectomy.
randomized controlled trial · 2024 · PMID 37232074
Transperitoneal vs retroperitoneal laparoscopic radical nephrectomy: a double-arm, parallel-group randomized clinical trial.
randomized controlled trial · 2024 · PMID 38310213
The efficacy and safety of duloxetine in treating refractory chronic cough: a randomized clinical trial.
randomized controlled trial · 2026 · PMID 41530764
07
Emerging and Experimental Research
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.
randomized controlled trial · 2026 · PMID 42633754
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
randomized controlled trial · 2026 · PMID 42507969
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.
randomized controlled trial · 2026 · PMID 42235464
Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191.
randomized controlled trial · 2026 · PMID 42158981
Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy.
randomized controlled trial · 2026 · PMID 41760424
Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters.
randomized controlled trial · 2026 · PMID 42138077
Progress in management of advanced clear-cell renal cell carcinoma.
phase 2 clinical trial · 2026 · PMID 41941086
Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses.
phase 2 clinical trial · 2026 · PMID 42431710
CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.
phase 2 clinical trial · 2026 · PMID 41895717
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.
phase 2 clinical trial · 2026 · PMID 42144019
08
Evidence Gaps
Detailed risk-of-bias assessment remains limited
PubMed abstracts often do not include enough methodological detail for a complete study-level risk-of-bias assessment.
R
Complete Ranked PubMed Index
The retrieval-priority score orders records using publication type, recency, sample-size signals, and replication signals. It is not a recommendation or a formal risk-of-bias grade.
Current Standard Of Care63 records
Rank112.0
Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium.
The Lancet. Oncology · 2025 · PMID 41038202
Pathological response is a surrogate marker of efficacy of neoadjuvant therapy in various tumour types, but there is no consensus on reporting pathological response for renal cell carcinoma. We aimed to assess the status of pathological response reporting in renal cell carcinoma and develop a recommendation on tissue preparation and response reporting for neoadjuvant treatment. We conducted a systematic review of publications on the PubMed and Web of Science databases to identify manuscripts reporting response to p…
Rank112.0
International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma Treated With Stereotactic Ablative Radiation Therapy.
International journal of radiation oncology, biology, physics · 2026 · PMID 41580163
PURPOSE: Stereotactic ablative body radiation therapy (SABR) is an emerging indication for localized renal cell carcinoma (RCC), yet there is a need for standardizing contouring practices, as accurate target delineation is essential to ensure optimal outcomes. Our objective was to develop consensus guidelines for target volume contouring for RCC SABR. METHODS AND MATERIALS: An international panel of RCC SABR experts affiliated with IROCK was convened. All were asked to contour target volumes for 4 relevant clinical…
Rank110.0
SNMMI/EANM/ACNM Procedure Standard/Procedure Guideline on the Use of Molecular Imaging for Renal Mass Characterization.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025 · PMID 41067863
Anatomic imaging of renal masses provides limited information on the histology or likely aggressiveness of the tumor, leading to the use of invasive procedures such as renal mass biopsy or empiric partial or radical nephrectomy. Molecular imaging can assist in risk stratification of indeterminate renal masses, potentially contributing to optimal patient decision-making. Two primary approaches have been explored for renal mass molecular imaging. The first is the use of agents that target carbonic anhydrase IX (CAIX)…
Rank110.0
Kidney transplantation from donors with cancer or history of cancer: Transplantation and cancerology committee of Association Française d'Urologie guidelines (CTAFU/CCAFU).
The French journal of urology · 2025 · PMID 41271370
INTRODUCTION: Potential donors for transplantation are screened for malignancies that can be transmitted on to the recipient. The discovery of cancer or a history of cancer often leads to contraindications for organ donation, while in some cases the cancer transmission risk is very low. The current context of organ shortage leads us to reconsider the use of organs from donors with cancer or a history of cancer when the risk of transmission is minimal or less than the risk of death on the waiting list. The Transplan…
Rank110.0
Updated 2025 French guidelines for renal cell carcinoma.
The French journal of urology · 2025 · PMID 41109639
The 2025 update of the French guidelines for localized renal cell carcinoma highlights several major advances. Renal biopsy reaffirms its central role in guiding therapeutic decisions and reducing overtreatment, with growing evidence supporting a broader "biopsy-all" strategy. Active surveillance is now established as a safe and effective option for small renal masses, including selected complex cystic lesions, providing oncological outcomes comparable to immediate intervention. Among alternative approaches, stereo…
Rank110.0
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.
Journal for immunotherapy of cancer · 2026 · PMID 41871874
Immunotherapy has been a pillar of the renal cell carcinoma (RCC) treatment landscape for over three decades. Some of the earliest cancer immunotherapies available, such as interleukin 2 and interferon-alpha, have resulted in complete responses, but only in a small number of patients. Immune checkpoint inhibitors (ICIs), however, have demonstrated improved response rates and prolonged survival for a greater number of patients, fully transforming the standard of care in first-line and subsequent-line settings. More …
Rank110.0
Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2025 · PMID 40763792
The NCCN Clinical Practice Guidelines (NCCN Guidelines) for Wilms Tumor (WT; nephroblastoma) cover strategies for the screening, diagnosis, and treatment of WT, which is the most frequent primary kidney tumor in children. WT can generally be separated into 2 histology types: favorable histology WT and anaplastic WT. Five-year survival is high for children with favorable histology WT who receive appropriate treatment; however, survival rates are much lower for patients who present with higher stage diffuse anaplasti…
Rank110.0
What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.
World journal of urology · 2026 · PMID 42373875
BACKGROUND AND OBJECTIVE: Renal cell carcinoma (RCC) is a common manifestation in Von-Hippel Lindau (VHL) syndrome, accounting for almost 30% of the patients. However, since VHL syndrome is relatively rare, there are no clear guidelines regarding the approach to VHL patients with RCC. This article aims to provide evidence-based insights for diagnosis, treatment, and surveillance in VHL patients with RCC. METHODS: The articles indexed between 1977 and 2025 in PubMed was searched. Only articles in English were includ…
Rank110.0
Role of radiotherapy in the management of primary renal cell carcinoma: Recommendations from the Société française de radiothérapie oncologique (SFRO, the French society for radiation oncology).
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique · 2025 · PMID 40934605
Renal cell carcinoma represents the 14th most frequent tumour worldwide, but its incidence is increasing partly due to incidental diagnoses. As a result, these tumours are diagnosed in patients at an increasingly advanced age, often frail and with comorbidities. Most renal cell carcinoma cases are clear cell carcinoma (80 %), with papillary tumours being the second most frequent histological subtype. The standard of care for localized RCC is surgery, with partial nephrectomy or radical nephrectomy being recommended…
Rank106.6
Salvage therapies for local recurrence of renal cell carcinoma: a systematic review and meta-analysis.
World journal of urology · 2026 · PMID 42604476
BACKGROUND: We aimed to systematically summarize data on efficacy of local salvage therapies for local recurrence of renal cell carcinoma (RCC). METHODS: We searched MEDLINE, Embase, Web of Science, CENTRAL, and Google Scholar through 05/08/2026, for studies on local salvage therapies for local recurrence of RCC following radical nephrectomy, partial nephrectomy, or ablation (PROSPERO: CRD42024623099). Meta-analyses were conducted using random-effects models. Risk of bias (RoB) was assessed using ROBINS-I. RESULTS:…
Rank105.7
Immune checkpoint inhibitors and other immunotherapies in the treatment of spinal column tumors: A systematic review and Meta-analysis of efficacy, and safety.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026 · PMID 40835773
PURPOSE: Spinal metastases affect up to 70% of systemic cancer patients, with overall survival averaging less than six months. Traditional chemotherapeutic agents have unsatisfactory results, leading to immunotherapy (IT) investigations. There is no clear consensus on the benefits and risks of IT for spinal tumors. This study assesses the current literature to determine IT safety and survival efficacy for tumors involving spinal column. METHODS: Following PRISMA guidelines, a systematic search was conducted across …
Rank103.9
Thermal Ablation Modalities That Best Compete with Partial Nephrectomy for T1A and T1B Renal Cell Carcinoma: A Network Meta-Analysis.
Journal of vascular and interventional radiology : JVIR · 2025 · PMID 40617477
PURPOSE: To address the lack of consensus on the ranking of thermal ablation (TA) for treating T1A and T1B renal cell carcinoma (RCC), a network meta-analysis was conducted to compare the efficacy and safety of different TA modalities for managing early-stage RCC. METHODS: The Cochrane Library, PubMed, Scopus, and Web of Science were systematically searched for studies comparing percutaneous and laparoscopic radiofrequency ablation (RFA), cryoablation (CRA), and microwave ablation (MWA) with open, laparoscopic, and…
Rank100.0
Quality Indicators for Renal Cancer Care: A Systematic Review.
European urology oncology · 2025 · PMID 40483206
BACKGROUND AND OBJECTIVE: Quality indicators (QIs) are crucial for evaluating health care delivery, including effectiveness, safety, and patient-centered outcomes. In contrast to other fields, the definition and implementation of QIs for renal cell carcinoma (RCC) present distinct challenges and remain unmet needs. We summarized the available data on QIs for RCC, focusing on their characterization throughout the care pathway and the potential areas for further development. METHODS: A systematic review of the Englis…
Rank96.0
Pan-cancer multi-omics machine learning defines a lactylation-associated immune-excluded tumor state with proteomic and experimental corroboration.
Computational biology and chemistry · 2026 · PMID 42556016
BACKGROUND: Histone lactylation links lactate metabolism to chromatin regulation, but whether lactylation-program-associated transcriptional patterns delineate recurrent pan-cancer tumor states remains unclear. METHODS: We integrated mRNA, lncRNA, and miRNA profiles from 9712 TCGA tumors across 33 cancer types with GTEx references, six GEO cohorts, IMvigor210, and an institutional clear-cell renal cell carcinoma (ccRCC) cohort used for exploratory DIA-NN proteomic corroboration. Random-effects co-expression meta-an…
Rank80.5
Comparative prognostic performance of KEYNOTE-564 and AUA risk stratification in nonmetastatic clear cell renal cell carcinoma.
Urologic oncology · 2026 · PMID 41266180
PURPOSE: To compare KEYNOTE-564 and American Urological Association (AUA) risk classifications in clear cell renal cell carcinoma (ccRCC), as recurrence after treatment for localized RCC remains a significant clinical challenge, and no consensus exists on how to define high-risk disease. MATERIALS AND METHODS: We conducted a retrospective multicenter study of surgically treated patients with nonmetastatic ccRCC. Patients were stratified by AUA and KEYNOTE-564 criteria, and overall survival (OS), cancer specific sur…
Rank79.5
Radiomics-Based Unsupervised Clustering Identifies Subtypes Associated With Prognosis and Immune Microenvironment in Clear Cell Renal Cell Carcinoma: A Multicenter Study.
Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025 · PMID 40539890
Clear cell renal cell carcinoma (ccRCC) exhibits marked clinical heterogeneity, limiting the prognostic accuracy of traditional staging. We developed an unsupervised radiomics-based subtyping system integrating multi-omics data to decode tumor biology and improve risk stratification. Analyzing five cohorts (n = 1700, including surgical cohorts and an advanced ccRCC cohort receiving combined tyrosine kinase inhibitor and immunotherapy [T-I] treatment), we extracted 1834 CT radiomic features, applying consensus clust…
Rank78.3
Node-RADS category on preoperative CT predicts prognosis in patients with papillary renal cell carcinoma.
European radiology · 2025 · PMID 39979621
OBJECTIVES: This research focused on investigating the relationship between the Node Reporting and Data System (Node-RADS) categories, determined via preoperative CT, and the outcomes of progression-free survival (PFS) and cancer-specific survival (CSS) in individuals diagnosed with papillary renal cell carcinoma (pRCC). METHODS: A retrospective multicenter study initially enrolled 454 patients, with 218 eligible for analysis following partial nephrectomy or radical resection for pRCC. Prognostic factors related to…
Rank73.4
Comparison of glass-based and whole-slide image-based grade assignment for clear-cell and papillary renal cell carcinoma: a multi-cohort, international reproducibility study.
Histopathology · 2026 · PMID 41171031
BACKGROUND AND AIMS: Histological grading of renal cell carcinoma (RCC) is an important part of diagnostic evaluation. Reproducibility of RCC grading using whole-slide imaging (WSI) compared to glass-slide microscopy is understudied. The aim of the study was a head-to-head evaluation of WSI-based and glass-based grading approaches in clear-cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) subtypes. METHODS: Four cohorts of patient cases with glass slides and corresponding digitized WSI were included …
Rank73.3
Radiological differentiation of succinate dehydrogenase-deficient renal cell carcinoma from renal oncocytoma and chromophobe renal cell carcinoma.
BMC cancer · 2026 · PMID 42067868
PURPOSE: To characterize the imaging features of succinate dehydrogenase-deficient renal cell carcinoma (SDH-RCC) and compare them with those of renal oncocytoma (RO) and chromophobe RCC (chRCC). METHODS: This retrospective two-center study was approved by the institutional review board, and informed consent was waived. Patients with histologically confirmed SDH-RCC, RO, or chRCC who underwent pre-treatment contrast-enhanced CT between November 2015 and October 2024 were included. Imaging features were independentl…
Rank73.0
Evaluating the Feasibility of Standard Ultrasound in the Bosniak Classification of Cystic Renal Masses Compared with Computed Tomography/Magnetic Resonance Imaging: A Multicenter Study.
Ultrasound in medicine & biology · 2026 · PMID 41238458
OBJECTIVE: To investigate the diagnostic performance of standard ultrasound (US) using a US-adapted Bosnian classification for characterizing cystic renal masses (CRMs) compared with computed tomography/magnetic resonance imaging (CT/MRI) as the current standard. METHODS: From July 2016 to June 2022, pathology-proven CRMs and CRMs with ≥3 y of follow-up from six centers were reviewed. Four readers with varying levels of expertise in US categorized CRMs using a US-based Bosnian classification, followed by a consensu…
Rank54.5
Generation of Automated Nephrometry Scores Through Direct Prediction of Each Component.
Urology · 2026 · PMID 41856377
OBJECTIVE: To evaluate whether a deep learning model could automate R.E.N.A.L. nephrometry score generation and predict clinically significant outcomes. METHODS: A ResNet-50 neural network was trained on 599 patients from the 2023 KiTS Challenge dataset to predict numeric R.E.N.A.L. score components (excluding the anterior/posterior designation) using preoperative CT images and expert-derived segmentation masks. Five-fold cross-validation produced automated scores, which were compared with consensus human scores fr…
Rank53.8
Immunotherapy utilization patterns in patients with advanced cancer and autoimmune disease.
PloS one · 2024 · PMID 38625861
PURPOSE: Immunotherapy has been shown to improve cancer survival, but there are no consensus guidelines to inform use in patients with both cancer and autoimmune disease (AD). We sought to examine immunotherapy utilization patterns between cancer patients with and without AD. PATIENTS AND METHODS: This retrospective cohort study utilized data from a de-identified nationwide oncology database. Patients diagnosed with advanced melanoma, non-small cell lung cancer, and renal cell carcinoma were included. Outcomes of i…
Rank53.1
Prognostic and Predictive Value of the Clearseq1-4 Tumor Microenvironment Classification in Localized and Metastatic Clear-Cell Renal Cell Carcinoma.
Cancer research communications · 2026 · PMID 42008739
UNLABELLED: The ccrcc1-4 transcriptomic subtypes were previously identified in fresh-frozen clear-cell renal cell carcinoma (ccRCC) samples and have proven their prognostic value after nephrectomy/metastasectomy and predictive value for first-line vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKI). We aimed to create a consensus molecular classification approach called Clearseq1-4 on formalin-fixed, paraffin-embedded (FFPE) tissues and to evaluate its prognostic and predictive value …
Rank50.1
Construction and validation of renal cell carcinoma tumor cell differentiation-related prognostic classification (RCC-TCDC): an integrated bioinformatic analysis and clinical study.
Annals of medicine · 2025 · PMID 40248945
BACKGROUND: Renal cell carcinoma (RCC) is a heterogeneous malignancy with diverse gene expression patterns, molecular landscapes, and differentiation characteristics of tumor cells. It is imperative to develop molecular RCC classification based on tumor cell differentiation for precise risk stratification and personalized therapy. METHODS: We obtained scRNA-seq profiles from GSE159115 and bulk RNA-seq profiles from TCGA-KIRC cohort. We then performed scRNA-seq cluster analysis, monocle2 pseudotime analysis, and pro…
Rank49.4
Computed tomography-based unsupervised clustering identifies clusters associated with progression free survival in clear cell renal cell carcinoma.
Cancer imaging : the official publication of the International Cancer Imaging Society · 2025 · PMID 41287074
BACKGROUND: This study aimed to develop and validate a radiologic clustering model using CT imaging features to stratify clear cell renal cell carcinoma (ccRCC) patients by prognosis and identify key imaging predictors of 5-year progression free survival (PFS). METHODS: This retrospective study included 164 ccRCC patients with multiphase kidney CT and next-generation sequencing (NGS) between September 2003 and October 2024. Qualitative imaging features were extracted, and unsupervised consensus clustering was perfo…
Diagnosis And Screening131 records
Rank114.2
Performance of Machine Learning Models Based on Medical Imaging in Predicting Pathological Grade of Clear Cell Renal Cell Carcinoma.
Cancer medicine · 2026 · PMID 42693958
BACKGROUND: Predicting clear cell renal cell carcinoma (ccRCC) pathological grade preoperatively is critical for clinical management. This study aims to evaluate the diagnostic accuracy and clinical utility of machine learning (ML)-based imaging models. METHODS: The Cochrane Library, PubMed, Embase, and Scopus databases were searched systematically for studies published before January 2026. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 and the Radiomics Quality Score. Pool…
Rank110.0
The impact of social determinants of health on access to partial nephrectomy, minimally invasive surgery, and robotic-assisted approaches for renal cell carcinoma.
World journal of urology · 2026 · PMID 42611330
PURPOSE: Social determinants of health (SDOH), including race/ethnicity, socioeconomic status (SES), insurance coverage, and geographic location, are established drivers of disparities in surgical access and outcomes. Robotic-assisted partial nephrectomy (RAPN) has become the preferred minimally invasive approach for localized renal cell carcinoma (RCC), yet the extent to which SDOH influence access to partial nephrectomy, minimally invasive surgery, and RAPN specifically, as well as postoperative outcomes has not …
Rank109.1
Machine Learning for Predicting Ki-67 Expression in Renal Tumors: A Systematic Review And Meta-Analysis.
Academic radiology · 2026 · PMID 42443009
RATIONALE AND OBJECTIVES: To systematically evaluate the diagnostic performance of machine learning (ML) models for predicting Ki-67 expression in renal tumors and assess their potential for clinical translation. MATERIALS AND METHODS: We systematically searched PubMed, Web of Science, Cochrane Library, and Embase up to November 2025. Studies using ML to predict Ki-67 with immunohistochemistry as reference standard were included. Quality was assessed with QUADAS-2. A bivariate random-effects model pooled diagnostic…
Rank109.0
Mortality risk in patients with urological malignancies and human immunodeficiency virus (HIV) coinfection: A systematic review and meta-analysis of cohort studies.
Cancer pathogenesis and therapy · 2026 · PMID 42643168
BACKGROUND: The extended survival of people living with human immunodeficiency virus (HIV) (PLWH) has shifted cancer burdens toward urological malignancies. PLWH exhibit unique clinical patterns, including a younger age at diagnosis for renal cell carcinoma and more advanced stage at presentation of prostate and bladder cancers, which are compounded by inequities in health care access and HIV-specific mechanisms such as chronic immunosuppression. METHODS: A systematic search was conducted across five databases (Web…
Rank108.7
Age-Related Survival Disparities in Advanced Renal Carcinoma in the Immune Checkpoint Inhibitor Era using the SEER Database and Meta-analysis.
Scientific reports · 2025 · PMID 41339655
Immunosenescence, the gradual deterioration of the immune system with age, reduces the efficacy of immune checkpoint inhibitors (ICI) in cancer management. Although ICI offer promising survival benefits for advanced renal cell carcinoma (aRCC), their effectiveness across different age groups remains poorly understood. This study aimed to evaluate age-related survival outcomes in aRCC patients receiving ICI using integrated cohorts. Using data from the Surveillance, Epidemiology, and End Results (SEER) program (2004…
Rank106.8
Elevated C-reactive protein to albumin ratio is a promising predictive biomarker for prognosis in patients with renal cell carcinoma.
Annals of medicine · 2026 · PMID 41566198
BACKGROUND AND AIMS: Systemic inflammation is closely linked to the development and progression of various cancers, as well as poorer patient outcomes. The role of the c-reactive protein to albumin ratio (CAR) as a predictor of poor prognosis in renal cell carcinoma (RCC) remains insufficiently recognized. METHODS: A literature search was conducted in major English-language databases, including PubMed, EMBASE, and the Cochrane Library, with the search updated to 25 June 2025. Both the odds ratio (OR) and diagnostic…
Rank106.6
A systematic review of the latest progress of drug resistance and clinical application of immunotherapy in renal cell carcinoma in the past five years based on bibliometrics.
Human vaccines & immunotherapeutics · 2025 · PMID 40667694
Renal cell carcinoma (RCC), an aggressive form of kidney cancer resistant to chemotherapy, encounters challenges from immunotherapy resistance and low response rates. Employing bibliometric tools (VOSviewer, CiteSpace, Bibliometrix), this study analyzed 2020-2024 research on RCC immunotherapy resistance, identifying prominent authors, journals, and trends. Guo Jianming, Wang Jiajun, and Wang Ying are prolific collaborators, whilst Moon, James J. leads in influence. Significant research emphasis PD-1 blockage, autop…
Rank106.5
Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis.
Frontiers in immunology · 2024 · PMID 39544934
BACKGROUND: Tertiary lymphoid structures (TLS) play a crucial role in tumor immunity, yet their relationship with the efficacy of immune checkpoint inhibitors (ICI) in cancer therapy is not fully understood. This study aims to systematically evaluate how TLS density influences treatment outcomes in cancer patients receiving ICI therapy. METHODS: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published before January 22, 2024. Our analysis encompassed odds ratio…
Rank106.3
Albumin-globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients.
Annals of medicine · 2025 · PMID 41283335
BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet the heterogeneity of treatment responses underscores the need for reliable prognostic biomarkers. The albumin-to-globulin ratio (AGR), an indicator of systemic inflammation and nutritional status, has emerged as a potential predictor of ICI outcomes. This study aimed to systematically evaluate the prognostic significance of AGR in patients receiving ICIs through a meta-analysis and to validate the findings in a single-centre cohort…
Rank104.5
Renal medullary carcinoma: a systematic review of clinical and radiological findings.
International urology and nephrology · 2026 · PMID 41954690
BACKGROUND AND AIMS: Renal medullary carcinoma (RMC) is a rare subtype of renal cell carcinoma, typically described in young patients with sickle cell trait, which follows an aggressive course. We aimed to perform a systematic review of all published cases of RMC from 1995 to 2024, to summarise the clinico-pathological and radiological features. METHODS: A systematic review of all published cases of RMC from 1995 to 2024 was performed. Patient demographics, clinical presentation, radiological features, metastatic p…
Rank100.0
Ultrasound Radiomics for Differential Diagnosis of Renal Masses: A Systematic Review and Meta-Analysis.
Technology in cancer research & treatment · 2026 · PMID 42640784
IntroductionGiven the importance of early renal cancer diagnosis and the limitations of conventional imaging assessment, ultrasound radiomics has emerged as a promising non-invasive technique for differentiating benign from malignant renal masses. This meta-analysis is aimed to assess the ability of ultrasound radiomics in differentiating benign and malignant renal masses.Materials and MethodsLiterature was systematically retrieved from the inception of the databases to April 27, 2025. Meta-analysis was conducted u…
Rank100.0
Circulating KIM-1 and survival outcomes in renal cell carcinoma: A systematic review and meta-analysis.
Urologic oncology · 2026 · PMID 42493401
BACKGROUND: Renal cell carcinoma (RCC) exhibits substantial clinical heterogeneity, and conventional clinicopathological models have limited ability to provide precise individualized risk stratification. Circulating kidney injury molecule-1 (KIM-1) is an emerging, minimally invasive biomarker with potential prognostic relevance in RCC. However, existing studies have reported inconsistent findings. This meta-analysis aimed to systematically synthesize current evidence and clarify the prognostic significance of circu…
Rank100.0
[Microbiome as a Novel Player in the Development and Treatment of Renal Cancer: A Systematic Review and Meta-Analysis].
Urologiia (Moscow, Russia : 1999) · 2026 · PMID 42687557
RELEVANCE: Growing evidence highlights the significant role of the human microbiota and microbiome in the pathogenesis of malignant tumors, including renal cell carcinoma (RCC). This systematic review evaluates studies addressing the associations between the microbiota/microbiome and the development and progression of RCC, as well as the influence of the microbiota on therapeutic efficacy in this malignancy. MATERIALS AND METHODS: The review was conducted in accordance with PRISMA guidelines. A systematic search of…
Rank100.0
The Local Effects of Systemic Therapies in Urological Oncology: A Systematic Review.
Cancer medicine · 2026 · PMID 42630020
BACKGROUND: Systemic therapies can impact local disease progression in genitourinary malignancies, potentially reducing the necessity for extensive surgery. Understanding these effects is crucial for optimizing treatment approaches in urologic oncology. METHODS: Through PubMed and Scopus databases search up to May 2026, we identified studies focusing on surgical outcomes after systemic therapy in prostate, kidney, testicular, and bladder cancers. RESULTS: In prostate cancer (PC), neoadjuvant hormonal therapy improv…
Rank100.0
A systematic review and meta-analysis of mortality and kidney function in uranium-exposed individuals.
Environmental research · 2024 · PMID 38242418
BACKGROUND: Humans are exposed to uranium (U) in a variety of applications. Both animal and observational human studies support an associated U nephrotoxicity. Few statistical syntheses of the human data have been performed and these analyses are limited in the types of exposures considered. OBJECTIVES: This study aims to evaluate the state of current evidence and to expand on existing meta-analyses by systematically evaluating kidney-associated causes of mortality in multiple U-exposed populations. This study also…
Rank100.0
Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group.
Cancer metastasis reviews · 2026 · PMID 42645539
Immune checkpoint inhibitor (ICI)-based combinations represent the standard first-line treatment for metastatic clear cell renal cell carcinoma (mRCC), although robust biomarkers for treatment selection remain undefined. We conducted a systematic review to identify biomarkers assessed in randomized clinical trials (RCTs) on first-line ICI-based regimens. Following PRISMA guidelines, we searched PubMed, Web of Science and Scopus (January 2018-October 2025) for phase III RCTs investigating first-line ICI-based therap…
Rank96.2
KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma.
European urology · 2026 · PMID 41934036
Kidney injury molecule 1 (KIM-1) is a promising biomarker in adjuvant clear cell renal cell carcinoma (ccRCC), but its relevance in advanced ccRCC or papillary RCC (pRCC) remains unclear. CALYPSO (NCT02819596) was a prospective, multi-arm trial that evaluated durvalumab alone or in combination with tremelimumab or savolitinib in metastatic ccRCC and pRCC. Circulating KIM-1 levels were measured at baseline and on-treatment. The primary endpoint was to explore if KIM-1 levels were raised in pRCC. Analyses were explor…
Rank96.0
Molecular mechanisms and therapeutic targets of traditional Chinese Medicine compounds in renal cell carcinoma: A comprehensive narrative review.
Journal of ethnopharmacology · 2026 · PMID 42276388
ETHNOPHARMACOLOGICAL RELEVANCE: Advanced renal cell carcinoma (RCC) often stops responding to targeted drugs, and those drugs can be toxic. Traditional Chinese Medicine (TCM) works differently: it hits many targets at once and tries to rebalance the whole body. That makes TCM a plausible add-on, not a replacement. AIM OF THE REVIEW: This review aims to comprehensively summarize and critically appraise the molecular mechanisms by which TCM components and formulas exert anti-RCC activities, focusing on key signaling …
Rank83.0
Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial.
International journal of radiation oncology, biology, physics · 2025 · PMID 40158734
PURPOSE: Stereotactic body radiation therapy (SBRT) is an advanced technique that enables precise delivery of radiation directly to a tumor, typically in ≤5 fractions. Single-fraction SBRT for visceral tumors is uncommon, likely related to concerns about risks of geographic tumor miss because of suboptimal cone beam computed tomography scan quality on conventional linear accelerators (linacs). Magnetic resonance (MR) guided linacs are a novel technology offering superior imaging that might facilitate the safe deliv…
Rank81.5
Immune Checkpoint Inhibitor-Associated Uveitis: Insights From Comparative Analyses Across Malignancies and Drug Classes.
American journal of ophthalmology · 2026 · PMID 42229563
PURPOSE: Understanding how the risk of immune checkpoint inhibitor (ICI)-associated noninfectious uveitis (NIU) differs by malignancy and drug class may help understand its pathophysiology and guide targeted ophthalmic surveillance. This study aims to evaluate the comparative risk of ICI-associated NIU across different malignancies and drug classes. DESIGN: Retrospective, multicenter clinical cohort study. SUBJECTS: Adults with metastatic melanoma, lung cancer, renal cell carcinoma (RCC), urothelial carcinoma, hepa…
Rank80.7
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42149133
PURPOSE: We investigated components of the immune tumor microenvironment as determinants of clinical outcome to anti-PD-1 therapy in patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with first-line nivolumab in the phase II, nonrandomized HCRN GU16-260 trial. EXPERIMENTAL DESIGN: Pretreatment primary ccRCCs from 72 patients were analyzed via multiplex immunofluorescence and image analysis to assess nonterminally exhausted CD8+ (CD8+PD-1+TIM-3-LAG-3-) tumor-infiltrating lymphocytes (TIL), PD-…
Rank80.0
Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study.
International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42179010
OBJECTIVES: Cabozantinib treatment is associated with improved survival in renal cell carcinoma (RCC) patients with bone metastasis. We evaluated the direct effects of cabozantinib on bone metastasis in advanced RCC (aRCC). METHODS: In this multicenter, open-label study, adult Japanese aRCC patients with bone metastasis received oral cabozantinib 60 mg once daily until drug discontinuation/data cut-off. The primary endpoint was the objective response rate (ORR) of bone target lesions (modified MD Anderson criteria)…
Rank79.4
Prognostic significance of systemic immunoinflammatory biomarkers and pathological features in clear cell renal cell carcinoma: a multicenter study.
Annals of medicine · 2026 · PMID 42669053
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) exhibits heterogeneous postoperative outcomes. This study aimed to evaluate systemic immunoinflammatory biomarkers and pathological features and develop an integrated prognostic model for overall survival (OS) in patients with ccRCC. METHODS: This multicenter retrospective study initially screened 1,662 patients who underwent surgery between January 2010 and December 2024. After excluding 27 patients with substantial missing data, 1,635 were included in baseline a…
Rank78.5
Radiomics analysis of CT imaging for predicting MIT family translocation renal cell carcinoma: a multicenter retrospective clinical study.
BMC cancer · 2026 · PMID 42323535
OBJECTIVE: This study aimed to investigate the imaging characteristics of Microphthalmia Transcription Factor (MIT) Family Translocation Renal Cell Carcinoma (MIT-RCC), assess the relationship between CT-based radiomics and MIT-RCC, and develop a predictive model to improve preoperative non-invasive diagnosis. MATERIALS AND METHODS: A retrospective analysis was conducted using preoperative computed tomography (CT) images and clinical data from 746 RCC patients (77 MIT-RCC and 669 other RCC subtypes) across multiple…
Rank77.8
MRI-based habitat radiomics for assessing synchronous metastatic risk in renal cell carcinoma: a multicenter study.
Abdominal radiology (New York) · 2026 · PMID 41711878
PURPOSE: To explore the role of MRI-based habitat radiomics in assessing the metastatic status of renal cell carcinoma (RCC). METHODS: This study retrospectively collected 241 patients with RCC who underwent nephrectomy and lymphadenectomy at four centers. MRI data from the first center were split into a training set (n = 150) and an internal test set (n = 38); data from the other centers (n = 53) were used for external testing. Based on corticomedullary-phase enhancement and T2WI signal intensity, primary lesions …
Evidence Syntheses74 records
Rank114.2
Performance of Machine Learning Models Based on Medical Imaging in Predicting Pathological Grade of Clear Cell Renal Cell Carcinoma.
Cancer medicine · 2026 · PMID 42693958
BACKGROUND: Predicting clear cell renal cell carcinoma (ccRCC) pathological grade preoperatively is critical for clinical management. This study aims to evaluate the diagnostic accuracy and clinical utility of machine learning (ML)-based imaging models. METHODS: The Cochrane Library, PubMed, Embase, and Scopus databases were searched systematically for studies published before January 2026. Study quality was assessed using the Quality Assessment of Diagnostic Accuracy Studies 2 and the Radiomics Quality Score. Pool…
Rank112.0
International Radiosurgery Oncology Consortium of the Kidney (IROCK) Contouring Guidelines for Renal Cell Carcinoma Treated With Stereotactic Ablative Radiation Therapy.
International journal of radiation oncology, biology, physics · 2026 · PMID 41580163
PURPOSE: Stereotactic ablative body radiation therapy (SABR) is an emerging indication for localized renal cell carcinoma (RCC), yet there is a need for standardizing contouring practices, as accurate target delineation is essential to ensure optimal outcomes. Our objective was to develop consensus guidelines for target volume contouring for RCC SABR. METHODS AND MATERIALS: An international panel of RCC SABR experts affiliated with IROCK was convened. All were asked to contour target volumes for 4 relevant clinical…
Rank111.1
Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review.
Targeted oncology · 2026 · PMID 42218357
BACKGROUND: Immune checkpoint inhibitor (ICI)-based regimens are the standard first-line therapy for advanced renal cell carcinoma (RCC). However, their comparative effectiveness and safety in routine clinical practice remain incompletely characterised. OBJECTIVE: The aim of this study was to systematically synthesise comparative real-world evidence on the efficacy and safety of ICI-based regimens in patients with advanced RCC. METHODS: A systematic search of MEDLINE, Embase, and Scopus was conducted from database …
Rank110.0
What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.
World journal of urology · 2026 · PMID 42373875
BACKGROUND AND OBJECTIVE: Renal cell carcinoma (RCC) is a common manifestation in Von-Hippel Lindau (VHL) syndrome, accounting for almost 30% of the patients. However, since VHL syndrome is relatively rare, there are no clear guidelines regarding the approach to VHL patients with RCC. This article aims to provide evidence-based insights for diagnosis, treatment, and surveillance in VHL patients with RCC. METHODS: The articles indexed between 1977 and 2025 in PubMed was searched. Only articles in English were includ…
Rank110.0
The impact of social determinants of health on access to partial nephrectomy, minimally invasive surgery, and robotic-assisted approaches for renal cell carcinoma.
World journal of urology · 2026 · PMID 42611330
PURPOSE: Social determinants of health (SDOH), including race/ethnicity, socioeconomic status (SES), insurance coverage, and geographic location, are established drivers of disparities in surgical access and outcomes. Robotic-assisted partial nephrectomy (RAPN) has become the preferred minimally invasive approach for localized renal cell carcinoma (RCC), yet the extent to which SDOH influence access to partial nephrectomy, minimally invasive surgery, and RAPN specifically, as well as postoperative outcomes has not …
Rank109.2
Comparative outcomes of robot-assisted and open radical nephrectomy with inferior vena cava thrombectomy for renal cell carcinoma: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42624966
For patients with renal cell carcinoma (RCC) complicated by inferior vena cava (IVC) tumor thrombus, radical nephrectomy combined with thrombectomy remains a key surgical option. Open radical nephrectomy with IVC thrombectomy (O-RNTT) has long been regarded as the traditional operative strategy, whereas robot-assisted radical nephrectomy with IVC thrombectomy (R-RNTT) is now being used more frequently in high-experience centers. Direct comparative data, however, remain limited. This study aimed to compare periopera…
Rank109.1
Partial versus radical nephrectomy for pT3a renal cell carcinoma: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42010212
The surgical management of pathologic T3a (pT3a) renal cell carcinoma (RCC) remains contentious due to the lack of high-level evidence guiding the choice between partial nephrectomy (PN) and radical nephrectomy (RN). This systematic review and meta-analysis aims to evaluate whether PN represents a safe and effective alternative to RN. A comprehensive search of PubMed, Web of Science, and Scopus was conducted through July 2025. The study included comparative trials of adult pT3a RCC patients undergoing PN or RN, foc…
Rank109.1
Machine Learning for Predicting Ki-67 Expression in Renal Tumors: A Systematic Review And Meta-Analysis.
Academic radiology · 2026 · PMID 42443009
RATIONALE AND OBJECTIVES: To systematically evaluate the diagnostic performance of machine learning (ML) models for predicting Ki-67 expression in renal tumors and assess their potential for clinical translation. MATERIALS AND METHODS: We systematically searched PubMed, Web of Science, Cochrane Library, and Embase up to November 2025. Studies using ML to predict Ki-67 with immunohistochemistry as reference standard were included. Quality was assessed with QUADAS-2. A bivariate random-effects model pooled diagnostic…
Rank109.1
Efficacy and safety of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: a risk-stratified systematic review and meta-analysis.
Frontiers in immunology · 2026 · PMID 42220544
BACKGROUND: This systematic review and meta-analysis consolidates findings from recent randomized controlled trials (RCTs) on the efficacy of first-line immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI-TKI) combination therapy for metastatic renal cell carcinoma (mRCC). We also explored prognostic biomarkers and clinical factors to inform treatment strategies. METHODS: We conducted a systematic search of PubMed, Embase, the Cochrane Library, Web of Science, and major conference proceedings for RCTs p…
Rank108.7
Age-Related Survival Disparities in Advanced Renal Carcinoma in the Immune Checkpoint Inhibitor Era using the SEER Database and Meta-analysis.
Scientific reports · 2025 · PMID 41339655
Immunosenescence, the gradual deterioration of the immune system with age, reduces the efficacy of immune checkpoint inhibitors (ICI) in cancer management. Although ICI offer promising survival benefits for advanced renal cell carcinoma (aRCC), their effectiveness across different age groups remains poorly understood. This study aimed to evaluate age-related survival outcomes in aRCC patients receiving ICI using integrated cohorts. Using data from the Surveillance, Epidemiology, and End Results (SEER) program (2004…
Rank108.3
Single-port versus multi-port robot-assisted partial nephrectomy for predominantly low-complexity renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42634038
Single-port robot-assisted partial nephrectomy (SP-RAPN) is increasingly used for selected renal tumors, but its comparative value over multi-port robot-assisted partial nephrectomy (MP-RAPN) remains uncertain. We performed a systematic review and meta-analysis of comparative studies, prioritizing propensity score-matched data when available. PubMed, Scopus, Web of Science, and Google Scholar were searched. Three studies involving 442 patients were included (210 SP-RAPN and 232 MP-RAPN). SP-RAPN was associated with…
Rank108.0
Disease-free survival as a surrogate outcome for localized kidney cancer-A systematic review and meta-analysis.
Cancer · 2026 · PMID 42590929
BACKGROUND: Disease-free survival (DFS) is commonly used as a primary end point in trials for localized renal cell carcinoma (RCC), although its validity as a surrogate for overall survival (OS) remains uncertain. The objective of this study was to evaluate whether DFS is a reliable surrogate end point for OS in this setting. METHODS: The authors conducted a systematic review and trial-level meta-analysis of randomized controlled trials assessing systemic or perioperative therapies in patients with localized RCC. D…
Rank107.8
Prognostic and Clinical Significance of Circulating Cystatin C Levels in Cancer Patients: A Meta-Analysis.
Asian Pacific journal of cancer prevention : APJCP · 2026 · PMID 42345173
BACKGROUND: Cystatin C (CysC) exhibits both tumor-promoting and tumor-suppressing effects. Although elevated circulating CysC levels have been reported in multiple cancer types, studies assessing its prognostic value have produced conflicting results. This study aims to resolve these discrepancies and clarify the role of CysC as a prognostic marker. METHODS: A literature search was conducted in multiple databases. The pooled Hazard Ratio (HR) with a 95% confidence interval (CI) was calculated to assess the prognost…
Rank107.6
Robot-assisted versus laparoscopic partial nephrectomy for localized renal tumors: a systematic review and meta-analysis of oncological, perioperative, and renal functional outcomes.
Journal of robotic surgery · 2026 · PMID 42474798
To update the comparative evidence on robot-assisted partial nephrectomy (RAPN) and laparoscopic partial nephrectomy (LPN) for patients with cT1-cT2 renal tumors, with emphasis on cancer control, perioperative recovery, and postoperative kidney function. Four databases were queried for English-language comparative studies published between January 30, 2016 and March 1, 2026. Eligible reports enrolled adults with localized renal tumors treated with RAPN or LPN and provided extractable oncological, perioperative, or …
Rank107.6
Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis.
JAMA network open · 2026 · PMID 42084869
IMPORTANCE: Circadian rhythms affect immunity, which could affect the effectiveness of immune checkpoint inhibitor (ICI). Whether the time of ICI administration is associated with clinical outcomes in advanced cancers remains unclear. OBJECTIVE: To evaluate the association between time of day of ICI administration and oncologic outcomes in patients with advanced solid tumors. DATA SOURCES: MEDLINE (via PubMed), Embase, and Web of Science Core Collection were searched in February 2026 to identify eligible studies. S…
Rank107.6
Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis.
Medical oncology (Northwood, London, England) · 2026 · PMID 42484760
To update a network meta-analysis of first-line immunotherapy combinations in advanced renal cell carcinoma (RCC) using short-term data for primary analysis and long-term plus newly published randomized controlled trials (RCTs) for subgroup analyses. We searched PubMed, Embase, Web of Science, Cochrane Library, and Chinese databases for articles from inception to 22 December 2024, performing a Bayesian network meta-analysis. Overall survival (OS), progression-free survival (PFS), objective response rates (ORR), and…
Rank107.2
A Systematic Review and Meta-analysis of Oncological Outcomes of Treated and Untreated Complex Cystic Renal Masses.
European urology focus · 2026 · PMID 41309407
BACKGROUND AND OBJECTIVE: Complex cystic renal masses, classified using the Bosniak system, pose diagnostic and therapeutic challenges due to their variable malignant potential. This systematic review and meta-analysis aimed to assess oncological outcomes in patients with cystic renal masses managed with active surveillance (AS) or active treatment (AT), and to report transitions from AS to AT. METHODS: A systematic literature search was conducted in MEDLINE, Embase, and Cochrane Library up to October 2024, followi…
Rank107.2
Robot-Assisted versus Laparoscopic Radical Nephrectomy for High-Complexity Renal Tumors: A Multidisciplinary Systematic Review and Meta-Analysis.
La Clinica terapeutica · 2026 · PMID 42340793
BACKGROUND: Radical nephrectomy for high-complexity renal tumors, stage T2-T4, size ≥7 cm, and/or inferior vena cava (IVC) involvement, represents one of the most technically demanding procedures in urologic oncology. Robot-assisted radical nephrectomy (RARN) has expanded rapidly in adoption, yet its comparative benefit over laparoscopic radical nephrectomy (LRN) in the high-complexity subpopulation remains undefined. No systematic review has restricted analysis to T2-T4 disease or applied a multidisciplinary outco…
Rank107.1
Adjunctive topical hemostatic agents combined with renorrhaphy versus renorrhaphy alone during partial nephrectomy: a systematic review and meta-analysis.
World journal of urology · 2026 · PMID 42627530
PURPOSE: Partial nephrectomy (PN) is the standard of care for T1 renal tumors, offering oncological outcomes equivalent to radical nephrectomy while preserving renal function. Intraoperative hemostasis remains a critical challenge, as warm ischemia time is independently associated with postoperative renal functional decline. Topical hemostatic agents have been increasingly adopted as adjuncts to renorrhaphy; however, their incremental benefit over suture alone remains unestablished. This study aimed to compare the …
Rank107.0
Surgical Management of Nonmetastatic Renal Cell Carcinoma with Inferior Vena Cava Thrombus: A Systematic Review and Network Meta-analysis.
European urology oncology · 2026 · PMID 41644363
BACKGROUND AND OBJECTIVE: Inferior vena cava (IVC) tumor thrombus can impact the surgical management of locally advanced renal cell carcinoma (RCC). While open surgery remains the standard for complex thrombi, minimally invasive surgery (MIS) is increasingly adopted. The aim of this review was to compare perioperative outcomes across the different surgical approaches for IVC thrombectomy in nonmetastatic RCC. METHODS: We systematically searched the PubMed, Embase, Scopus, and Web of Science databases from inception…
Rank107.0
Circulating KIM-1 as a prognostic biomarker and predictor of systemic treatment response in renal cell carcinoma: a systematic review and meta-analysis.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2026 · PMID 42070237
BACKGROUND: Renal cell carcinoma (RCC) exhibits heterogeneity and variable responses to systemic therapy. Kidney injury molecule-1 (KIM-1) has emerged as a biomarker in RCC, but its prognostic and treatment-response value has not been quantified. This review and meta-analysis evaluated whether baseline KIM-1 predicts survival in RCC and whether post-treatment changes in KIM-1 reflect systemic therapy response. METHODS: A search of PubMed, Embase and the Cochrane Library was conducted through November 2025. Eligible…
Rank106.8
Percutaneous thermal ablation versus robot-assisted partial nephrectomy for localized renal cell carcinoma: a systematic review and meta-analysis stratified by tumor complexity.
Journal of robotic surgery · 2026 · PMID 42223755
Robot-assisted partial nephrectomy (RAPN) and percutaneous thermal ablation (PTA) are established treatment options for localized renal tumors. While RAPN remains the standard-of-care, PTA is increasingly adopted, particularly in patients unfit for surgery. Evidence on how tumor complexity influences comparative outcomes between these two approaches remains limited. We conducted a systematic review of major database up to December 2025 and meta-analysis. Studies directly comparing PTA and RAPN in patients with loca…
Rank106.8
Elevated C-reactive protein to albumin ratio is a promising predictive biomarker for prognosis in patients with renal cell carcinoma.
Annals of medicine · 2026 · PMID 41566198
BACKGROUND AND AIMS: Systemic inflammation is closely linked to the development and progression of various cancers, as well as poorer patient outcomes. The role of the c-reactive protein to albumin ratio (CAR) as a predictor of poor prognosis in renal cell carcinoma (RCC) remains insufficiently recognized. METHODS: A literature search was conducted in major English-language databases, including PubMed, EMBASE, and the Cochrane Library, with the search updated to 25 June 2025. Both the odds ratio (OR) and diagnostic…
Rank106.8
Emerging robotic platforms in partial nephrectomy: a comparative systematic review and network meta-analysis.
Journal of robotic surgery · 2026 · PMID 42162309
Robotic-assisted partial nephrectomy (RAPN) is the preferred minimally invasive nephron-sparing technique, with outcomes comparable to open and laparoscopic surgery. While most evidence derives from the da Vinci system, newer robotic platforms such as Hugo, Hinotori, KangDuo and MP1000 are emerging. This systematic review and network meta-analysis evaluated perioperative outcomes across available RAPN platforms. A systematic search of PubMed, Cochrane Library, CINAHL, and Scopus identified studies reporting RAPN ou…
Rank106.7
First-Line Anti-PD-1 Immunotherapy With Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: A Meta-Analysis by PD-1 Subtype.
Urology practice · 2026 · PMID 41439745
INTRODUCTION: Immune checkpoint inhibitors targeting programmed death-1 (PD-1) in combination with tyrosine kinase inhibitors have reshaped the first-line treatment landscape of advanced renal cell carcinoma (RCC). However, the relative efficacy and safety of different PD-1-based regimens remain unclear. This meta-analysis aims to evaluate the efficacy and safety of first-line anti-PD-1-based combinations with tyrosine kinase inhibitors compared with sunitinib in metastatic RCC and to explore whether clinical outco…
Landmark Evidence46 records
Rank110.0
The impact of social determinants of health on access to partial nephrectomy, minimally invasive surgery, and robotic-assisted approaches for renal cell carcinoma.
World journal of urology · 2026 · PMID 42611330
PURPOSE: Social determinants of health (SDOH), including race/ethnicity, socioeconomic status (SES), insurance coverage, and geographic location, are established drivers of disparities in surgical access and outcomes. Robotic-assisted partial nephrectomy (RAPN) has become the preferred minimally invasive approach for localized renal cell carcinoma (RCC), yet the extent to which SDOH influence access to partial nephrectomy, minimally invasive surgery, and RAPN specifically, as well as postoperative outcomes has not …
Rank109.0
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update.
European urology · 2022 · PMID 35346519
CONTEXT: The European Association of Urology (EAU) Renal Cell Carcinoma (RCC) Guideline Panel has prepared evidence-based guidelines and recommendations for the management of RCC. OBJECTIVE: To present a summary of the 2022 RCC guideline, which is based on a standardised methodology including systematic reviews (SRs) and provides transparent and reliable evidence for the management of RCC. EVIDENCE ACQUISITION: For the 2022 update, a new literature search was carried out with a cutoff date of May 28, 2021, covering…
Rank108.7
Age-Related Survival Disparities in Advanced Renal Carcinoma in the Immune Checkpoint Inhibitor Era using the SEER Database and Meta-analysis.
Scientific reports · 2025 · PMID 41339655
Immunosenescence, the gradual deterioration of the immune system with age, reduces the efficacy of immune checkpoint inhibitors (ICI) in cancer management. Although ICI offer promising survival benefits for advanced renal cell carcinoma (aRCC), their effectiveness across different age groups remains poorly understood. This study aimed to evaluate age-related survival outcomes in aRCC patients receiving ICI using integrated cohorts. Using data from the Surveillance, Epidemiology, and End Results (SEER) program (2004…
Rank108.3
Single-port versus multi-port robot-assisted partial nephrectomy for predominantly low-complexity renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42634038
Single-port robot-assisted partial nephrectomy (SP-RAPN) is increasingly used for selected renal tumors, but its comparative value over multi-port robot-assisted partial nephrectomy (MP-RAPN) remains uncertain. We performed a systematic review and meta-analysis of comparative studies, prioritizing propensity score-matched data when available. PubMed, Scopus, Web of Science, and Google Scholar were searched. Three studies involving 442 patients were included (210 SP-RAPN and 232 MP-RAPN). SP-RAPN was associated with…
Rank107.9
Adjuvant therapy in renal cell carcinoma: Tyrosine kinase inhibitor versus immune checkpoint inhibitor.
Medicine · 2024 · PMID 39259118
BACKGROUND: To date, no meta-analysis has been conducted to compare the effectiveness and safety of adjuvant tyrosine kinase inhibitors (TKIs) and adjuvant immunotherapies (IMTs) in renal cell carcinoma (RCC) patients using reconstructed individual patient data (IPD). This study aims to fill that gap by assessing the efficacy and safety profiles of these treatments in such patients. METHODS: This study employed a systematic approach for identifying relevant literature from the PubMed and EMBASE databases. We includ…
Rank107.4
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis.
The Cochrane database of systematic reviews · 2023 · PMID 37146227
BACKGROUND: Since the approval of tyrosine kinase inhibitors, angiogenesis inhibitors and immune checkpoint inhibitors, the treatment landscape for advanced renal cell carcinoma (RCC) has changed fundamentally. Today, combined therapies from different drug categories have a firm place in a complex first-line therapy. Due to the large number of drugs available, it is necessary to identify the most effective therapies, whilst considering their side effects and impact on quality of life (QoL). OBJECTIVES: To evaluate …
Rank107.0
Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
Journal of the National Comprehensive Cancer Network : JNCCN · 2022 · PMID 34991070
The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor histology and risk stratification of patients is important in therapy selection. The NCCN Guidelines for Kidney Cancer stratify treatment recommendations by histology; recommendations for first-line treatment of ccRCC are also stratified by risk group. To further guide managem…
Rank106.7
Acquired Cystic Disease-Associated Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
Clinical genitourinary cancer · 2024 · PMID 38502982
Acquired cystic disease-associated renal cell carcinoma (ACD-RCC) is a common subtype of renal cell carcinoma (RCC) in end-stage renal disease (ESRD) patients. The current systematic review and meta-analysis was performed to evaluate the clinicopathological, and genetic characteristics of patients with ACD-RCC. A systematic search on three electronic databases including the Pubmed, Scopus, and Web of Science databases were performed until December 31, 2022. A meta-analysis was performed following the PRISMA 2020 Gu…
Rank106.5
Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis.
Frontiers in immunology · 2024 · PMID 39544934
BACKGROUND: Tertiary lymphoid structures (TLS) play a crucial role in tumor immunity, yet their relationship with the efficacy of immune checkpoint inhibitors (ICI) in cancer therapy is not fully understood. This study aims to systematically evaluate how TLS density influences treatment outcomes in cancer patients receiving ICI therapy. METHODS: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published before January 22, 2024. Our analysis encompassed odds ratio…
Rank106.2
Renal cell carcinoma detection: a systematic review in diagnostic urinary biomarkers.
BMC cancer · 2025 · PMID 41168704
BACKGROUND: Renal cell carcinoma (RCC) accounts for 90% of all renal neoplasms and is often incidentally detected through unrelated imaging procedures. Differentiating between benign and malignant renal masses remains challenging using imaging alone. Urinary biomarkers may aid in this distinction, yet none are currently implemented in the clinic. Moreover, a comprehensive overview of urinary diagnostic biomarkers for RCC is lacking. Therefore, we aimed to systematically review and summarize existing literature on p…
Rank104.1
Meta-analysis of perioperative immunotherapy in renal cell carcinoma: Available, but the jury is still out.
Urologic oncology · 2023 · PMID 37331822
INTRODUCTION: While surgical management of renal cell carcinoma (RCC) is curative for many patients, others may relapse and could benefit from adjuvant treatments. Immune checkpoint inhibitors (ICI) have been proposed as a potential adjuvant therapy for improving survival in these patients, but the benefit/risk ratio of ICI in the perioperative setting remains unclear. METHODS: A systematic review and a meta-analysis of phase III trials of perioperative ICI (anti PD1/PD-L1 alone or in combination with anti-CTLA4 ag…
Rank103.0
2017 AUA Renal Mass and Localized Renal Cancer Guidelines: Imaging Implications.
Radiographics : a review publication of the Radiological Society of North America, Inc · 2018 · PMID 30339517
Renal cell carcinoma (RCC) is a common cancer that is increasing in incidence because of the increased prevalence of risk factors, including tobacco use, hypertension, and obesity, and the improved detection of these tumors due to increased use of imaging. Localized renal cancer now accounts for more than 60%-70% of new RCC cases. Renal masses suggestive of cancer include enhancing solid renal lesions and Bosniak III and IV complex cystic lesions. Most of these tumors are detected incidentally, and many are slow gr…
Rank103.0
NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.
Journal of the National Comprehensive Cancer Network : JNCCN · 2020 · PMID 32886895
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also discuss the addition of a new section to the guidelines that identifies and describes the most common hereditary RCC syndromes and provides recommendations for…
Rank102.7
Genomics of Clear-cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis.
European urology · 2022 · PMID 34991918
CONTEXT: Although antiangiogenic treatments and immunotherapies have significantly improved the prognosis of metastatic renal cell carcinoma (RCC), many patients will develop resistance, leading to treatment failure. Genetic tumor heterogeneity is a major cause of this resistance. OBJECTIVE: To perform a meta-analysis of genomic data for clear-cell RCC obtained from primary tumors and metastases to assess the prevalence of gene mutations and copy number alterations (CNAs). EVIDENCE ACQUISITION: Articles were select…
Rank102.0
First-line immunotherapy of metastatic renal cell carcinoma: an updated network meta-analysis including triplet therapy.
BJU international · 2024 · PMID 38659099
OBJECTIVE: To compare the differential efficacy of first-line immune checkpoint inhibitor (ICI)-based combined therapies among patients with intermediate- and poor-risk metastatic renal cell carcinoma (mRCC), as recently, the efficacy of triplet therapy comprising nivolumab plus ipilimumab plus cabozantinib has been published. PATIENTS AND METHODS: Three databases were searched in December 2022 for randomised controlled trials (RCTs) analysing oncological outcomes in patients with mRCC treated with first-line ICI-b…
Rank101.8
EAU guidelines on renal cell carcinoma: 2014 update.
European urology · 2015 · PMID 25616710
CONTEXT: The European Association of Urology Guideline Panel for Renal Cell Carcinoma (RCC) has prepared evidence-based guidelines and recommendations for RCC management. OBJECTIVES: To provide an update of the 2010 RCC guideline based on a standardised methodology that is robust, transparent, reproducible, and reliable. EVIDENCE ACQUISITION: For the 2014 update, the panel prioritised the following topics: percutaneous biopsy of renal masses, treatment of localised RCC (including surgical and nonsurgical management…
Rank101.7
Trans-arterial embolization of renal cell carcinoma: a systematic review and meta-analysis.
Abdominal radiology (New York) · 2022 · PMID 35380246
PURPOSE: To evaluate if trans-arterial embolization (TAE) of the primary tumor in patients with renal cell carcinoma (RCC) improves symptomatology such as pain and hematuria or oncologic outcomes such as progression-free survival (PFS) and overall survival (OS). MATERIALS AND METHODS: The systematic review search included PubMed, Ovid/MEDLINE, and Embase for full-text English articles including randomized and non-randomized prospective trials as well as prospective and retrospective case series. To be included, pro…
Rank101.7
Robot-assisted Radical Nephrectomy: A Systematic Review and Meta-analysis of Comparative Studies.
European urology · 2021 · PMID 33218826
CONTEXT: Radical nephrectomy (RN) is the gold standard treatment for large and locally advanced renal tumors. Although robot-assisted radical nephrectomy (RRN) is being increasingly adopted, it remains unclear whether it offers benefits over standard laparoscopic radical nephrectomy (LRN) or open radical nephrectomy (ORN). OBJECTIVE: To compare the outcomes of robotic surgery to those of laparoscopic and open surgery in patients undergoing RN for renal cell carcinoma (RCC). EVIDENCE ACQUISITION: A systematic search…
Rank100.3
PTEN in kidney cancer: A review and meta-analysis.
Clinica chimica acta; international journal of clinical chemistry · 2018 · PMID 29408173
BACKGROUND: Kidney cancer is one of the most common cancers in the USA causing 14,400 deaths per year. The phosphatase and tensin homolog (PTEN) has been extensively documented as a tumor suppresser gene in cancer. However, there is unclear evidence for its clinicopathological and prognostic role in kidney cancer. METHODS: A systematic review of literature assessing PTEN expression and clinical outcome in patients with kidney cancer. Web of Science, PubMed, Embase, and Chinese databases were searched for collecting…
Rank100.0
Quality Indicators for Renal Cancer Care: A Systematic Review.
European urology oncology · 2025 · PMID 40483206
BACKGROUND AND OBJECTIVE: Quality indicators (QIs) are crucial for evaluating health care delivery, including effectiveness, safety, and patient-centered outcomes. In contrast to other fields, the definition and implementation of QIs for renal cell carcinoma (RCC) present distinct challenges and remain unmet needs. We summarized the available data on QIs for RCC, focusing on their characterization throughout the care pathway and the potential areas for further development. METHODS: A systematic review of the Englis…
Rank100.0
Genetic landscape and functional exploration of kidney cancer predisposition in cross-ancestral populations.
Nature communications · 2026 · PMID 42000752
Renal cell carcinoma (RCC) is the most common type of kidney cancer, but its genetic architecture has not been fully characterized, particularly in Asian populations. Here, we perform a multi-ancestry meta-analysis of 33,712 RCC cases and 845,786 controls, including individuals of East Asian (5,313 cases and 96,912 controls), European (25,890 cases and 743,585 controls), African American (897 cases and 3,109 controls), and Latin American ancestry (1,612 cases and 2,180 controls), which unveils 10 novel RCC-associat…
Rank100.0
Environmental Nonessential Element Exposure and Urologic Cancer: A Systematic Review and Meta-Analysis.
JAMA network open · 2026 · PMID 42172026
IMPORTANCE: Urologic cancers have been linked to nonessential chemical elements with no known beneficial role in the body, though associations between low-level environmental exposure and urologic cancer risk are poorly understood. OBJECTIVE: To systematically synthesize epidemiologic evidence on the association between environmental exposure to nonessential elements and risk of urologic cancers. DATA SOURCES: English- and Chinese-language databases, including PubMed, Embase, Web of Science, Scopus, Cumulated Index…
Rank100.0
Ultrasound Radiomics for Differential Diagnosis of Renal Masses: A Systematic Review and Meta-Analysis.
Technology in cancer research & treatment · 2026 · PMID 42640784
IntroductionGiven the importance of early renal cancer diagnosis and the limitations of conventional imaging assessment, ultrasound radiomics has emerged as a promising non-invasive technique for differentiating benign from malignant renal masses. This meta-analysis is aimed to assess the ability of ultrasound radiomics in differentiating benign and malignant renal masses.Materials and MethodsLiterature was systematically retrieved from the inception of the databases to April 27, 2025. Meta-analysis was conducted u…
Rank100.0
Antibiotic exposure and cancer risk: an umbrella review elucidating the direction of risk across 14 malignancies.
Journal of public health (Oxford, England) · 2026 · PMID 42361054
BACKGROUND: Antibiotics are among the most frequently prescribed medications worldwide. However, previous studies have yielded inconsistent findings regarding the association between antibiotic exposure and the risk of various cancers, and the credibility of the available evidence remains uncertain. METHODS: We conducted an umbrella review based on published meta-analyses and systematic reviews to evaluate the association between past or current antibiotic exposure and cancer risk. PubMed, Embase, Cochrane Library,…
Rank100.0
Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions.
Nature genetics · 2024 · PMID 38671320
Here, in a multi-ancestry genome-wide association study meta-analysis of kidney cancer (29,020 cases and 835,670 controls), we identified 63 susceptibility regions (50 novel) containing 108 independent risk loci. In analyses stratified by subtype, 52 regions (78 loci) were associated with clear cell renal cell carcinoma (RCC) and 6 regions (7 loci) with papillary RCC. Notably, we report a variant common in African ancestry individuals ( rs7629500 ) in the 3' untranslated region of VHL, nearly tripling clear cell RC…
Most Effective Evidence Supported Treatments80 records
Rank111.1
Real-World Comparative Effectiveness and Safety of Immune Checkpoint Inhibitors in Advanced Renal Cell Carcinoma: A Systematic Review.
Targeted oncology · 2026 · PMID 42218357
BACKGROUND: Immune checkpoint inhibitor (ICI)-based regimens are the standard first-line therapy for advanced renal cell carcinoma (RCC). However, their comparative effectiveness and safety in routine clinical practice remain incompletely characterised. OBJECTIVE: The aim of this study was to systematically synthesise comparative real-world evidence on the efficacy and safety of ICI-based regimens in patients with advanced RCC. METHODS: A systematic search of MEDLINE, Embase, and Scopus was conducted from database …
Rank110.0
The impact of social determinants of health on access to partial nephrectomy, minimally invasive surgery, and robotic-assisted approaches for renal cell carcinoma.
World journal of urology · 2026 · PMID 42611330
PURPOSE: Social determinants of health (SDOH), including race/ethnicity, socioeconomic status (SES), insurance coverage, and geographic location, are established drivers of disparities in surgical access and outcomes. Robotic-assisted partial nephrectomy (RAPN) has become the preferred minimally invasive approach for localized renal cell carcinoma (RCC), yet the extent to which SDOH influence access to partial nephrectomy, minimally invasive surgery, and RAPN specifically, as well as postoperative outcomes has not …
Rank110.0
What should the urologist know on the management of kidney cancer in patients with Von Hippel-Lindau syndrome? Recommendations of the European Association of Urology (EAU) Young Academic Urologists (YAU) Renal Cancer Working Group.
World journal of urology · 2026 · PMID 42373875
BACKGROUND AND OBJECTIVE: Renal cell carcinoma (RCC) is a common manifestation in Von-Hippel Lindau (VHL) syndrome, accounting for almost 30% of the patients. However, since VHL syndrome is relatively rare, there are no clear guidelines regarding the approach to VHL patients with RCC. This article aims to provide evidence-based insights for diagnosis, treatment, and surveillance in VHL patients with RCC. METHODS: The articles indexed between 1977 and 2025 in PubMed was searched. Only articles in English were includ…
Rank109.2
Comparative outcomes of robot-assisted and open radical nephrectomy with inferior vena cava thrombectomy for renal cell carcinoma: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42624966
For patients with renal cell carcinoma (RCC) complicated by inferior vena cava (IVC) tumor thrombus, radical nephrectomy combined with thrombectomy remains a key surgical option. Open radical nephrectomy with IVC thrombectomy (O-RNTT) has long been regarded as the traditional operative strategy, whereas robot-assisted radical nephrectomy with IVC thrombectomy (R-RNTT) is now being used more frequently in high-experience centers. Direct comparative data, however, remain limited. This study aimed to compare periopera…
Rank108.7
Age-Related Survival Disparities in Advanced Renal Carcinoma in the Immune Checkpoint Inhibitor Era using the SEER Database and Meta-analysis.
Scientific reports · 2025 · PMID 41339655
Immunosenescence, the gradual deterioration of the immune system with age, reduces the efficacy of immune checkpoint inhibitors (ICI) in cancer management. Although ICI offer promising survival benefits for advanced renal cell carcinoma (aRCC), their effectiveness across different age groups remains poorly understood. This study aimed to evaluate age-related survival outcomes in aRCC patients receiving ICI using integrated cohorts. Using data from the Surveillance, Epidemiology, and End Results (SEER) program (2004…
Rank108.3
Single-port versus multi-port robot-assisted partial nephrectomy for predominantly low-complexity renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42634038
Single-port robot-assisted partial nephrectomy (SP-RAPN) is increasingly used for selected renal tumors, but its comparative value over multi-port robot-assisted partial nephrectomy (MP-RAPN) remains uncertain. We performed a systematic review and meta-analysis of comparative studies, prioritizing propensity score-matched data when available. PubMed, Scopus, Web of Science, and Google Scholar were searched. Three studies involving 442 patients were included (210 SP-RAPN and 232 MP-RAPN). SP-RAPN was associated with…
Rank108.0
Disease-free survival as a surrogate outcome for localized kidney cancer-A systematic review and meta-analysis.
Cancer · 2026 · PMID 42590929
BACKGROUND: Disease-free survival (DFS) is commonly used as a primary end point in trials for localized renal cell carcinoma (RCC), although its validity as a surrogate for overall survival (OS) remains uncertain. The objective of this study was to evaluate whether DFS is a reliable surrogate end point for OS in this setting. METHODS: The authors conducted a systematic review and trial-level meta-analysis of randomized controlled trials assessing systemic or perioperative therapies in patients with localized RCC. D…
Rank107.6
Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis.
JAMA network open · 2026 · PMID 42084869
IMPORTANCE: Circadian rhythms affect immunity, which could affect the effectiveness of immune checkpoint inhibitor (ICI). Whether the time of ICI administration is associated with clinical outcomes in advanced cancers remains unclear. OBJECTIVE: To evaluate the association between time of day of ICI administration and oncologic outcomes in patients with advanced solid tumors. DATA SOURCES: MEDLINE (via PubMed), Embase, and Web of Science Core Collection were searched in February 2026 to identify eligible studies. S…
Rank107.6
Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis.
Medical oncology (Northwood, London, England) · 2026 · PMID 42484760
To update a network meta-analysis of first-line immunotherapy combinations in advanced renal cell carcinoma (RCC) using short-term data for primary analysis and long-term plus newly published randomized controlled trials (RCTs) for subgroup analyses. We searched PubMed, Embase, Web of Science, Cochrane Library, and Chinese databases for articles from inception to 22 December 2024, performing a Bayesian network meta-analysis. Overall survival (OS), progression-free survival (PFS), objective response rates (ORR), and…
Rank107.6
Robot-assisted versus laparoscopic partial nephrectomy for localized renal tumors: a systematic review and meta-analysis of oncological, perioperative, and renal functional outcomes.
Journal of robotic surgery · 2026 · PMID 42474798
To update the comparative evidence on robot-assisted partial nephrectomy (RAPN) and laparoscopic partial nephrectomy (LPN) for patients with cT1-cT2 renal tumors, with emphasis on cancer control, perioperative recovery, and postoperative kidney function. Four databases were queried for English-language comparative studies published between January 30, 2016 and March 1, 2026. Eligible reports enrolled adults with localized renal tumors treated with RAPN or LPN and provided extractable oncological, perioperative, or …
Rank107.2
Robot-Assisted versus Laparoscopic Radical Nephrectomy for High-Complexity Renal Tumors: A Multidisciplinary Systematic Review and Meta-Analysis.
La Clinica terapeutica · 2026 · PMID 42340793
BACKGROUND: Radical nephrectomy for high-complexity renal tumors, stage T2-T4, size ≥7 cm, and/or inferior vena cava (IVC) involvement, represents one of the most technically demanding procedures in urologic oncology. Robot-assisted radical nephrectomy (RARN) has expanded rapidly in adoption, yet its comparative benefit over laparoscopic radical nephrectomy (LRN) in the high-complexity subpopulation remains undefined. No systematic review has restricted analysis to T2-T4 disease or applied a multidisciplinary outco…
Rank107.1
Adjunctive topical hemostatic agents combined with renorrhaphy versus renorrhaphy alone during partial nephrectomy: a systematic review and meta-analysis.
World journal of urology · 2026 · PMID 42627530
PURPOSE: Partial nephrectomy (PN) is the standard of care for T1 renal tumors, offering oncological outcomes equivalent to radical nephrectomy while preserving renal function. Intraoperative hemostasis remains a critical challenge, as warm ischemia time is independently associated with postoperative renal functional decline. Topical hemostatic agents have been increasingly adopted as adjuncts to renorrhaphy; however, their incremental benefit over suture alone remains unestablished. This study aimed to compare the …
Rank107.0
Circulating KIM-1 as a prognostic biomarker and predictor of systemic treatment response in renal cell carcinoma: a systematic review and meta-analysis.
Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals · 2026 · PMID 42070237
BACKGROUND: Renal cell carcinoma (RCC) exhibits heterogeneity and variable responses to systemic therapy. Kidney injury molecule-1 (KIM-1) has emerged as a biomarker in RCC, but its prognostic and treatment-response value has not been quantified. This review and meta-analysis evaluated whether baseline KIM-1 predicts survival in RCC and whether post-treatment changes in KIM-1 reflect systemic therapy response. METHODS: A search of PubMed, Embase and the Cochrane Library was conducted through November 2025. Eligible…
Rank106.8
Percutaneous thermal ablation versus robot-assisted partial nephrectomy for localized renal cell carcinoma: a systematic review and meta-analysis stratified by tumor complexity.
Journal of robotic surgery · 2026 · PMID 42223755
Robot-assisted partial nephrectomy (RAPN) and percutaneous thermal ablation (PTA) are established treatment options for localized renal tumors. While RAPN remains the standard-of-care, PTA is increasingly adopted, particularly in patients unfit for surgery. Evidence on how tumor complexity influences comparative outcomes between these two approaches remains limited. We conducted a systematic review of major database up to December 2025 and meta-analysis. Studies directly comparing PTA and RAPN in patients with loca…
Rank106.6
A systematic review of the latest progress of drug resistance and clinical application of immunotherapy in renal cell carcinoma in the past five years based on bibliometrics.
Human vaccines & immunotherapeutics · 2025 · PMID 40667694
Renal cell carcinoma (RCC), an aggressive form of kidney cancer resistant to chemotherapy, encounters challenges from immunotherapy resistance and low response rates. Employing bibliometric tools (VOSviewer, CiteSpace, Bibliometrix), this study analyzed 2020-2024 research on RCC immunotherapy resistance, identifying prominent authors, journals, and trends. Guo Jianming, Wang Jiajun, and Wang Ying are prolific collaborators, whilst Moon, James J. leads in influence. Significant research emphasis PD-1 blockage, autop…
Rank106.6
Salvage therapies for local recurrence of renal cell carcinoma: a systematic review and meta-analysis.
World journal of urology · 2026 · PMID 42604476
BACKGROUND: We aimed to systematically summarize data on efficacy of local salvage therapies for local recurrence of renal cell carcinoma (RCC). METHODS: We searched MEDLINE, Embase, Web of Science, CENTRAL, and Google Scholar through 05/08/2026, for studies on local salvage therapies for local recurrence of RCC following radical nephrectomy, partial nephrectomy, or ablation (PROSPERO: CRD42024623099). Meta-analyses were conducted using random-effects models. Risk of bias (RoB) was assessed using ROBINS-I. RESULTS:…
Rank106.6
Selective P2X3 versus dual P2X2/3 receptor antagonists in refractory chronic cough: a systematic review and dose-response meta-analysis of randomized controlled trials.
Purinergic signalling · 2026 · PMID 42319606
Extracellular adenosine triphosphate (ATP)-mediated purinergic signalling via P2X3 and heteromeric P2X2/3 ion channel receptors underlies hypersensitisation of vagal airway afferents in refractory chronic cough (RCC), making this pathway a key therapeutic target. Two pharmacological strategies have emerged: dual P2X2/3 receptor antagonism and selective P2X3 inhibition. While dual antagonists (gefapixant) demonstrate robust antitussive efficacy, their clinical use is limited by taste disturbance resulting from P2X2/…
Rank106.5
Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis.
Frontiers in immunology · 2024 · PMID 39544934
BACKGROUND: Tertiary lymphoid structures (TLS) play a crucial role in tumor immunity, yet their relationship with the efficacy of immune checkpoint inhibitors (ICI) in cancer therapy is not fully understood. This study aims to systematically evaluate how TLS density influences treatment outcomes in cancer patients receiving ICI therapy. METHODS: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published before January 22, 2024. Our analysis encompassed odds ratio…
Rank106.4
Prognostic role of preoperative plasma fibrinogen-to-albumin ratio in urological carcinomas: a systematic review and meta-analysis.
BMC urology · 2026 · PMID 42310688
BACKGROUND: Growing evidence indicates that the pre-operative ratio of fibrinogen to albumin (FAR/AFR) can act as a prognostic predictor for different kinds of cancer. Although a previous meta-analysis briefly involved urological malignancies, it only incorporated one study for bladder cancer (BC) and one for renal cell carcinoma (RCC) with limited data. To date, a comprehensive and systematic quantitative assessment of plasma FAR/AFR as a prognostic indicator in urological cancers remains lacking. OBJECTIVE: This …
Rank106.3
Albumin-globulin ratio is a predictive biomarker of antitumour effect of immune checkpoint inhibitors in cancer patients.
Annals of medicine · 2025 · PMID 41283335
BACKGROUND: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet the heterogeneity of treatment responses underscores the need for reliable prognostic biomarkers. The albumin-to-globulin ratio (AGR), an indicator of systemic inflammation and nutritional status, has emerged as a potential predictor of ICI outcomes. This study aimed to systematically evaluate the prognostic significance of AGR in patients receiving ICIs through a meta-analysis and to validate the findings in a single-centre cohort…
Rank105.8
Sutureless versus renorrhaphy in robot-assisted off-clamp partial nephrectomy: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42704544
BACKGROUND: The necessity of routine parenchymal renorrhaphy during off-clamp robot-assisted partial nephrectomy (RAPN) remains uncertain. This study aimed to compare perioperative, functional, safety, and oncological outcomes between sutureless and conventional renorrhaphy. METHODS: We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines. Comparative studies evaluating sutureless versus conventional renorrhaphy during purely off-clamp RAPN were included. Trifecta achievement was the pri…
Rank105.4
Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.
Clinical genitourinary cancer · 2026 · PMID 42350220
Immune checkpoint inhibitor (ICI)-based combination therapies have transformed the management of metastatic renal cell carcinoma (mRCC). However, their benefit in International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) favorable-risk disease remains uncertain, raising concerns about potential overtreatment. We conducted a meta-analysis incorporating extended follow-up survival data to evaluate the long-term benefits of ICI-based combinations in this subgroup. PubMed, EMBASE, Web of Science, and the…
Rank105.2
Transperitoneal versus retroperitoneal single-port robot-assisted partial nephrectomy: systematic review and meta-analysis of perioperative and functional outcomes.
Journal of robotic surgery · 2026 · PMID 42474829
To systematically compare the safety and efficacy of the transperitoneal (TP) and retroperitoneal (RP) approaches in single-port robot-assisted partial nephrectomy (SP-RAPN). PubMed, Web of Science, and Embase were searched for comparative studies published before October 2025. The primary evaluated outcomes were grouped as Perioperative Outcomes (operative time, blood loss, ischemia time, positive surgical margin, postoperative eGFR, and hospital stay) and Surgical Safety (complication rate). Study inclusion and e…
Rank105.1
A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma.
European urology oncology · 2026 · PMID 41241654
BACKGROUND AND OBJECTIVE: Radical nephroureterectomy is the standard of care for management of upper tract urothelial carcinoma (UTUC), but treatment-associated morbidity is not uncommon. Intracavitary therapy has emerged as a less invasive alternative for selected cases, particularly carcinoma in situ (CIS) and low-grade papillary tumors. We conducted a systematic review to evaluate the outcomes, recurrence rates, and adverse events associated with intracavitary therapy (immunotherapy or chemoablation) for UTUC. M…
Rank102.0
What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta-analysis of ocular immune-related adverse events.
Acta ophthalmologica · 2026 · PMID 41800487
PURPOSE: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune-related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI-associated DED and to evaluate factors contributing to variability across studies. METHODS: A systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in the International Prospective Register o…
New Research Last 24 Months116 records
Rank110.0
The impact of social determinants of health on access to partial nephrectomy, minimally invasive surgery, and robotic-assisted approaches for renal cell carcinoma.
World journal of urology · 2026 · PMID 42611330
PURPOSE: Social determinants of health (SDOH), including race/ethnicity, socioeconomic status (SES), insurance coverage, and geographic location, are established drivers of disparities in surgical access and outcomes. Robotic-assisted partial nephrectomy (RAPN) has become the preferred minimally invasive approach for localized renal cell carcinoma (RCC), yet the extent to which SDOH influence access to partial nephrectomy, minimally invasive surgery, and RAPN specifically, as well as postoperative outcomes has not …
Rank108.7
Age-Related Survival Disparities in Advanced Renal Carcinoma in the Immune Checkpoint Inhibitor Era using the SEER Database and Meta-analysis.
Scientific reports · 2025 · PMID 41339655
Immunosenescence, the gradual deterioration of the immune system with age, reduces the efficacy of immune checkpoint inhibitors (ICI) in cancer management. Although ICI offer promising survival benefits for advanced renal cell carcinoma (aRCC), their effectiveness across different age groups remains poorly understood. This study aimed to evaluate age-related survival outcomes in aRCC patients receiving ICI using integrated cohorts. Using data from the Surveillance, Epidemiology, and End Results (SEER) program (2004…
Rank108.3
Single-port versus multi-port robot-assisted partial nephrectomy for predominantly low-complexity renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42634038
Single-port robot-assisted partial nephrectomy (SP-RAPN) is increasingly used for selected renal tumors, but its comparative value over multi-port robot-assisted partial nephrectomy (MP-RAPN) remains uncertain. We performed a systematic review and meta-analysis of comparative studies, prioritizing propensity score-matched data when available. PubMed, Scopus, Web of Science, and Google Scholar were searched. Three studies involving 442 patients were included (210 SP-RAPN and 232 MP-RAPN). SP-RAPN was associated with…
Rank106.8
Elevated C-reactive protein to albumin ratio is a promising predictive biomarker for prognosis in patients with renal cell carcinoma.
Annals of medicine · 2026 · PMID 41566198
BACKGROUND AND AIMS: Systemic inflammation is closely linked to the development and progression of various cancers, as well as poorer patient outcomes. The role of the c-reactive protein to albumin ratio (CAR) as a predictor of poor prognosis in renal cell carcinoma (RCC) remains insufficiently recognized. METHODS: A literature search was conducted in major English-language databases, including PubMed, EMBASE, and the Cochrane Library, with the search updated to 25 June 2025. Both the odds ratio (OR) and diagnostic…
Rank106.5
Associations between tertiary lymphoid structure density and immune checkpoint inhibitor efficacy in solid tumors: systematic review and meta-analysis.
Frontiers in immunology · 2024 · PMID 39544934
BACKGROUND: Tertiary lymphoid structures (TLS) play a crucial role in tumor immunity, yet their relationship with the efficacy of immune checkpoint inhibitors (ICI) in cancer therapy is not fully understood. This study aims to systematically evaluate how TLS density influences treatment outcomes in cancer patients receiving ICI therapy. METHODS: The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for eligible studies published before January 22, 2024. Our analysis encompassed odds ratio…
Rank100.1
Belzutifan in Von Hippel-Lindau-associated Hemangioblastomas: A Systematic Review and Meta-analysis.
Journal of neurological surgery. Part B, Skull base · 2026 · PMID 42626756
INTRODUCTION: Belzutifan, a selective hypoxia-inducible factor 2 α inhibitor, was recently approved for treating renal cell carcinoma in patients with Von Hippel-Lindau (VHL) disease. Given the lack of effective systemic therapies for VHL-associated hemangioblastomas (HBs), we conducted a systematic review and meta-analysis to evaluate its efficacy in this patient population. METHODS: Scientific databases and clinical trial registries were systematically reviewed for studies evaluating belzutifan in VHL-associated …
Rank100.0
Environmental Nonessential Element Exposure and Urologic Cancer: A Systematic Review and Meta-Analysis.
JAMA network open · 2026 · PMID 42172026
IMPORTANCE: Urologic cancers have been linked to nonessential chemical elements with no known beneficial role in the body, though associations between low-level environmental exposure and urologic cancer risk are poorly understood. OBJECTIVE: To systematically synthesize epidemiologic evidence on the association between environmental exposure to nonessential elements and risk of urologic cancers. DATA SOURCES: English- and Chinese-language databases, including PubMed, Embase, Web of Science, Scopus, Cumulated Index…
Rank100.0
Antibiotic exposure and cancer risk: an umbrella review elucidating the direction of risk across 14 malignancies.
Journal of public health (Oxford, England) · 2026 · PMID 42361054
BACKGROUND: Antibiotics are among the most frequently prescribed medications worldwide. However, previous studies have yielded inconsistent findings regarding the association between antibiotic exposure and the risk of various cancers, and the credibility of the available evidence remains uncertain. METHODS: We conducted an umbrella review based on published meta-analyses and systematic reviews to evaluate the association between past or current antibiotic exposure and cancer risk. PubMed, Embase, Cochrane Library,…
Rank100.0
Ultrasound Radiomics for Differential Diagnosis of Renal Masses: A Systematic Review and Meta-Analysis.
Technology in cancer research & treatment · 2026 · PMID 42640784
IntroductionGiven the importance of early renal cancer diagnosis and the limitations of conventional imaging assessment, ultrasound radiomics has emerged as a promising non-invasive technique for differentiating benign from malignant renal masses. This meta-analysis is aimed to assess the ability of ultrasound radiomics in differentiating benign and malignant renal masses.Materials and MethodsLiterature was systematically retrieved from the inception of the databases to April 27, 2025. Meta-analysis was conducted u…
Rank96.0
Molecular mechanisms and therapeutic targets of traditional Chinese Medicine compounds in renal cell carcinoma: A comprehensive narrative review.
Journal of ethnopharmacology · 2026 · PMID 42276388
ETHNOPHARMACOLOGICAL RELEVANCE: Advanced renal cell carcinoma (RCC) often stops responding to targeted drugs, and those drugs can be toxic. Traditional Chinese Medicine (TCM) works differently: it hits many targets at once and tries to rebalance the whole body. That makes TCM a plausible add-on, not a replacement. AIM OF THE REVIEW: This review aims to comprehensively summarize and critically appraise the molecular mechanisms by which TCM components and formulas exert anti-RCC activities, focusing on key signaling …
Rank89.7
Preliminary study on the efficacy of pazopanib combined with toripalimab as first-line therapy for metastatic renal cell carcinoma: Real-world data from a single center.
Oncology letters · 2026 · PMID 42597921
The present study aimed to explore the clinical efficacy and safety of pazopanib combined with toripalimab as first-line therapy for metastatic renal cell carcinoma (mRCC), providing a reference for clinical decision-making. In the present study, clinical data from 22 patients with mRCC who received pazopanib combined with toripalimab treatment at Shanxi Province Cancer Hospital (Taiyuan, China) were retrospectively collected. The objective response rate (ORR), disease control rate (DCR), progression-free survival …
Rank83.0
Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial.
International journal of radiation oncology, biology, physics · 2025 · PMID 40158734
PURPOSE: Stereotactic body radiation therapy (SBRT) is an advanced technique that enables precise delivery of radiation directly to a tumor, typically in ≤5 fractions. Single-fraction SBRT for visceral tumors is uncommon, likely related to concerns about risks of geographic tumor miss because of suboptimal cone beam computed tomography scan quality on conventional linear accelerators (linacs). Magnetic resonance (MR) guided linacs are a novel technology offering superior imaging that might facilitate the safe deliv…
Rank80.7
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42149133
PURPOSE: We investigated components of the immune tumor microenvironment as determinants of clinical outcome to anti-PD-1 therapy in patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with first-line nivolumab in the phase II, nonrandomized HCRN GU16-260 trial. EXPERIMENTAL DESIGN: Pretreatment primary ccRCCs from 72 patients were analyzed via multiplex immunofluorescence and image analysis to assess nonterminally exhausted CD8+ (CD8+PD-1+TIM-3-LAG-3-) tumor-infiltrating lymphocytes (TIL), PD-…
Rank80.0
Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study.
International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42179010
OBJECTIVES: Cabozantinib treatment is associated with improved survival in renal cell carcinoma (RCC) patients with bone metastasis. We evaluated the direct effects of cabozantinib on bone metastasis in advanced RCC (aRCC). METHODS: In this multicenter, open-label study, adult Japanese aRCC patients with bone metastasis received oral cabozantinib 60 mg once daily until drug discontinuation/data cut-off. The primary endpoint was the objective response rate (ORR) of bone target lesions (modified MD Anderson criteria)…
Rank79.4
Prognostic significance of systemic immunoinflammatory biomarkers and pathological features in clear cell renal cell carcinoma: a multicenter study.
Annals of medicine · 2026 · PMID 42669053
BACKGROUND: Clear cell renal cell carcinoma (ccRCC) exhibits heterogeneous postoperative outcomes. This study aimed to evaluate systemic immunoinflammatory biomarkers and pathological features and develop an integrated prognostic model for overall survival (OS) in patients with ccRCC. METHODS: This multicenter retrospective study initially screened 1,662 patients who underwent surgery between January 2010 and December 2024. After excluding 27 patients with substantial missing data, 1,635 were included in baseline a…
Rank78.5
Radiomics analysis of CT imaging for predicting MIT family translocation renal cell carcinoma: a multicenter retrospective clinical study.
BMC cancer · 2026 · PMID 42323535
OBJECTIVE: This study aimed to investigate the imaging characteristics of Microphthalmia Transcription Factor (MIT) Family Translocation Renal Cell Carcinoma (MIT-RCC), assess the relationship between CT-based radiomics and MIT-RCC, and develop a predictive model to improve preoperative non-invasive diagnosis. MATERIALS AND METHODS: A retrospective analysis was conducted using preoperative computed tomography (CT) images and clinical data from 746 RCC patients (77 MIT-RCC and 669 other RCC subtypes) across multiple…
Rank78.1
Baseline Risk of Treatment Abandonment and Survival of Children With Common and Curable Cancers in the Zero Abandonment Cash Transfer Programme-A Multi-Centre Prospective CANCaRe Africa Study.
Pediatric blood & cancer · 2026 · PMID 42578510
BACKGROUND: The WHO Global Initiative for Childhood Cancer (GICC) targets a global survival rate of 60% for childhood cancer, focusing initially on six common and curable cancers. This study assessed the risk of treatment abandonment (TxA) and the impact on survival of five of these cancers in sub-Saharan Africa in preparation for a cash transfer intervention. METHODS: This multi-centre, prospective, observational cohort study included newly diagnosed children (<16 years) with Burkitt lymphoma (BL), acute lymphobla…
Rank77.8
MRI-based habitat radiomics for assessing synchronous metastatic risk in renal cell carcinoma: a multicenter study.
Abdominal radiology (New York) · 2026 · PMID 41711878
PURPOSE: To explore the role of MRI-based habitat radiomics in assessing the metastatic status of renal cell carcinoma (RCC). METHODS: This study retrospectively collected 241 patients with RCC who underwent nephrectomy and lymphadenectomy at four centers. MRI data from the first center were split into a training set (n = 150) and an internal test set (n = 38); data from the other centers (n = 53) were used for external testing. Based on corticomedullary-phase enhancement and T2WI signal intensity, primary lesions …
Rank77.0
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma.
Melanoma research · 2026 · PMID 42070986
To assess the combination of high dose interleukin 2 (HD IL2) and nivolumab in patients with checkpoint inhibitor-refractory melanoma or renal cell carcinoma (RCC), we performed a single-arm, Simon two-stage phase II trial for patients with unresectable stage III or IV melanoma or any histology RCC. The primary endpoint was overall response rate (ORR); secondary endpoints were adverse events and progression-free survival (PFS), defined as time to radiographic or clinical progression, whichever occurred first. Five …
Rank76.6
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
Oncoimmunology · 2026 · PMID 42366526
Non-clear cell renal cell carcinoma (nccRCC) represents a biologically heterogeneous group of tumors for which optimal systemic treatment strategies remain poorly defined despite recent therapeutic advances. To address this gap, we evaluated the clinical activity and safety of cabozantinib plus nivolumab in patients with advanced nccRCC. In this nationwide, multicenter retrospective cohort study conducted in the Republic of Korea, 62 patients received the combination across multiple lines of therapy, with most trea…
Rank75.5
Prognostic outcomes of multifocal bilateral Wilms tumor: A Chinese multicenter cohort study.
Journal of pediatric urology · 2026 · PMID 42191506
BACKGROUND: Synchronous multifocal bilateral Wilms tumor (mBWT) is rare. This study aimed to evaluate long-term outcomes in children with mBWT and to identify treatment-related risk factors for renal impairment. METHODS: Patients with synchronous mBWT were identified from a multicenter retrospective cohort. Multifocal disease was defined radiologically as the presence of more than two discrete nodules, each measuring >1 cm in diameter, in one or both kidneys before neoadjuvant chemotherapy (NAC). Survival outcomes …
Rank75.2
Genetic variations in the base excision repair pathway and susceptibility to Wilms tumor in eastern Chinese children: a six-center case-control study.
Gene · 2026 · PMID 42462820
BACKGROUND: Wilms tumor (WT) is the most common embryonal kidney cancer in children, and the base excision repair (BER) mechanism is crucial for repairing DNA damage from reactive oxygen species. Genetic polymorphisms in BER genes may impact cancer risk by affecting DNA repair capacity. METHODS: The research included 416 individuals with WT and 936 without the condition, examining 20 single nucleotide polymorphisms (SNPs) in BER genes to determine their correlation with the risk of developing WT, utilizing odds rat…
Rank75.0
Ultra-processed food intake and risk of renal cell carcinoma in the NIH-AARP Diet and health study: a prospective cohort analysis.
Lancet regional health. Americas · 2026 · PMID 42404163
BACKGROUND: Ultra-processed foods (UPF) are widely consumed and have been linked to obesity and hypertension, risk factors of renal cell carcinoma (RCC) and the common clear cell (cc) RCC subtype. We evaluated the association between UPF and RCC. METHODS: In the NIH-AARP Diet and Health Study, a US prospective cohort, participants with no cancer history at baseline (October 1995-May 1996) were followed until the date of first cancer diagnosis, death, or end of follow-up (December 31, 2018). Diet was self-reported u…
Rank62.0
Single-port robotic partial nephrectomy with the Da Vinci SP platform: Feasibility and early outcomes from the first Spanish series.
Actas urologicas espanolas · 2026 · PMID 41935783
INTRODUCTION: Single-port robot-assisted partial nephrectomy (SP-RAPN) is an emerging minimally invasive technique that integrates all instruments through a single multichannel port. Despite its increasing international use, European experience remains limited and no prior clinical series have been reported in Spain. This study aims to assess the feasibility, perioperative safety, and early outcomes of SP-RAPN in the first Spanish institutional experience. MATERIALS AND METHODS: Prospective observational study incl…
Rank60.0
The Role of Large-Bore Mechanical Thrombectomy Devices in Tumor Thrombus.
Annals of vascular surgery · 2026 · PMID 42398810
BACKGROUND: Tumor thrombus presents specific challenges, with patients requiring thrombus removal for diagnosis, staging, symptom relief, or curative treatment; however, many patients are not offered intervention due to risks and low success rate of traditional options. In select patients open surgical thrombectomy remains the standard curative approach but carries significant morbidity. Large-bore mechanical thrombectomy devices may provide a minimally invasive alternative with potential diagnostic and therapeutic…
Preclinical Research66 records
Rank47.4
Impact of additive solutions on haematocrit measurement and red blood cell integrity: A comparative study of SAGM and PAGGSM.
Vox sanguinis · 2026 · PMID 42656168
BACKGROUND AND OBJECTIVES: Accurate haematocrit (Ht) measurement of red cell concentrates (RCCs) is critical because it is used to calculate the level of haemolysis, a key RCC quality control parameter. The hypothesis was that Ht depends on both the measurement method (microcapillary vs. haematology analysers) and the additive solution (hypertonic saline-adenine-glucose-mannitol [SAGM] vs. isotonic phosphate-adenine-glucose-guanosine-saline-mannitol [PAGGSM]). We quantified method- and solution-related effects on H…
Rank36.3
Ambient PM2.5 exposure is associated with clear cell renal cell carcinoma aggressiveness and promotes tumor progression through ROS-mediated AKT/HIF-2α signaling.
Chemico-biological interactions · 2026 · PMID 42456526
Ambient fine particulate matter (PM2.5) is an established environmental health hazard, but its role in clear cell renal cell carcinoma (ccRCC) progression remains incompletely understood. This study integrated epidemiological analysis, mechanistic experiments, transcriptomic profiling, and clinical tissue validation to investigate the association between ambient PM2.5 exposure and ccRCC aggressiveness. Among 1410 patients with pathologically confirmed ccRCC, long-term residential PM2.5 exposure during the 36 months…
Rank36.1
Association of SGLT2 Inhibitor Use with Clinical Outcomes in Patients Receiving Immune Checkpoint Inhibitors: A Pan-Tumor Propensity-Matched Analysis.
The oncologist · 2026 · PMID 42569919
BACKGROUND: Recently, sodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as a treatment option for type 2 diabetes mellitus (T2DM) and have also shown promising anti-tumor activity in preclinical models. Limited clinical data exist regarding the use of SGLT2i in patients with metastatic solid tumor malignancies treated with immune checkpoint inhibitors (ICIs). PATIENTS AND METHODS: A retrospective, multi-center, matched cohort analysis of patients with a diagnosis of either T2DM and/or congestive heart…
Rank35.6
Glutaredoxin 1 promotes sorafenib resistance in renal cell carcinoma through ferroptosis suppression: Integrative bioinformatics analysis and experimental validation.
Tissue & cell · 2026 · PMID 41990693
BACKGROUND: Sorafenib resistance has limited the therapeutic efficacy in advanced renal cell carcinoma (RCC). Glutaredoxin 1 (GRX1, also known as GLRX), a redox-regulating oxidoreductase belonging to the thioredoxin superfamily, may mediate this resistance through ferroptosis suppression, but the underlying mechanisms remain incompletely understood. METHODS: GRX1 expression and sorafenib sensitivity were analyzed using The Cancer Genome Atlas-Kidney Renal Clear Cell Carcinoma (TCGA-KIRC, n = 601), Gene Expression O…
Rank35.0
Metastatic Leiomyosarcoma Involving Bone and Kidney in an Adult Budgerigar (Melopsittacus undulatus).
Veterinary medicine and science · 2026 · PMID 42638206
Leiomyosarcoma (LMS), a malignant neoplasm of smooth muscle cell origin, is relatively rare in birds. This study presents the occurrence of this tumour in a 2-year-old male budgerigar. The bird was brought to the Ashian Veterinary Hospital with complaints of swelling in the medial area of the left leg. Clinical examination and radiological imaging confirmed the presence of soft tissue swelling in the medial region of the left leg. Empirical antibiotic and anti-inflammatory therapy were used to distinguish infectiou…
Rank33.4
Design, Preclinical Evaluation, and Clinical Translation of [68Ga]Ga/[177Lu]Lu-JH120061, a Novel Radiopharmaceutical Targeting CXCR4.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42189873
PURPOSE: We designed and synthesized a novel compound targeting C-X-C motif chemokine receptor 4 (CXCR4), JH120061. Using clinically established Pentixafor and Pentixather as references, we evaluated the potential of [68Ga]Ga/[177Lu]Lu-JH120061 in a series of preclinical and clinical studies. PATIENTS AND METHODS: Preclinical studies of [68Ga]Ga/[177Lu]Lu-JH120061 were conducted on CXCR4-expressing cell lines (HT1080-hCXCR4) and HT1080-hCXCR4 tumor-bearing mice. A head-to-head comparison of [68Ga]Ga-JH120061 with […
Rank33.0
Microbiome-Driven Carcinogenesis and Circulating Microbial Signals in Genitourinary Cancers.
Cancer science · 2026 · PMID 42333742
The microbiome is increasingly recognized as a regulator of carcinogenesis, tumor immunity, and response to immune checkpoint inhibitors (ICIs), but its role in genitourinary cancers remains less clearly defined than in melanoma or colorectal cancer. In this review, we summarize evidence that microbiome-related pathways influence urothelial carcinoma (UC) and renal cell carcinoma (RCC) across the continuum from tumor initiation to immunotherapy outcome. We highlight recent preclinical studies showing that gut micro…
Rank30.0
IL-2 based cancer immunotherapies: an evolving paradigm.
Frontiers in immunology · 2024 · PMID 39114660
Discovered over 4 decades ago in the supernatants of activated T cells, interleukin-2 (IL-2) is a potent pleiotropic cytokine involved in the regulation of immune responses. It is required for effector T cell expansion and differentiation as well as for peripheral tolerance induced by regulatory T cells. High-dose IL-2 treatment was the first FDA-approved immunotherapy for renal cell carcinoma and melanoma, achieving single agent complete and durable responses, albeit only in a small proportion of patients. The the…
Rank30.0
Design, Synthesis, and In Silico Insights of new 4-Piperazinylquinolines as Antiproliferative Agents against NCI Renal Cancer Cell Lines.
ChemistryOpen · 2025 · PMID 39910865
In the search for new anticancer compounds, quinoline and piperazine moieties represent the most promising pharmacophoric fragments for the development of more effective drugs. A particularly interesting approach in medicinal chemistry is molecular hybridization, where different known components are integrated into a single chemical entity, resulting in hybrid molecules with enhanced biological activity. In this study, we have developed a new series of 4-(4-benzoylpiperazin-1-yl)-6-nitroquinoline-3-carbonitrile com…
Rank30.0
Fructose induces PERK-dependent ER stress and mitochondrial dysfunction via nucleotide depletion in clear cell renal cell carcinoma.
Cell death & disease · 2026 · PMID 42675041
Clear cell renal cell carcinoma (ccRCC) exhibits a paradoxical fructose metabolism signature characterized by upregulation of the fructose transporter GLUT5 alongside downregulation of the catabolic enzymes (ketohexokinase, aldolase B, and triokinase), a pattern associated with poor prognosis. Functionally, unlike the pro-survival effect of fructose under glucose deprivation, in the presence of glucose, fructose co-treatment suppresses ccRCC cell proliferation, and induces profound mitochondrial dysfunction, includ…
Rank30.0
HER2 and Other ErbB Receptors' Expression and Their Involvement in the Oncogenesis of Clear Cell Renal Cell Carcinoma.
Anticancer research · 2026 · PMID 42674699
BACKGROUND/AIM: Clear cell renal cell carcinoma (ccRCC) is the predominant subtype of renal cancer with poor prognosis at advanced stages. The ErbB receptor family, including HER2, EGFR, and ErbB3, is implicated in tumor progression through membrane signaling and nuclear functions, but their roles in ccRCC remain incompletely understood. MATERIALS AND METHODS: We analyzed membrane and nuclear expression of HER2, EGFR, and ErbB3 in ccRCC tissue samples by immunohistochemistry. Pearson correlation analyses evaluated …
Rank30.0
ENPP3 drives ccRCC progression by cGAMP hydrolysis and STING-IFN suppression.
Cancer biology & therapy · 2026 · PMID 41715305
OBJECTIVE: Clear-cell renal cell carcinoma (ccRCC) is an immune-desert tumor. This study investigates the role of ectonucleotide pyrophosphatase/phosphodiesterase 3 (ENPP3) as a potential therapeutic target and immune-checkpoint enzyme in ccRCC. METHODS: ENPP3 expression and its link to hypoxia and prognosis were analyzed in ccRCC. Functional roles were tested using gain/loss-of-function studies in vitro and in xenograft models, followed by therapeutic anti-ENPP3 antibody administration, alone or with anti-PD-L1. M…
Rank30.0
Histotripsy for renal cell carcinoma: from animal studies to clinical application.
International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · PMID 42495873
BACKGROUND/OBJECTIVE: Histotripsy is a novel non-thermal, noninvasive, non-ionising ablation modality that is under investigation for the treatment of renal cell carcinoma (RCC). Histotripsy utilizes a focused ultrasound transducer that creates high peak negative pressures at a focal point to cause cavitation in tissue. The rapid expansion and collapse of endogenous gas bubbles mechanically destroy targeted tissue while sparing collagen-containing critical structures such as the renal pelvis and ureter. This review…
Rank30.0
POU2F2 as a dual oncogenic and immunomodulatory driver in kidney renal clear cell carcinoma.
Cell adhesion & migration · 2026 · PMID 42421306
Kidney renal clear cell carcinoma (KIRC) features an immunosuppressive tumor microenvironment (TME). We investigated the role of transcription factor POU2F2 in KIRC oncogenesis and macrophage polarization. Single-cell and spatial transcriptomics showed that POU2F2 is upregulated in KIRC and associated with metastasis and poor prognosis. POU2F2 knockdown inhibited KIRC cell proliferation, migration, and invasion in vitro. POU2F2 expression correlated with macrophage infiltration and JAK-STAT signaling. Co-culture as…
Rank30.0
Drug repurposing of ticagrelor suppresses renal cell carcinoma growth by blockading the EGFR/PI3K/AKT axis.
Annals of medicine · 2026 · PMID 41741334
BACKGROUND: Renal cell carcinoma (RCC) remains one of the most prevalent urological malignancies. Although targeted therapies have expanded therapeutic options, a substantial proportion of patients still experience poor outcomes, underscoring the need for more effective and less toxic strategies. Ticagrelor, a novel antiplatelet agent, has recently shown antineoplastic potential in several cancers; however, its role and mechanism in RCC remain undefined. METHODS: In vitro effects of ticagrelor on RCC cells were eva…
Rank30.0
Drug-loaded biomorphic scaffolds for tissue regeneration and targeted antitumor therapy in bone metastasis models.
Biomaterials advances · 2026 · PMID 42385450
Renal cell (RCC) and breast carcinoma (BC) frequently develop lytic bone metastases (BM) that are usually treated with systemic and locoregional therapies. Surgery plays a crucial role when pathological fractures or lesions involve a load-bearing bone and consists in the removal of tumor area followed by replacement with implant or prosthesis. In the present study, a proof of concept of novel locoregional therapies for BM patients was evaluated, consisting in the functionalization of biomorphic apatitic scaffolds w…
Rank30.0
NDUFA4L2 acts as a mitochondrial checkpoint against ferroptosis in hypoxic clear cell renal cell carcinoma.
Cellular signalling · 2026 · PMID 42331208
This study aimed to define the functional role of the HIF-1α target gene NDUFA4L2 in clear cell renal cell carcinoma (ccRCC), specifically its regulation of mitochondrial function and the ferroptosis cell death pathway. Through TCGA data analysis and in vitro and in vivo models, we confirmed that HIF-1α induces NDUFA4L2 expression and mitochondrial localization. Using shRNA-mediated knockdown combined with rescue experiments employing the ferroptosis inhibitor ferrostatin-1 and the mitochondrial antioxidant mitoTEM…
Rank30.0
BMP5 suppresses malignant progression of clear cell renal cell carcinoma by promoting DNA damage accumulation and sustained DNA damage response signaling.
Cellular signalling · 2026 · PMID 42303195
Clear cell renal cell carcinoma (ccRCC) is a prevalent malignancy of the urinary system that lacks effective biomarkers for early diagnosis and prognosis. Bone morphogenetic protein 5 (BMP5), a member of the bone morphogenetic protein family within the TGF-β superfamily, is known to participate in the regulation of cellular differentiation, proliferation, and apoptosis. Bioinformatics analyses indicated that BMP5 expression is significantly reduced in ccRCC and is associated with unfavorable patient outcomes. Gain-…
Rank30.0
Synergistic apoptosis-sensitizing effect of PD-L1 inhibitor ARB-272572 encapsulated in TRAIL-expressing extracellular vesicles for renal cell carcinoma therapy.
Biochimica et biophysica acta. Molecular basis of disease · 2026 · PMID 42297118
Renal cell carcinoma(RCC) is a therapy-resistant malignancy with rising global incidence, highlighting an urgent need for innovative treatments. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells, but its clinical translation is hindered by cancer resistance. Extracellular vesicle-delivery of TRAIL (EV-T) has enhanced TRAIL activity. Recent studies reveal that programmed death-ligand 1(PD-L1), beyond its established role in immune evasion, exerts pro-surviv…
Rank30.0
HIF-2α/TRIB3/PARP1 axis promotes progression by orchestrating DNA repair in clear cell renal cell carcinoma.
Biochimica et biophysica acta. Molecular basis of disease · 2026 · PMID 42242437
In clear cell renal cell carcinoma (ccRCC), aberrant accumulation of hypoxia-inducible factor-2α (HIF-2α) due to VHL gene mutation is a central event driving tumorigenesis and progression. Although DNA damage is a hallmark of renal cancer development, it remains unclear whether and how HIF-2α regulates downstream targets to modulate the DNA damage and repair process. Here, we demonstrate that HIF-2α transcriptionally activates TRIB3 expression. Further we found that TRIB3 interacts with PARP1, a key DNA repair prot…
Rank30.0
Integration of network toxicology, WGCNA, and explainable machine learning to decipher the toxic molecular basis underlying DEGDB plasticizer-induced clear cell renal cell carcinoma (ccRCC) progression.
Computational biology and chemistry · 2026 · PMID 42224996
Diethylene glycol dibenzoate (DEGDB), an emerging eco-friendly plasticizer, remains critically understudied with mechanistic and molecular-level evidence linking it to clear cell renal cell carcinoma (ccRCC) progression, representing a major knowledge gap. To fill this gap, we conducted a cross-scale investigation using network toxicology, WGCNA, machine learning, SHAP explainable modeling, and molecular docking as methodological tools to elucidate DEGDB‑induced ccRCC progression. By jointly mining the ChEMBL, PubC…
Rank30.0
Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC.
Molecular therapy. Oncology · 2026 · PMID 42375394
Immunotherapy has revolutionized cancer treatment, yet clinical success remains limited, with only a fraction of patients responding. Tumor heterogeneity and patient-specificity hinder response prediction, emphasizing the need for human-based models that accurately reproduce tumor-immune interactions. Conventional preclinical platforms, such as murine models, lack the human-specific HLA-TCR complexity, limiting their ability to accurately evaluate immunotherapy responses. To address this, we established a patient-s…
Rank30.0
LGALS1 promotes the malignant progression and sunitinib resistance of clear cell renal cell carcinoma by reprogramming fatty acid metabolism.
International immunopharmacology · 2026 · PMID 42322858
OBJECTIVE: Abnormal fatty acid metabolism drives clear cell renal cell carcinoma (ccRCC) occurrence, progression, and tyrosine kinase inhibitor (TKI) resistance, with unclear regulatory mechanisms. To investigate the role and molecular mechanism of fatty acid metabolism key gene LGALS1 in ccRCC malignant progression and TKI resistance. METHODS: LGALS1 was screened via TCGA-KIRC and fatty acid metabolism gene sets. Its expression, association with ccRCC prognosis, and effects on cell behaviors, fatty acid metabolism…
Rank30.0
ALOX5 mediates sunitinib resistance in renal cell carcinoma by reprogramming lipid metabolism through the p38/ERK/PPARα axis.
International immunopharmacology · 2026 · PMID 42287957
OBJECTIVE: To investigate the molecular mechanisms of lipid metabolic reprogramming promoting tyrosine kinase inhibitors (TKIs) resistance in renal cell carcinoma (RCC). METHODS: To establish a sunitinib resistant renal cell carcinoma cell line (786O-R) and screen out arachidonic acid 5-lipoxygenase (ALOX5), a key gene regulating lipid metabolism, by transcriptome sequencing. To explore the expression of ALOX5 in TKI-resistant RCC tissues and cells, and the relationship between ALOX5 expression and the prognosis of…
Rank30.0
Renal Cell Carcinoma: Histopathology, Molecular Features, and the Emerging Role of Organoid Models.
Gene · 2026 · PMID 42142672
Renal cell carcinoma (RCC) accounts for approximately 90% of kidney malignancies and comprises a heterogeneous group of tumors with distinct histological and molecular features. More than 20 histological subtypes have been defined within an integrated classification framework that incorporates histomorphology and is increasingly informed by recurrent molecular differences. Given the intrinsic resistance to conventional chemotherapies, treatment of advanced RCC primarily relies on tyrosine kinase inhibitors and immu…
Promising Experimental Therapies62 records
Rank99.4
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.
The Lancet. Oncology · 2026 · PMID 42633754
BACKGROUND: Total mesorectal excision (TME) is the standard treatment for most early-stage and intermediate-stage rectal cancer but can cause substantial perioperative morbidity, functional impairment, and reduced quality of life. We assessed whether long-course chemoradiotherapy (LCCRT) or short-course radiotherapy (SCRT) could increase organ preservation and reduce surgery, toxicity, and quality-of-life harms without compromising oncological outcomes. METHODS: STAR-TREC is an international, multicentre, open-labe…
Rank98.0
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42507969
PURPOSE: Bone metastases (BM) occur in approximately 30% of patients with metastatic renal cell carcinoma (mRCC) and are associated with poor survival and symptomatic skeletal events (SSEs). Radium-223, an alpha-emitting bone-seeking radioisotope, and cabozantinib, a tyrosine kinase inhibitor, have demonstrated activity in BM. RADICAL (Alliance A031801; ClinicalTrials.gov identifier: NCT04071223) evaluated cabozantinib ± radium-223 in mRCC with BM. METHODS: This phase II trial enrolled patients with mRCC of any his…
Rank96.2
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42235464
BACKGROUND: Papillary renal cell cancer (pRCC) represents the largest subgroup within non-clear cell (ncc) RCC. Compared with clear cell RCC (ccRCC), pRCC is considered less sensitive to currently available systemic therapies. Here, we report exploratory results from the pRCC subgroup of the SUNNIFORECAST trial comparing ipilimumab/nivolumab with standard of care (SOC) based on central pathological review. METHODS AND PATIENTS: SUNNIFORECAST was a prospective, investigator-initiated, phase II trial evaluating ipili…
Rank95.6
Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191.
Hypertension (Dallas, Tex. : 1979) · 2026 · PMID 42158981
BACKGROUND: The objective of this cluster randomized controlled trial was to determine the feasibility and safety of an intensive (systolic blood pressure [SBP] <120 mm Hg) versus usual care (SBP <140 mm Hg) approach to SBP control in patients with renal cell or thyroid cancer initiating VEGFR (vascular endothelial growth factor)-tyrosine kinase inhibitors. METHODS: A phase II site-based cluster randomized controlled trial compared intensive SBP control to usual care, incorporating a centralized BP advisory core to…
Rank95.4
Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy.
European urology focus · 2026 · PMID 41760424
BACKGROUND AND OBJECTIVE: Robot-assisted partial nephrectomy (RAPN) is increasingly used to treat renal cell carcinoma (RCC), but randomized data comparing long-term outcomes to those after open partial nephrectomy (OPN) remain limited. Our aim was to compare oncological, renal function, and health-related quality of life (HRQOL) outcomes at 2 yr for patients who underwent RAPN versus OPN. METHODS: This single-center phase 2 randomized controlled trial included 50 patients with suspected localized RCC who were rand…
Rank92.0
Metastatic tropism of molecularly defined clear-cell renal cell carcinoma clusters.
The Journal of clinical investigation · 2026 · PMID 42138077
BACKGROUNDThe relationship between molecular subgroups in clear-cell renal cell carcinoma (ccRCC) and metastatic tropism is poorly understood.METHODSWe analyzed over 5,000 metastatic sites from 305 treatment-naive ccRCC patients in the IMmotion150 phase II clinical trial, where patients were randomized to atezolizumab, atezolizumab/bevacizumab, or sunitinib.RESULTSAngiogenic tumors (clusters 1 and 2) had a higher rate of pancreatic (21% vs. 6.9%; P = 0.002) and lower absolute number of lymph node (2.5 vs. 4.2; P = …
Rank83.9
Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses.
Journal for immunotherapy of cancer · 2026 · PMID 42431710
PURPOSE: Patients with very-high risk clear cell renal cell carcinoma (ccRCC) remain at substantial risk of recurrence after nephrectomy. However, heterogeneity in benefit from adjuvant immunotherapy observed in the KEYNOTE-564 trial, together with limited prospective data in this population, warrants further investigation. METHODS: This multicenter, prospective, non-randomized, controlled phase II trial enrolled patients with very-high risk ccRCC following nephrectomy. Patients received either adjuvant penpulimab …
Rank83.1
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.
The Lancet. Oncology · 2026 · PMID 42144019
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is a non-invasive therapy for inoperable primary renal cell carcinoma. However, long-term prospective clinical trial data are scarce. We aimed to use pooled data from two clinical trials (FASTRACK and FASTRACK II) to evaluate activity and safety of SABR in the long term. METHODS: In this pooled analysis, we used data from FASTRACK, a single-institutional, phase 1, prospective clinical trial conducted at the Peter MacCallum Cancer Centre (Melbourne, VIC, Aus…
Rank83.0
Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial.
International journal of radiation oncology, biology, physics · 2025 · PMID 40158734
PURPOSE: Stereotactic body radiation therapy (SBRT) is an advanced technique that enables precise delivery of radiation directly to a tumor, typically in ≤5 fractions. Single-fraction SBRT for visceral tumors is uncommon, likely related to concerns about risks of geographic tumor miss because of suboptimal cone beam computed tomography scan quality on conventional linear accelerators (linacs). Magnetic resonance (MR) guided linacs are a novel technology offering superior imaging that might facilitate the safe deliv…
Rank82.8
Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 41946178
BACKGROUND: The phase II trial CABRAMET evaluates the efficacy of the VEGFR tyrosine kinase inhibitor (TKI) cabozantinib in patients with non-locally pretreated brain metastases (BM) from renal cell carcinoma (RCC). Faced with historical challenges in treating BM in RCC, this study aimed to provide prospective data on systemic treatment outcomes. PATIENTS AND METHODS: This multicenter open-label trial included RCC patients with BM with less than three prior systemic treatments excluding cabozantinib. Eligible patie…
Rank82.5
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma.
Clinical genitourinary cancer · 2026 · PMID 42336709
BACKGROUND: Anti-PD1 immune checkpoint inhibitors (ICI) are effective in clear-cell renal-cell carcinoma (ccRCC). Preliminary data suggest inhibition of Receptor Activator of Nuclear Factor-κB Ligand (RANKL) signaling may potentiate ICI efficacy. We evaluated the activity and safety of the RANKL-inhibitor denosumab with pembrolizumab in people with pretreated advanced ccRCC. METHODS: This single-arm, multi-center phase 2 trial enrolled participants with metastatic or unresectable ccRCC progressing on or after VEGFR…
Rank81.4
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.
European urology · 2026 · PMID 42049596
Radiotherapy-based metastasis-directed therapy (MDT) has emerged as a treatment strategy for oligometastatic clear cell renal cell carcinoma (ccRCC). However, optimal integration of MDT with immune checkpoint inhibition (ICI) is unclear, especially in light of the M1 no evidence of disease subgroup analysis of KEYNOTE-564. We undertook an exploratory cohort study of two previously reported trials evaluating either MDT+ICI (NCT02855203) or MDT (NCT03575611) for oligometastatic ccRCC. The objective was primarily to c…
Rank80.8
Long-term follow-up from the OMNIVORE trial: response-adaptive nivolumab and ipilimumab in advanced renal cell carcinoma.
Journal for immunotherapy of cancer · 2026 · PMID 42386345
BACKGROUND: Immune checkpoint inhibitor-based combinations represent the standard of care for advanced renal cell carcinoma. The OMNIVORE trial investigated a response-adaptive strategy, including treatment discontinuation in early nivolumab responders (Arm A) and salvage ipilimumab addition in non-responders (Arm B). Here we report outcomes with extended follow-up. METHODS: OMNIVORE was a phase II response-adaptive trial in which patients received induction nivolumab monotherapy. Patients achieving a confirmed com…
Rank80.7
Long-term outcomes of stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a multicentre, non-randomised, phase 2 study.
The Lancet. Oncology · 2026 · PMID 42144018
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is an emerging, non-invasive alternative for primary renal cell carcinoma. We aimed to provide the final long-term trial outcomes of TransTasman Radiation Oncology Group (TROG) 15.03 FASTRACK II, the first phase 2 trial investigating SABR for primary renal cell carcinoma to our knowledge. METHODS: FASTRACK II was a non-randomised, phase 2 study conducted in eight hospitals in Australia and the Netherlands by TROG and the Australian and New Zealand Urogenita…
Rank80.7
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42149133
PURPOSE: We investigated components of the immune tumor microenvironment as determinants of clinical outcome to anti-PD-1 therapy in patients with metastatic clear-cell renal cell carcinoma (ccRCC) treated with first-line nivolumab in the phase II, nonrandomized HCRN GU16-260 trial. EXPERIMENTAL DESIGN: Pretreatment primary ccRCCs from 72 patients were analyzed via multiplex immunofluorescence and image analysis to assess nonterminally exhausted CD8+ (CD8+PD-1+TIM-3-LAG-3-) tumor-infiltrating lymphocytes (TIL), PD-…
Rank80.0
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.
Nature communications · 2026 · PMID 42420295
Biomarkers that predict response to combined radiation and anti-PD-1 therapy in clear cell renal cell carcinoma (ccRCC) are poorly defined. RAPPORT trial (NCT02855203) is a prospective phase I/II study of stereotactic ablative body radiotherapy (SABR) and pembrolizumab in 30 patients with oligometastatic ccRCC. The primary endpoint was safety; secondary endpoints included overall survival, time to local progression, distant progression-free survival, objective and disease control rates, duration of response and pat…
Rank80.0
Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study.
International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42179010
OBJECTIVES: Cabozantinib treatment is associated with improved survival in renal cell carcinoma (RCC) patients with bone metastasis. We evaluated the direct effects of cabozantinib on bone metastasis in advanced RCC (aRCC). METHODS: In this multicenter, open-label study, adult Japanese aRCC patients with bone metastasis received oral cabozantinib 60 mg once daily until drug discontinuation/data cut-off. The primary endpoint was the objective response rate (ORR) of bone target lesions (modified MD Anderson criteria)…
Rank79.8
Pembrolizumab plus high-dose IL-2 in advanced clear cell renal cell carcinoma: six-year survival outcomes and molecular signatures from a phase 2 trial.
Nature communications · 2026 · PMID 42185255
Prolonged or indefinite systemic therapy remains standard for advanced clear cell renal cell carcinoma (ccRCC), often resulting in cumulative toxicities and treatment burden. We conducted a single-arm phase 2 trial (ClinicalTrials.gov identifier: NCT02964078) of a fixed-duration regimen of anti-PD1 pembrolizumab plus high-dose interleukin-2 in treatment-naive advanced ccRCC. Primary objectives of safety and response were previously reported. The study met its primary endpoint with an overall response rate exceeding…
Rank79.8
Stereotactic body radiotherapy plus sunitinib vs. sunitinib alone in treatment-naive oligometastatic renal cell carcinoma: A phase 2 clinical trial.
Cell reports. Medicine · 2026 · PMID 42013852
Comparative data on stereotactic body radiotherapy (SBRT) in oligometastatic renal cell carcinoma (RCC) is lacking. This single-center, phase 2 non-randomized controlled trial enrolls patients with treatment-naive oligometastatic RCC. Patients choose to receive sunitinib alone (control arm, n = 24) or plus SBRT (SBRT arm, n = 24). The primary endpoint, objective response rate (83.3% vs. 29.2%; p < 0.001), is higher in the SBRT arm. With a median follow-up of 40.6 months, the 1-year local control rate is 91.5%. Prog…
Rank79.2
Safety and efficacy of fecal microbiota transplantation in solid cancers resistant to immune checkpoint inhibitors: results of the MITRIC trial.
Journal for immunotherapy of cancer · 2026 · PMID 42476727
BACKGROUND: Fecal microbiota transplantation (FMT) has shown promise in overcoming resistance to immune checkpoint inhibitors (ICIs) in early-phase cancer trials. We investigated the safety, feasibility and efficacy of FMT from ICI responders to patients with advanced cancers progressing on ICIs. METHODS: This was a single-arm phase IIa basket trial (MITRIC; NCT05286294) including patients with ICI-refractory cancer. Long-term ICI responders were used as FMT donors. Patients received FMTs in combination with ICIs; …
Rank79.1
Phase II Trial of Ixazomib Combined with Gemcitabine and Doxorubicin in Patients with SMARCB1-Deficient Renal Medullary Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2026 · PMID 42007903
PURPOSE: SMARCB1-deficient renal medullary carcinoma (RMC) is an aggressive kidney cancer lacking mechanism-directed therapies. We conducted a single-center, single-arm, phase II study (NCT03587662) testing the proteasome inhibitor ixazomib combined with gemcitabine and doxorubicin. PATIENTS AND METHODS: Ixazomib 5.5 mg, gemcitabine 756 mg/m2, and doxorubicin 42 mg/m2 were given every 2 weeks for up to 13 cycles, followed by ixazomib plus gemcitabine maintenance. Coprimary endpoints were objective response rate (OR…
Rank77.0
HPK1 inhibitor NDI-101150 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: Phase 1/2 trial results.
Cell reports. Medicine · 2026 · PMID 42097144
Hematopoietic progenitor kinase 1 (HPK1) induces potent anti-tumor immunity in preclinical models by activating and recruiting T cells, B cells, and dendritic cells into the tumor microenvironment (TME). Here, we evaluate NDI-101150, a potent, selective HPK1 inhibitor, in a phase 1/2 trial as a monotherapy or in combination with pembrolizumab in patients with advanced solid tumors. The monotherapy maximum tolerated dose (MTD) is 150 mg once daily, and doses tested up to 100 mg once daily are combinable with pembrol…
Rank77.0
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma.
Melanoma research · 2026 · PMID 42070986
To assess the combination of high dose interleukin 2 (HD IL2) and nivolumab in patients with checkpoint inhibitor-refractory melanoma or renal cell carcinoma (RCC), we performed a single-arm, Simon two-stage phase II trial for patients with unresectable stage III or IV melanoma or any histology RCC. The primary endpoint was overall response rate (ORR); secondary endpoints were adverse events and progression-free survival (PFS), defined as time to radiographic or clinical progression, whichever occurred first. Five …
Rank77.0
Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI.
Abdominal radiology (New York) · 2026 · PMID 41369900
Despite recent therapeutic advances, renal cell carcinoma (RCC) has a high mortality rate. The development of new neoadjuvant strategies requires reliable companion biomarkers of early and successful response to treatment. A change in tumor size is a late measure of response and novel targeted imaging-based biomarkers may be more accurate for treatment response prediction. Here we evaluated the potential of hyperpolarized carbon-13 MRI (HP 13C-MRI), following the injection of hyperpolarized 13C-pyruvate, to assess …
Rank68.0
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of cergutuzumab amunaleukin: a phase I study in patients with advanced and/or metastatic solid tumors.
ESMO open · 2026 · PMID 42127887
BACKGROUND: Cergutuzumab amunaleukin (CA) is a novel immunocytokine comprising an interleukin-2 variant moiety with abolished CD25 (interleukin-2 receptor α) binding, fused to a bivalent anti-carcinoembryonic antigen (CEA) monoclonal antibody. This first-in-human phase I study evaluated the maximum tolerated dose (MTD), safety, pharmacokinetics, pharmacodynamics, and antitumor activity of CA. MATERIAL AND METHODS: Patients had CEA-positive advanced and/or metastatic solid tumors that had progressed on standard-of-c…
Prospective Cohort Studies63 records
Rank107.6
Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis.
JAMA network open · 2026 · PMID 42084869
IMPORTANCE: Circadian rhythms affect immunity, which could affect the effectiveness of immune checkpoint inhibitor (ICI). Whether the time of ICI administration is associated with clinical outcomes in advanced cancers remains unclear. OBJECTIVE: To evaluate the association between time of day of ICI administration and oncologic outcomes in patients with advanced solid tumors. DATA SOURCES: MEDLINE (via PubMed), Embase, and Web of Science Core Collection were searched in February 2026 to identify eligible studies. S…
Rank106.0
Dose-response association of dietary inflammatory potential with risk of cancer: systematic review and meta-analysis of prospective cohort studies.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2026 · PMID 40536070
Observational studies indicated that the overall inflammatory potential of diets has been implicated in cancer etiology; however, the results were inconsistent. We aimed to estimate the dose-response association of dietary inflammatory potential with cancer outcomes based on prospective cohort studies. PubMed, Embase and Web of Science databases were searched up to 11 November 2023 for prospective cohort studies. The dietary inflammatory potential was assessed by the dietary inflammatory index (DII) or energy-adjus…
Rank96.6
Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy.
The Journal of urology · 2026 · PMID 41360001
PURPOSE: Hemostatic agents (HAs) are typically used during robotic-assisted laparoscopic partial nephrectomy (RALPN) to minimize perioperative bleeding. However, high-quality evidence supporting their effectiveness is limited. We aimed to determine whether HAs reduce perioperative blood loss in patients undergoing RALPN. MATERIALS AND METHODS: We conducted a prospective, randomized controlled trial of patients undergoing RALPN. Patients were randomized to HA+, in which HAs were assigned, and HA-, no HA. The primary…
Rank96.2
KIM-1 in Advanced Papillary and Clear Cell Renal Cell Carcinoma.
European urology · 2026 · PMID 41934036
Kidney injury molecule 1 (KIM-1) is a promising biomarker in adjuvant clear cell renal cell carcinoma (ccRCC), but its relevance in advanced ccRCC or papillary RCC (pRCC) remains unclear. CALYPSO (NCT02819596) was a prospective, multi-arm trial that evaluated durvalumab alone or in combination with tremelimumab or savolitinib in metastatic ccRCC and pRCC. Circulating KIM-1 levels were measured at baseline and on-treatment. The primary endpoint was to explore if KIM-1 levels were raised in pRCC. Analyses were explor…
Rank96.2
Papillary renal cell carcinoma - exploratory results of the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first line therapy based on central pathological review.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 42235464
BACKGROUND: Papillary renal cell cancer (pRCC) represents the largest subgroup within non-clear cell (ncc) RCC. Compared with clear cell RCC (ccRCC), pRCC is considered less sensitive to currently available systemic therapies. Here, we report exploratory results from the pRCC subgroup of the SUNNIFORECAST trial comparing ipilimumab/nivolumab with standard of care (SOC) based on central pathological review. METHODS AND PATIENTS: SUNNIFORECAST was a prospective, investigator-initiated, phase II trial evaluating ipili…
Rank95.3
[A comparative study on perioperative outcomes and learning curves of domestic robot-assisted versus Da Vinci Xi robot-assisted partial nephrectomy].
Zhonghua wai ke za zhi [Chinese journal of surgery] · 2026 · PMID 41881798
Objective: To compare perioperative outcomes of robot-assisted partial nephrectomy (RAPN) performed with a China-made robotic surgical system versus the Da Vinci Xi system, and to evaluate the learning curve of the domestic system. Methods: This single-center, prospective, randomized controlled study enrolled patients scheduled for RAPN at Harbin Medical University Cancer Hospital from August 2024 to May 2025 who met predefined inclusion and exclusion criteria. Using simple randomization, patients were assigned to …
Rank94.0
Vegetarian diets and cancer risk: pooled analysis of 1.8 million women and men in nine prospective studies on three continents.
British journal of cancer · 2026 · PMID 41748939
BACKGROUND: Vegetarian diets might influence cancer risk. METHODS: We studied 1,645,555 meat eaters, 57,016 poultry eaters, 42,910 pescatarians, 63,147 vegetarians and 8849 vegans in 9 cohorts (UK, US, Taiwan, India). After a median 16 years follow-up, incident cancers were: 4504 mouth and pharynx, 1308 oesophagus (squamous cell), 2105 oesophagus (adenocarcinoma), 3578 stomach, 30,528 colorectum, 2970 liver, 8030 pancreas, 3077 lung (never smokers), 61,368 breast, 11,220 endometrium, 8076 ovary, 45,946 prostate, 71…
Rank88.4
Multimodal imaging to analyze the biomechanical properties of kidney tumors, evaluating feasibility, inter-modality correspondence, and diagnostic value (UroCCR-115).
PloS one · 2026 · PMID 42418537
INTRODUCTION: Assessment of renal tissue and renal tumor stiffness may provide complementary information for tissue characterization; however, conventional imaging modalities such as multiphasic computed tomography (CT) do not directly quantify biomechanical properties. Elastography techniques, including magnetic resonance elastography (MRE) and ultrasound elastography (US-E), allow noninvasive measurement of tissue stiffness but are not routinely available in standard clinical practice. This study protocol aims to…
Rank83.9
Adjuvant penpulimab in very-high risk clear cell renal cell carcinoma: a prospective, non-randomized, controlled phase II trial with integrated plasma multi-omics analyses.
Journal for immunotherapy of cancer · 2026 · PMID 42431710
PURPOSE: Patients with very-high risk clear cell renal cell carcinoma (ccRCC) remain at substantial risk of recurrence after nephrectomy. However, heterogeneity in benefit from adjuvant immunotherapy observed in the KEYNOTE-564 trial, together with limited prospective data in this population, warrants further investigation. METHODS: This multicenter, prospective, non-randomized, controlled phase II trial enrolled patients with very-high risk ccRCC following nephrectomy. Patients received either adjuvant penpulimab …
Rank83.4
CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study.
Journal for immunotherapy of cancer · 2026 · PMID 41895717
BACKGROUND: CD8 T cells mediate the effects of cancer immunotherapies. CD8 positron emission tomography (PET) imaging with [89Zr]Zr-berdoxam-crefmirlimab enables whole body CD8 cell assessment and has been shown to be safe in Phase I evaluation. The correlation between CD8 PET imaging parameters and the quantity of CD8 cells assessed by the gold standard of immunohistochemistry (IHC) is unknown. METHODS: The Phase II, prospective multicenter study (iCorrelate) tested the correlation between CD8 PET and CD8 cells by…
Rank83.1
Ultra-hypofractionated stereotactic ablative body radiotherapy for primary renal cell carcinoma: 5-year outcomes from a pooled analysis of the FASTRACK trials.
The Lancet. Oncology · 2026 · PMID 42144019
BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is a non-invasive therapy for inoperable primary renal cell carcinoma. However, long-term prospective clinical trial data are scarce. We aimed to use pooled data from two clinical trials (FASTRACK and FASTRACK II) to evaluate activity and safety of SABR in the long term. METHODS: In this pooled analysis, we used data from FASTRACK, a single-institutional, phase 1, prospective clinical trial conducted at the Peter MacCallum Cancer Centre (Melbourne, VIC, Aus…
Rank82.8
Cabozantinib in patients with non-locally pretreated brain metastases from renal cell carcinoma: Results of the multicenter phase II trial CABRAMET.
European journal of cancer (Oxford, England : 1990) · 2026 · PMID 41946178
BACKGROUND: The phase II trial CABRAMET evaluates the efficacy of the VEGFR tyrosine kinase inhibitor (TKI) cabozantinib in patients with non-locally pretreated brain metastases (BM) from renal cell carcinoma (RCC). Faced with historical challenges in treating BM in RCC, this study aimed to provide prospective data on systemic treatment outcomes. PATIENTS AND METHODS: This multicenter open-label trial included RCC patients with BM with less than three prior systemic treatments excluding cabozantinib. Eligible patie…
Rank81.4
Metastasis-directed Therapy With or Without Pembrolizumab for Oligometastatic Clear Cell Renal Cell Carcinoma: Pooled Analysis of Two Prospective Single-arm Phase 2 Trials.
European urology · 2026 · PMID 42049596
Radiotherapy-based metastasis-directed therapy (MDT) has emerged as a treatment strategy for oligometastatic clear cell renal cell carcinoma (ccRCC). However, optimal integration of MDT with immune checkpoint inhibition (ICI) is unclear, especially in light of the M1 no evidence of disease subgroup analysis of KEYNOTE-564. We undertook an exploratory cohort study of two previously reported trials evaluating either MDT+ICI (NCT02855203) or MDT (NCT03575611) for oligometastatic ccRCC. The objective was primarily to c…
Rank80.9
Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT.
International journal of cancer · 2026 · PMID 41159297
The combination of two immune checkpoint inhibitors (CPI) or a CPI with a tyrosine kinase inhibitor (TKI) has expanded the therapeutic options for advanced/metastatic renal cell carcinoma (aRCC) beyond TKI monotherapy. In the absence of head-to-head randomized trials comparing these strategies, we estimate their real-world effectiveness by emulating a hypothetical randomized trial. A total of 936 patients with aRCC from the prospective, observational, multicenter clinical registry CARAT (NCT03374267) starting first…
Rank80.0
Stereotactic Body Radiation Therapy for Renal Tumors: A Prospective Phase 2 Clinical Trial.
International journal of radiation oncology, biology, physics · 2026 · PMID 41290048
PURPOSE: Stereotactic body radiation therapy (SBRT) represents a novel, efficacious treatment for patients with kidney tumors who are medically inoperable or decline surgery. There is limited prospective data on the impact of kidney SBRT on renal function. METHODS AND MATERIALS: This was a prospective phase 2 single-arm clinical trial (clinicaltrials.gov NCT03747133) of kidney-directed SBRT in patients with primary or metastatic renal lesions who were medically inoperable or declined surgery. The primary outcome wa…
Rank80.0
Dynamic immune profiling predicts response to radiation plus anti-PD-1 therapy in oligometastatic renal cell carcinoma.
Nature communications · 2026 · PMID 42420295
Biomarkers that predict response to combined radiation and anti-PD-1 therapy in clear cell renal cell carcinoma (ccRCC) are poorly defined. RAPPORT trial (NCT02855203) is a prospective phase I/II study of stereotactic ablative body radiotherapy (SABR) and pembrolizumab in 30 patients with oligometastatic ccRCC. The primary endpoint was safety; secondary endpoints included overall survival, time to local progression, distant progression-free survival, objective and disease control rates, duration of response and pat…
Rank79.0
Four-Year Feasibility and Safety Results of a Phase 1/2 Single-Arm Prospective Clinical Trial of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy for Metachronous Oligometastatic Abdominopelvic Lymph Node and Soft Tissue Metastases.
International journal of radiation oncology, biology, physics · 2026 · PMID 41529791
PURPOSE: Metachronous oligometastases may represent a favorable disease state for local therapy after prior curative treatment. Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) provides precise targeting of nodal and soft tissue metastases. The primary objective was to assess the feasibility and safety of SMART for abdominopelvic metachronous oligometastases. Secondary objectives included assessing rates of toxicities and evaluating local control (LC). METHODS AND MATERIALS: Ten patients we…
Rank78.1
Baseline Risk of Treatment Abandonment and Survival of Children With Common and Curable Cancers in the Zero Abandonment Cash Transfer Programme-A Multi-Centre Prospective CANCaRe Africa Study.
Pediatric blood & cancer · 2026 · PMID 42578510
BACKGROUND: The WHO Global Initiative for Childhood Cancer (GICC) targets a global survival rate of 60% for childhood cancer, focusing initially on six common and curable cancers. This study assessed the risk of treatment abandonment (TxA) and the impact on survival of five of these cancers in sub-Saharan Africa in preparation for a cash transfer intervention. METHODS: This multi-centre, prospective, observational cohort study included newly diagnosed children (<16 years) with Burkitt lymphoma (BL), acute lymphobla…
Rank77.0
Evaluating the metabolic effects of neoadjuvant treatment in clear cell renal cell carcinoma using hyperpolarized [1-13 C]pyruvate MRI.
Abdominal radiology (New York) · 2026 · PMID 41369900
Despite recent therapeutic advances, renal cell carcinoma (RCC) has a high mortality rate. The development of new neoadjuvant strategies requires reliable companion biomarkers of early and successful response to treatment. A change in tumor size is a late measure of response and novel targeted imaging-based biomarkers may be more accurate for treatment response prediction. Here we evaluated the potential of hyperpolarized carbon-13 MRI (HP 13C-MRI), following the injection of hyperpolarized 13C-pyruvate, to assess …
Rank75.2
[Healthcare Research in Renal Cell Cancer: 7-Year-Data from the VERSUS Study by d-uo].
Aktuelle Urologie · 2026 · PMID 41698400
INTRODUCTION: Renal cell carcinoma (RCC) accounts for approximately 13.5% of all urological tumors. Healthcare research analyses whether treatment concepts developed in controlled clinical trials and recommended in clinical guidelines are implemented in routine care. This article presents healthcare research data on RCC based on current results from the prospective VERSUS study (VERSorgUngsStudie) by d-uo ("Deutsche Uro-Onkologen", German Uro-Oncologists). MATERIAL AND METHODS: The VERSUS study is a non-interventio…
Rank75.0
Joint effects and dynamic trajectories of metabolic insulin resistance and systemic inflammation in the risk of renal cell carcinoma: a UK Biobank cohort analysis.
World journal of urology · 2026 · PMID 42207184
BACKGROUND: Renal cell carcinoma (RCC) is a significant urological malignancy with a rising incidence, increasingly linked to metabolic dysregulation and chronic systemic inflammation. While traditional metrics such as body mass index (BMI) are commonly used, they may not fully capture the biological heterogeneity underlying carcinogenesis. This study investigated the associations of the Metabolic Score for Insulin Resistance (METS-IR) and the Systemic Inflammation Response Index (SIRI) with subsequent RCC risk, to…
Rank75.0
Post-Marketing Surveillance of the Safety and Effectiveness of Cabozantinib in Japanese Patients With Advanced Renal Cell Carcinoma.
International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42464667
OBJECTIVES: This post-marketing surveillance study evaluated the real-world safety and effectiveness of cabozantinib in Japanese patients with advanced renal cell carcinoma (aRCC). METHODS: This prospective, observational study enrolled patients with histologically or cytologically confirmed aRCC across 102 sites in Japan. Patients received cabozantinib as monotherapy or in combination with nivolumab according to approved label regimens and were monitored for 26 weeks. The primary outcome was the incidence of adver…
Rank75.0
Associations of Outdoor Air Pollution With Incidence of Cancers Other Than Lung Cancer in a Large US Prospective Cohort.
International journal of cancer · 2026 · PMID 42071337
Outdoor air pollution, including particulate matter (PM), is a Group 1 carcinogen based on evidence for lung cancer; however, evidence for other cancers is limited. Further research on cancer incidence rather than mortality endpoints is needed as well as examinations in non-smokers. In the Cancer Prevention Study-II Nutrition Cohort, annual predictions of particulate and gaseous pollutant concentrations were assigned to residential addresses. Extended Cox regression estimated hazard ratios (HR) and 95% confidence i…
Rank74.9
Association between physical activity patterns and renal cell carcinoma risk: evidence from the UK biobank large-scale prospective cohort.
Scientific reports · 2026 · PMID 41974929
While physical inactivity is an established risk factor for renal cell carcinoma (RCC), prospective evidence comparing the efficacy of distinct physical activity (PA) patterns—specifically the “weekend warrior” (WW) versus regularly distributed activity—remains limited. This study analyzed data from 89,000 participants in the UK Biobank cohort who had no prior diagnosis of RCC. PA data were collected using the Axivity AX3 wrist-worn accelerometer. Participants were categorized into three subgroups: the inactive sub…
Rank73.8
Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial.
Pediatric blood & cancer · 2026 · PMID 41834439
BACKGROUND: The United Kingdom relapsed Wilms tumour (UKW-R) trial aimed to improve the historically low survival rates after relapse of Wilms tumour (WT) through a prospective national risk-stratified protocol. The trial also evaluated efficacy and toxicity of high-dose melphalan. METHODS: Patients with relapsed/refractory WT were allocated to one of three treatment groups based on time to relapse and initial therapy. Group A: Patients with Stage 1 non-anaplastic WT treated only with vincristine (VCR) or up to two…
Quality Of Life61 records
Rank110.0
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0.
Journal for immunotherapy of cancer · 2026 · PMID 41871874
Immunotherapy has been a pillar of the renal cell carcinoma (RCC) treatment landscape for over three decades. Some of the earliest cancer immunotherapies available, such as interleukin 2 and interferon-alpha, have resulted in complete responses, but only in a small number of patients. Immune checkpoint inhibitors (ICIs), however, have demonstrated improved response rates and prolonged survival for a greater number of patients, fully transforming the standard of care in first-line and subsequent-line settings. More …
Rank102.0
What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta-analysis of ocular immune-related adverse events.
Acta ophthalmologica · 2026 · PMID 41800487
PURPOSE: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune-related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI-associated DED and to evaluate factors contributing to variability across studies. METHODS: A systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in the International Prospective Register o…
Rank99.5
Patient-Reported Outcome Design and Analysis in Randomized Controlled Trials of Renal Cell Carcinoma: A Systematic Review.
Clinical genitourinary cancer · 2026 · PMID 42468185
The clinical utility of patient-reported outcome (PRO) endpoints in renal cell carcinoma (RCC) trials depends on prespecification, clinically meaningful thresholds, and transparent analysis. We evaluated PRO design, analysis, and reporting in RCC randomized controlled trials using the independently developed PRO Endpoint Analysis Score (PROEAS), a 24-item framework based on SISAQOL recommendations. We searched Embase, MEDLINE, Web of Science Core Collection, CENTRAL, CINAHL, and PsycINFO through December 31, 2025, …
Rank99.4
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.
The Lancet. Oncology · 2026 · PMID 42633754
BACKGROUND: Total mesorectal excision (TME) is the standard treatment for most early-stage and intermediate-stage rectal cancer but can cause substantial perioperative morbidity, functional impairment, and reduced quality of life. We assessed whether long-course chemoradiotherapy (LCCRT) or short-course radiotherapy (SCRT) could increase organ preservation and reduce surgery, toxicity, and quality-of-life harms without compromising oncological outcomes. METHODS: STAR-TREC is an international, multicentre, open-labe…
Rank96.0
Exercise, nutrition, and psychological support for kidney cancer: a scoping review.
BJU international · 2026 · PMID 41549535
OBJECTIVES: To comprehensively review the available literature on prehabilitation and rehabilitation exercise, nutrition, and psychological support interventions for patients with kidney cancer (KC), to summarise the clinically relevant efficacy and cost-effectiveness of interventions, to expose key knowledge gaps, and to inform future investigations and initiatives. METHODS: This review was performed according to the per Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Extension for Scop…
Rank95.6
Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191.
Hypertension (Dallas, Tex. : 1979) · 2026 · PMID 42158981
BACKGROUND: The objective of this cluster randomized controlled trial was to determine the feasibility and safety of an intensive (systolic blood pressure [SBP] <120 mm Hg) versus usual care (SBP <140 mm Hg) approach to SBP control in patients with renal cell or thyroid cancer initiating VEGFR (vascular endothelial growth factor)-tyrosine kinase inhibitors. METHODS: A phase II site-based cluster randomized controlled trial compared intensive SBP control to usual care, incorporating a centralized BP advisory core to…
Rank95.4
Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy.
European urology focus · 2026 · PMID 41760424
BACKGROUND AND OBJECTIVE: Robot-assisted partial nephrectomy (RAPN) is increasingly used to treat renal cell carcinoma (RCC), but randomized data comparing long-term outcomes to those after open partial nephrectomy (OPN) remain limited. Our aim was to compare oncological, renal function, and health-related quality of life (HRQOL) outcomes at 2 yr for patients who underwent RAPN versus OPN. METHODS: This single-center phase 2 randomized controlled trial included 50 patients with suspected localized RCC who were rand…
Rank95.0
Effectiveness of a personalised 6-month programme on physical frailty in older patients treated for bladder or kidney cancer - FRAGECO program - multicenter, controlled, randomized study protocol.
BMC geriatrics · 2026 · PMID 42286520
BACKGROUND: Older adults with bladder or kidney cancer are particularly vulnerable to functional decline and postoperative complications that can exacerbate frailty. Conventional care models focus mainly on surgery and postoperative recovery, with limited continuity of support, resulting in suboptimal long-term functional outcomes. The aim is to evaluate the effectiveness of a personalized 6-month care pathway on reducing physical frailty in older adults undergoing surgery for bladder or kidney cancer, compared wit…
Rank93.2
The ITALIC-RCC: A Randomized Trial on Clinical and Humoral Impact of Primary Tumor Ablation by Surgery or Radiotherapy in Metastatic Renal Cell Carcinoma Treated with Checkpoint Inhibitors.
European urology open science · 2026 · PMID 42433301
BACKGROUND: Immunotherapy-based combinations have improved overall survival (OS) in metastatic renal cell carcinoma (mRCC), but recent evidence suggests a therapeutic plateau, underscoring the need for more personalized strategies. Many patients start systemic therapy with the primary kidney tumor still in situ, and the role of cytoreductive nephrectomy (CN) in the immunotherapy era remains uncertain after CARMENA and SURTIME trials. In parallel, stereotactic body radiotherapy (SBRT) has emerged as a noninvasive op…
Rank91.7
Real-World Data on the Use of Nivolumab Monotherapy in the Treatment of Advanced Renal Cell Carcinoma After Prior Therapy: Final Results from the Non-Interventional NORA Study.
Cancers · 2026 · PMID 42449619
Background/Objectives: Nivolumab monotherapy is a standard of care in previously treated advanced renal cell carcinoma (aRCC) and was approved based on the results of the randomized clinical trial Checkmate-025. The non-interventional study (NIS) NORA collected data on the effectiveness and safety of nivolumab monotherapy in real-world clinical routine. Its final, long-term follow-up data are presented here. Methods: NORA was a prospective, multicentre NIS recruiting at 54 German sites, evaluating the effectiveness…
Rank90.2
PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial.
Trials · 2026 · PMID 41863008
BACKGROUND: Localised renal cell carcinoma is treated with radical nephrectomy (RN) or partial nephrectomy (PN). Nephron-sparing PN increases preservation of renal function, reducing incidence of end stage renal failure and associated cardiovascular events. In patients with exophytic T1a (≤ 4 cm) tumours and normal contralateral kidney, PN is standard of care. In patients with T1b (> 4-7 cm) or endophytic T1a tumours and normal contralateral kidney, the benefits of PN over RN are less clear as there are increased s…
Rank88.6
Geriatric prehabilitation prior to surgery for kidney tumors: Study protocol for Pre-KiT - A randomized controlled trial.
Journal of geriatric oncology · 2026 · PMID 41592385
INTRODUCTION: Renal cell carcinoma (RCC) primarily affects older adults who often present with frailty, increasing their risk of surgical complications and delayed recovery. Prehabilitation, incorporating exercise, nutrition, and psychological support, may improve postoperative outcomes. However, no studies have investigated prehabilitation prior to surgery for RCC. The aim is to assess whether a one-month multimodal prehabilitation program including geriatric interventions improves recovery in patients with frailt…
Rank87.0
International analysis of reimbursement rates and clinical benefit of genitourinary cancer drugs across Canada, France, England, Wales, Scotland, Spain, Italy, and Portugal.
International journal of cancer · 2026 · PMID 41653082
We analysed reimbursement differences for prostate (PC), renal cell (RCC), and urothelial (UC) cancers drugs in Canada, France, England, Wales, Scotland, Spain, Italy, and Portugal, assessing substantial clinical benefit (SCB) and pivotal trials characteristics. This is a retrospective analysis of PC, RCC, and UC drug-indication pairs (2005-2024). Approvals were identified via FDA and EMA. Reimbursement recommendations were reviewed. Primary endpoint was reimbursement rate by SCB, tumour type, and country. Trial ch…
Rank85.0
De-escalation of Treatment in Metastatic Renal Cell Carcinoma: Why? How? Who? When?
Clinical genitourinary cancer · 2026 · PMID 42435529
The therapeutic landscape of metastatic renal cell carcinoma (mRCC) has evolved considerably with the introduction of immune checkpoint inhibitors (ICIs) and VEGFR-targeted therapies, leading to unprecedented improvements in survival. As durable responses and deep remissions become more frequent, the question of how to optimize treatment intensity has gained prominence. Therapeutic de-escalation, through reduced dose intensity, extended dosing intervals, treatment interruption, or integration of local therapies, ha…
Rank85.0
Role of stereotactic body radiotherapy (SBRT) for metastatic cancer patients beyond the traditional oligometastatic setting: a narrative review for an evolving concept.
Annals of palliative medicine · 2026 · PMID 42576469
BACKGROUND AND OBJECTIVE: The management of metastatic cancer is shifting from a strict division between curative local therapy and palliative systemic treatment toward a biology-driven continuum. In this setting, stereotactic body radiotherapy (SBRT), or stereotactic ablative radiotherapy (SABR), has emerged as an effective consolidative approach for patients with limited metastatic burden. Its role is now being explored beyond the classical oligometastatic paradigm, including oligoprogressive and selected polymet…
Rank85.0
Remote Exercise Program for Patients With Metastatic Renal Cell Carcinoma Undergoing Immunotherapy: An EXIO Case Series Report.
Oncology (Williston Park, N.Y.) · 2026 · PMID 41701866
BACKGROUND: Patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICIs), alone or in combination with tyrosine kinase inhibitors (TKIs), often experience significant treatment-related adverse events, including fatigue, that can impair health-related quality of life (HRQOL). Structured exercise interventions may mitigate these symptoms, but data in mRCC are limited. OBJECTIVE: To evaluate the feasibility and impact of a 12-week supervised remote exercise program on HRQOL, fa…
Rank85.0
Low-dose morphine and airway sensations in refractory chronic cough: a randomised control trial.
ERJ open research · 2026 · PMID 42683193
BACKGROUND: Low-dose morphine is recommended as an antitussive agent for refractory chronic cough (RCC), although its precise mechanism of action remains unknown. We hypothesised that noxious airway sensations (e.g. throat irritation, tickle, urge to cough) described by RCC patients play a role in initiating coughing and are lessened by morphine. METHODS: 22 RCC patients (median age 65 years; 83% female) reporting a clinical response to low-dose morphine withdrew from therapy and enrolled in a double-blinded, rando…
Rank85.0
Intraindividual Perception of Open versus Robot-Assisted Partial Nephrectomy (PERCEPTION Trial): An Important Complementing Perspective to Randomized Controlled Trials.
Urologia internationalis · 2026 · PMID 40188818
UNLABELLED: <p>Introduction: Randomized controlled trials comparing patients' experience with open (OPN) vs. robot-assisted (RAPN) partial nephrectomy showed no clear advantages for RAPN. This contradicts our clinical impression, so we analyzed a cohort that underwent both approaches for bilateral renal tumors. The aim of our study was to compare their intraindividual perceptions of OPN and RAPN. METHODS: Scar assessment and evaluation of patient-reported outcome measures were conducted. The questionnaires were ret…
Rank80.9
Head-to-head comparison of TKI and CPI first-line treatment strategies in advanced renal cell carcinoma-Real-world data from the German research platform CARAT.
International journal of cancer · 2026 · PMID 41159297
The combination of two immune checkpoint inhibitors (CPI) or a CPI with a tyrosine kinase inhibitor (TKI) has expanded the therapeutic options for advanced/metastatic renal cell carcinoma (aRCC) beyond TKI monotherapy. In the absence of head-to-head randomized trials comparing these strategies, we estimate their real-world effectiveness by emulating a hypothetical randomized trial. A total of 936 patients with aRCC from the prospective, observational, multicenter clinical registry CARAT (NCT03374267) starting first…
Rank80.0
Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study.
International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42179010
OBJECTIVES: Cabozantinib treatment is associated with improved survival in renal cell carcinoma (RCC) patients with bone metastasis. We evaluated the direct effects of cabozantinib on bone metastasis in advanced RCC (aRCC). METHODS: In this multicenter, open-label study, adult Japanese aRCC patients with bone metastasis received oral cabozantinib 60 mg once daily until drug discontinuation/data cut-off. The primary endpoint was the objective response rate (ORR) of bone target lesions (modified MD Anderson criteria)…
Rank79.8
Stereotactic body radiotherapy plus sunitinib vs. sunitinib alone in treatment-naive oligometastatic renal cell carcinoma: A phase 2 clinical trial.
Cell reports. Medicine · 2026 · PMID 42013852
Comparative data on stereotactic body radiotherapy (SBRT) in oligometastatic renal cell carcinoma (RCC) is lacking. This single-center, phase 2 non-randomized controlled trial enrolls patients with treatment-naive oligometastatic RCC. Patients choose to receive sunitinib alone (control arm, n = 24) or plus SBRT (SBRT arm, n = 24). The primary endpoint, objective response rate (83.3% vs. 29.2%; p < 0.001), is higher in the SBRT arm. With a median follow-up of 40.6 months, the 1-year local control rate is 91.5%. Prog…
Rank73.0
Improved Shared Decision-making for Patients with Renal Cell Carcinoma: Results of the SDM-RCC Study.
European urology oncology · 2026 · PMID 42242942
BACKGROUND AND OBJECTIVE: To improve shared decision-making (SDM) for renal cell carcinoma (RCC), we implemented an SDM intervention consisting of a patient decision aid and health care professional (HCP) training. This study evaluates its effectiveness. DESIGN, SETTING, AND PARCTICIPANTS: Multicenter prospective pretest-post-test study including adults with localized RCC or metastatic clear cell RCC. The pretest group received standard care; the post-test group was included after SDM intervention implementation. O…
Rank68.2
The effectiveness of telemonitoring, either self-administered or professionally assisted, in cancer care management: a descriptive, retrospective, observational cohort study.
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026 · PMID 41540183
PURPOSE: Remote patient monitoring of symptoms is now recommended by International oncology guidelines. In France, knowledge of real-world outcomes using telemonitoring is limited. This real-world French study aimed to evaluate the effectiveness of a telemonitoring solution in patients receiving cancer care. METHODS: The Continuum + Connect solution enables the sending of questionnaires and messages to the oncology team. All patients using the solution between October 1, 2021, and June 30, 2023, were eligible. Pati…
Rank67.4
Fecal microbiota transplantation plus immunotherapy in metastatic renal cell carcinoma: the phase 1 PERFORM trial.
Nature medicine · 2026 · PMID 41606120
Immune checkpoint inhibitors (ICIs) improve outcomes in metastatic renal cell carcinoma (mRCC) but are hindered by immune-related adverse events (irAEs). Modulation of the gut microbiome may enhance efficacy and mitigate toxicity, yet the safety and mechanisms of healthy donor fecal microbiota transplantation (FMT) in mRCC remain unexplored. In this phase 1 trial, 20 treatment-naive patients with mRCC received encapsulated healthy donor FMT (LND101) combined with ipilimumab/nivolumab (n = 16), pembrolizumab/axitini…
Rank64.4
A retrospective study to understand the journey and health status of patients with unexplained or refractory chronic cough in the Netherlands.
Chronic respiratory disease · 2026 · PMID 42175528
IntroductionThis study aims to characterize the patient journey for refractory chronic cough (RCC) or unexplained chronic cough (UCC) before visiting the Isala Chronic Cough Clinic (ICCC) in the Netherlands.MethodData from 152 patients with RCC or UCC was collected between January 2017 and September 2021from General Practitioner (GP) and hospital charts, the EQ-5D-5L questionnaire, and a patient survey about the care pathway and cough impact on everyday life, based on a single-centre, observational, retrospective s…
Randomized Controlled Trials69 records
Rank109.1
Efficacy and safety of immune checkpoint inhibitors combined with tyrosine kinase inhibitors in patients with metastatic renal cell carcinoma: a risk-stratified systematic review and meta-analysis.
Frontiers in immunology · 2026 · PMID 42220544
BACKGROUND: This systematic review and meta-analysis consolidates findings from recent randomized controlled trials (RCTs) on the efficacy of first-line immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI-TKI) combination therapy for metastatic renal cell carcinoma (mRCC). We also explored prognostic biomarkers and clinical factors to inform treatment strategies. METHODS: We conducted a systematic search of PubMed, Embase, the Cochrane Library, Web of Science, and major conference proceedings for RCTs p…
Rank108.7
Age-Related Survival Disparities in Advanced Renal Carcinoma in the Immune Checkpoint Inhibitor Era using the SEER Database and Meta-analysis.
Scientific reports · 2025 · PMID 41339655
Immunosenescence, the gradual deterioration of the immune system with age, reduces the efficacy of immune checkpoint inhibitors (ICI) in cancer management. Although ICI offer promising survival benefits for advanced renal cell carcinoma (aRCC), their effectiveness across different age groups remains poorly understood. This study aimed to evaluate age-related survival outcomes in aRCC patients receiving ICI using integrated cohorts. Using data from the Surveillance, Epidemiology, and End Results (SEER) program (2004…
Rank108.3
Single-port versus multi-port robot-assisted partial nephrectomy for predominantly low-complexity renal tumors: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42634038
Single-port robot-assisted partial nephrectomy (SP-RAPN) is increasingly used for selected renal tumors, but its comparative value over multi-port robot-assisted partial nephrectomy (MP-RAPN) remains uncertain. We performed a systematic review and meta-analysis of comparative studies, prioritizing propensity score-matched data when available. PubMed, Scopus, Web of Science, and Google Scholar were searched. Three studies involving 442 patients were included (210 SP-RAPN and 232 MP-RAPN). SP-RAPN was associated with…
Rank108.0
Disease-free survival as a surrogate outcome for localized kidney cancer-A systematic review and meta-analysis.
Cancer · 2026 · PMID 42590929
BACKGROUND: Disease-free survival (DFS) is commonly used as a primary end point in trials for localized renal cell carcinoma (RCC), although its validity as a surrogate for overall survival (OS) remains uncertain. The objective of this study was to evaluate whether DFS is a reliable surrogate end point for OS in this setting. METHODS: The authors conducted a systematic review and trial-level meta-analysis of randomized controlled trials assessing systemic or perioperative therapies in patients with localized RCC. D…
Rank107.6
Time-of-Day Immunotherapy Administration and Outcomes in Advanced Cancers: A Systematic Review and Meta-Analysis.
JAMA network open · 2026 · PMID 42084869
IMPORTANCE: Circadian rhythms affect immunity, which could affect the effectiveness of immune checkpoint inhibitor (ICI). Whether the time of ICI administration is associated with clinical outcomes in advanced cancers remains unclear. OBJECTIVE: To evaluate the association between time of day of ICI administration and oncologic outcomes in patients with advanced solid tumors. DATA SOURCES: MEDLINE (via PubMed), Embase, and Web of Science Core Collection were searched in February 2026 to identify eligible studies. S…
Rank107.6
Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis.
Medical oncology (Northwood, London, England) · 2026 · PMID 42484760
To update a network meta-analysis of first-line immunotherapy combinations in advanced renal cell carcinoma (RCC) using short-term data for primary analysis and long-term plus newly published randomized controlled trials (RCTs) for subgroup analyses. We searched PubMed, Embase, Web of Science, Cochrane Library, and Chinese databases for articles from inception to 22 December 2024, performing a Bayesian network meta-analysis. Overall survival (OS), progression-free survival (PFS), objective response rates (ORR), and…
Rank107.2
Robot-Assisted versus Laparoscopic Radical Nephrectomy for High-Complexity Renal Tumors: A Multidisciplinary Systematic Review and Meta-Analysis.
La Clinica terapeutica · 2026 · PMID 42340793
BACKGROUND: Radical nephrectomy for high-complexity renal tumors, stage T2-T4, size ≥7 cm, and/or inferior vena cava (IVC) involvement, represents one of the most technically demanding procedures in urologic oncology. Robot-assisted radical nephrectomy (RARN) has expanded rapidly in adoption, yet its comparative benefit over laparoscopic radical nephrectomy (LRN) in the high-complexity subpopulation remains undefined. No systematic review has restricted analysis to T2-T4 disease or applied a multidisciplinary outco…
Rank107.2
A Systematic Review and Meta-analysis of Oncological Outcomes of Treated and Untreated Complex Cystic Renal Masses.
European urology focus · 2026 · PMID 41309407
BACKGROUND AND OBJECTIVE: Complex cystic renal masses, classified using the Bosniak system, pose diagnostic and therapeutic challenges due to their variable malignant potential. This systematic review and meta-analysis aimed to assess oncological outcomes in patients with cystic renal masses managed with active surveillance (AS) or active treatment (AT), and to report transitions from AS to AT. METHODS: A systematic literature search was conducted in MEDLINE, Embase, and Cochrane Library up to October 2024, followi…
Rank106.8
Emerging robotic platforms in partial nephrectomy: a comparative systematic review and network meta-analysis.
Journal of robotic surgery · 2026 · PMID 42162309
Robotic-assisted partial nephrectomy (RAPN) is the preferred minimally invasive nephron-sparing technique, with outcomes comparable to open and laparoscopic surgery. While most evidence derives from the da Vinci system, newer robotic platforms such as Hugo, Hinotori, KangDuo and MP1000 are emerging. This systematic review and network meta-analysis evaluated perioperative outcomes across available RAPN platforms. A systematic search of PubMed, Cochrane Library, CINAHL, and Scopus identified studies reporting RAPN ou…
Rank106.8
Single-port versus multi-port robotic-assisted partial nephrectomy in perioperative, oncological, and renal function outcomes: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 41925796
As a novel surgical method for partial nephrectomy (PN), single-port robot-assisted partial nephrectomy (SP-RAPN) is becoming widely used. The efficacy and safety outcomes comparison between SP-RAPN and traditional multi-port RAPN (MP-RAPN) is still unclear. Hence, this study aims to compare the perioperative, oncological, and renal function outcomes between SP-RAPN and MP-RAPN based on updated evidence. A literature search was performed online in Web of Science, PubMed, Embase, Cochrane Library, and ClinicalTrials…
Rank106.7
First-Line Anti-PD-1 Immunotherapy With Tyrosine Kinase Inhibitors in Metastatic Renal Cell Carcinoma: A Meta-Analysis by PD-1 Subtype.
Urology practice · 2026 · PMID 41439745
INTRODUCTION: Immune checkpoint inhibitors targeting programmed death-1 (PD-1) in combination with tyrosine kinase inhibitors have reshaped the first-line treatment landscape of advanced renal cell carcinoma (RCC). However, the relative efficacy and safety of different PD-1-based regimens remain unclear. This meta-analysis aims to evaluate the efficacy and safety of first-line anti-PD-1-based combinations with tyrosine kinase inhibitors compared with sunitinib in metastatic RCC and to explore whether clinical outco…
Rank106.6
Selective P2X3 versus dual P2X2/3 receptor antagonists in refractory chronic cough: a systematic review and dose-response meta-analysis of randomized controlled trials.
Purinergic signalling · 2026 · PMID 42319606
Extracellular adenosine triphosphate (ATP)-mediated purinergic signalling via P2X3 and heteromeric P2X2/3 ion channel receptors underlies hypersensitisation of vagal airway afferents in refractory chronic cough (RCC), making this pathway a key therapeutic target. Two pharmacological strategies have emerged: dual P2X2/3 receptor antagonism and selective P2X3 inhibition. While dual antagonists (gefapixant) demonstrate robust antitussive efficacy, their clinical use is limited by taste disturbance resulting from P2X2/…
Rank105.8
Sutureless versus renorrhaphy in robot-assisted off-clamp partial nephrectomy: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42704544
BACKGROUND: The necessity of routine parenchymal renorrhaphy during off-clamp robot-assisted partial nephrectomy (RAPN) remains uncertain. This study aimed to compare perioperative, functional, safety, and oncological outcomes between sutureless and conventional renorrhaphy. METHODS: We conducted a systematic review and meta-analysis following PRISMA 2020 guidelines. Comparative studies evaluating sutureless versus conventional renorrhaphy during purely off-clamp RAPN were included. Trifecta achievement was the pri…
Rank105.7
Immune checkpoint inhibitors and other immunotherapies in the treatment of spinal column tumors: A systematic review and Meta-analysis of efficacy, and safety.
European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society · 2026 · PMID 40835773
PURPOSE: Spinal metastases affect up to 70% of systemic cancer patients, with overall survival averaging less than six months. Traditional chemotherapeutic agents have unsatisfactory results, leading to immunotherapy (IT) investigations. There is no clear consensus on the benefits and risks of IT for spinal tumors. This study assesses the current literature to determine IT safety and survival efficacy for tumors involving spinal column. METHODS: Following PRISMA guidelines, a systematic search was conducted across …
Rank105.4
Long-Term Survival Outcomes of Immune Checkpoint Inhibitor-based Combination Therapies in Favorable-Risk Metastatic Renal Cell Carcinoma: An Updated Pairwise and Network Meta-Analysis.
Clinical genitourinary cancer · 2026 · PMID 42350220
Immune checkpoint inhibitor (ICI)-based combination therapies have transformed the management of metastatic renal cell carcinoma (mRCC). However, their benefit in International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) favorable-risk disease remains uncertain, raising concerns about potential overtreatment. We conducted a meta-analysis incorporating extended follow-up survival data to evaluate the long-term benefits of ICI-based combinations in this subgroup. PubMed, EMBASE, Web of Science, and the…
Rank105.2
Transperitoneal versus retroperitoneal single-port robot-assisted partial nephrectomy: systematic review and meta-analysis of perioperative and functional outcomes.
Journal of robotic surgery · 2026 · PMID 42474829
To systematically compare the safety and efficacy of the transperitoneal (TP) and retroperitoneal (RP) approaches in single-port robot-assisted partial nephrectomy (SP-RAPN). PubMed, Web of Science, and Embase were searched for comparative studies published before October 2025. The primary evaluated outcomes were grouped as Perioperative Outcomes (operative time, blood loss, ischemia time, positive surgical margin, postoperative eGFR, and hospital stay) and Surgical Safety (complication rate). Study inclusion and e…
Rank105.1
A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma.
European urology oncology · 2026 · PMID 41241654
BACKGROUND AND OBJECTIVE: Radical nephroureterectomy is the standard of care for management of upper tract urothelial carcinoma (UTUC), but treatment-associated morbidity is not uncommon. Intracavitary therapy has emerged as a less invasive alternative for selected cases, particularly carcinoma in situ (CIS) and low-grade papillary tumors. We conducted a systematic review to evaluate the outcomes, recurrence rates, and adverse events associated with intracavitary therapy (immunotherapy or chemoablation) for UTUC. M…
Rank102.0
What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta-analysis of ocular immune-related adverse events.
Acta ophthalmologica · 2026 · PMID 41800487
PURPOSE: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune-related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI-associated DED and to evaluate factors contributing to variability across studies. METHODS: A systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in the International Prospective Register o…
Rank100.1
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 41786248
BACKGROUND: Nivolumab plus ipilimumab (NIVO + IPI) demonstrated significant long-term survival and response benefits in patients with previously untreated advanced renal cell carcinoma (aRCC) in the phase III CheckMate 214 trial (NCT02231749). We report final efficacy and safety results with 9.3 years median follow-up. PATIENTS AND METHODS: Patients (N = 1096) were randomized to NIVO 3 mg/kg plus IPI 1 mg/kg every 3 weeks × four doses, followed by NIVO (3 mg/kg or 240 mg every 2 weeks or 480 mg every 4 weeks); or s…
Rank100.0
A Systematic Review and Meta-Analysis of the Significance of Diabetes on Kidney Cancer Outcomes and the Role of Metformin.
Clinical genitourinary cancer · 2026 · PMID 41856872
BACKGROUND AND OBJECTIVES: The effect of diabetes and metformin on renal cell carcinoma (RCC) outcomes has not been well established. METHODS: A systematic review and meta-analysis were performed to investigate the influence of diabetes on various outcome measures in renal cell carcinoma (RCC). We have also investigated the effect of metformin as a potential strategy to improve prognosis. A computerized systematic search of Medline, Embase, ProQuest, PubMed, and Google Scholar for literature was performed between i…
Rank100.0
Endoscopic Ultrasound-Guided Radiofrequency Ablation (EUS-RFA): Are We Getting Evidence-Based Results? A Systematic Review According to the Levels of Evidence.
Medicina (Kaunas, Lithuania) · 2026 · PMID 42512924
Background and Objectives: Endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) is an emerging minimally invasive therapeutic option for pancreatic and selected extra-pancreatic lesions. However, its clinical adoption is limited by heterogeneous indications, non-standardized techniques, and variable quality of evidence. This systematic review assessed the published literature on EUS-RFA and classified available evidence according to the Oxford Centre for Evidence-Based Medicine levels of evidence. Materia…
Rank100.0
Impact of 3D-Assisted Preoperative Planning on Surgical and Functional Outcomes of Partial Nephrectomy in Adults: A Systematic Review.
Archivos espanoles de urologia · 2026 · PMID 42438868
BACKGROUND: Three-dimensional (3D) imaging is used for preoperative planning of partial-nephrectomy, enhancing visualisation of tumour anatomy, vascular structures, and their spatial relationships. This systematic review evaluated the impact of 3D-assisted planning on surgical, perioperative, and functional outcomes in adults undergoing partial-nephrectomy. METHODS: A systematic review was conducted according to PRISMA 2020 guidelines. Eligible studies included adults with clinically localised T1-T2 renal tumours u…
Rank100.0
Performance of percutaneous core biopsy in predicting renal tumour pathology: a systematic review.
BJU international · 2026 · PMID 41269070
OBJECTIVES: To systematically assess the diagnostic accuracy of renal tumour core biopsy for detecting malignancy in adults with localised renal masses. MATERIALS AND METHODS: A search of the Cochrane, Embase and Medline databases and the grey literature published up to September 2024 was performed using pre-published methods. Eligible studies were published in English, reported all true- and false-positive and -negative results for localised renal tumour core biopsies in unique adult cohorts, and used surgical his…
Rank100.0
One-stop shopping for recovery? A systematic review of the evidence on U.S. recovery community centers.
Journal of substance use and addiction treatment · 2025 · PMID 40447107
BACKGROUND: Increased recognition of the need for community-based substance use disorder (SUD) recovery support services (RSS) to complement and extend clinical care efforts has led to growth in a variety of RSS including recovery community centers (RCCs). Given increased national focus on expanding RCC research, this systematic review examined published research on RCCs. METHOD: We searched five publicly available empirical databases to retrieve existing studies on the effects of RCC participation through May 2024…
Rank100.0
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.
JCO oncology practice · 2026 · PMID 40658913
PURPOSE: In the era of prolonged survival for advanced renal cell carcinoma (aRCC) with standard-of-care first-line therapy now including immune checkpoint inhibitor, re-evaluation of the Memorial Sloan Kettering Cancer Center (MSKCC) and International Metastatic RCC Database Consortium (IMDC) prognostic models is overdue. METHODS: Data from 1,052 patients with aRCC treated on the CheckMate-214 phase III randomized trial with first-line nivolumab + ipilimumab or sunitinib were analyzed after minimum 5 years of foll…
Safety And Adverse Effects88 records
Rank110.0
The impact of social determinants of health on access to partial nephrectomy, minimally invasive surgery, and robotic-assisted approaches for renal cell carcinoma.
World journal of urology · 2026 · PMID 42611330
PURPOSE: Social determinants of health (SDOH), including race/ethnicity, socioeconomic status (SES), insurance coverage, and geographic location, are established drivers of disparities in surgical access and outcomes. Robotic-assisted partial nephrectomy (RAPN) has become the preferred minimally invasive approach for localized renal cell carcinoma (RCC), yet the extent to which SDOH influence access to partial nephrectomy, minimally invasive surgery, and RAPN specifically, as well as postoperative outcomes has not …
Rank109.2
Comparative outcomes of robot-assisted and open radical nephrectomy with inferior vena cava thrombectomy for renal cell carcinoma: a systematic review and meta-analysis.
Journal of robotic surgery · 2026 · PMID 42624966
For patients with renal cell carcinoma (RCC) complicated by inferior vena cava (IVC) tumor thrombus, radical nephrectomy combined with thrombectomy remains a key surgical option. Open radical nephrectomy with IVC thrombectomy (O-RNTT) has long been regarded as the traditional operative strategy, whereas robot-assisted radical nephrectomy with IVC thrombectomy (R-RNTT) is now being used more frequently in high-experience centers. Direct comparative data, however, remain limited. This study aimed to compare periopera…
Rank107.1
Adjunctive topical hemostatic agents combined with renorrhaphy versus renorrhaphy alone during partial nephrectomy: a systematic review and meta-analysis.
World journal of urology · 2026 · PMID 42627530
PURPOSE: Partial nephrectomy (PN) is the standard of care for T1 renal tumors, offering oncological outcomes equivalent to radical nephrectomy while preserving renal function. Intraoperative hemostasis remains a critical challenge, as warm ischemia time is independently associated with postoperative renal functional decline. Topical hemostatic agents have been increasingly adopted as adjuncts to renorrhaphy; however, their incremental benefit over suture alone remains unestablished. This study aimed to compare the …
Rank105.1
A Systematic Review of Intracavitary Therapies for Upper Tract Urothelial Carcinoma.
European urology oncology · 2026 · PMID 41241654
BACKGROUND AND OBJECTIVE: Radical nephroureterectomy is the standard of care for management of upper tract urothelial carcinoma (UTUC), but treatment-associated morbidity is not uncommon. Intracavitary therapy has emerged as a less invasive alternative for selected cases, particularly carcinoma in situ (CIS) and low-grade papillary tumors. We conducted a systematic review to evaluate the outcomes, recurrence rates, and adverse events associated with intracavitary therapy (immunotherapy or chemoablation) for UTUC. M…
Rank102.0
What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta-analysis of ocular immune-related adverse events.
Acta ophthalmologica · 2026 · PMID 41800487
PURPOSE: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy but may cause immune-related adverse events (irAEs), including dry eye disease (DED). This study aimed to quantify the incidence of ICI-associated DED and to evaluate factors contributing to variability across studies. METHODS: A systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered in the International Prospective Register o…
Rank100.1
Belzutifan in Von Hippel-Lindau-associated Hemangioblastomas: A Systematic Review and Meta-analysis.
Journal of neurological surgery. Part B, Skull base · 2026 · PMID 42626756
INTRODUCTION: Belzutifan, a selective hypoxia-inducible factor 2 α inhibitor, was recently approved for treating renal cell carcinoma in patients with Von Hippel-Lindau (VHL) disease. Given the lack of effective systemic therapies for VHL-associated hemangioblastomas (HBs), we conducted a systematic review and meta-analysis to evaluate its efficacy in this patient population. METHODS: Scientific databases and clinical trial registries were systematically reviewed for studies evaluating belzutifan in VHL-associated …
Rank100.0
A systematic review and meta-analysis of mortality and kidney function in uranium-exposed individuals.
Environmental research · 2024 · PMID 38242418
BACKGROUND: Humans are exposed to uranium (U) in a variety of applications. Both animal and observational human studies support an associated U nephrotoxicity. Few statistical syntheses of the human data have been performed and these analyses are limited in the types of exposures considered. OBJECTIVES: This study aims to evaluate the state of current evidence and to expand on existing meta-analyses by systematically evaluating kidney-associated causes of mortality in multiple U-exposed populations. This study also…
Rank100.0
Optimizing intermittent dosing of oral small molecule inhibitors.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2026 · PMID 40116755
IntroductionWith recent expansion of oral small molecule inhibitors, the drug development studies need to provide insight into optimal dose selection for these agents with vastly different mechanism and pharmacokinetic considerations compared to our traditional chemotherapy agents. Currently there is one published meta-analysis that examines intermittent and alternative dosing of oral small molecule inhibitors and it is unclear what guidance is available for treatment personalization beyond package insert labeling …
Rank100.0
Antibiotic exposure and cancer risk: an umbrella review elucidating the direction of risk across 14 malignancies.
Journal of public health (Oxford, England) · 2026 · PMID 42361054
BACKGROUND: Antibiotics are among the most frequently prescribed medications worldwide. However, previous studies have yielded inconsistent findings regarding the association between antibiotic exposure and the risk of various cancers, and the credibility of the available evidence remains uncertain. METHODS: We conducted an umbrella review based on published meta-analyses and systematic reviews to evaluate the association between past or current antibiotic exposure and cancer risk. PubMed, Embase, Cochrane Library,…
Rank100.0
Environmental Nonessential Element Exposure and Urologic Cancer: A Systematic Review and Meta-Analysis.
JAMA network open · 2026 · PMID 42172026
IMPORTANCE: Urologic cancers have been linked to nonessential chemical elements with no known beneficial role in the body, though associations between low-level environmental exposure and urologic cancer risk are poorly understood. OBJECTIVE: To systematically synthesize epidemiologic evidence on the association between environmental exposure to nonessential elements and risk of urologic cancers. DATA SOURCES: English- and Chinese-language databases, including PubMed, Embase, Web of Science, Scopus, Cumulated Index…
Rank99.4
Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial.
The Lancet. Oncology · 2026 · PMID 42633754
BACKGROUND: Total mesorectal excision (TME) is the standard treatment for most early-stage and intermediate-stage rectal cancer but can cause substantial perioperative morbidity, functional impairment, and reduced quality of life. We assessed whether long-course chemoradiotherapy (LCCRT) or short-course radiotherapy (SCRT) could increase organ preservation and reduce surgery, toxicity, and quality-of-life harms without compromising oncological outcomes. METHODS: STAR-TREC is an international, multicentre, open-labe…
Rank99.2
Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial.
Lancet (London, England) · 2026 · PMID 42586114
BACKGROUND: The identification of a clear standard of care for patients with advanced clear-cell renal cell carcinoma following anti-PD-1 or anti-PD-L1 therapy warrants study as an unmet need. We aimed to investigate belzutifan plus lenvatinib versus cabozantinib in participants with clear-cell renal cell carcinoma previously treated with immune checkpoint inhibitors. METHODS: LITESPARK-011 is a phase 3, open-label, randomised, active-controlled study conducted at 184 medical centres in 25 countries in Asia, Austra…
Rank98.0
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42507969
PURPOSE: Bone metastases (BM) occur in approximately 30% of patients with metastatic renal cell carcinoma (mRCC) and are associated with poor survival and symptomatic skeletal events (SSEs). Radium-223, an alpha-emitting bone-seeking radioisotope, and cabozantinib, a tyrosine kinase inhibitor, have demonstrated activity in BM. RADICAL (Alliance A031801; ClinicalTrials.gov identifier: NCT04071223) evaluated cabozantinib ± radium-223 in mRCC with BM. METHODS: This phase II trial enrolled patients with mRCC of any his…
Rank96.0
Immune checkpoint inhibitor combinations across clinically distinct metastatic renal cell carcinoma populations with limited or heterogeneous trial evidence: A systematic review, evidence map, and meta-analysis.
Critical reviews in oncology/hematology · 2026 · PMID 42641831
Immune checkpoint inhibitor (ICI) combinations are standard for metastatic renal cell carcinoma (mRCC), but evidence is uneven across distinct populations. We searched PubMed, Embase and Cochrane CENTRAL through June 3, 2026, and synthesized original studies reporting efficacy or safety in non-clear cell RCC, brain, bone or liver metastases, adults aged 75 years or older, poor performance status, trial ineligibility, frailty, renal impairment or hemodialysis, and sarcomatoid differentiation. Independent studies wer…
Rank91.0
Adjuvant pembrolizumab for the treatment of clear cell renal cell carcinoma: Five-year results from the phase III KEYNOTE-564 study.
Annals of oncology : official journal of the European Society for Medical Oncology · 2026 · PMID 42648402
BACKGROUND: The randomized phase III study KEYNOTE-564 (NCT03142334) established pembrolizumab after surgery as the standard of care for patients with clear cell renal cell carcinoma (ccRCC) at increased risk of recurrence. Prior analyses showed significantly improved disease-free survival (DFS) and overall survival (OS) with adjuvant pembrolizumab versus placebo. We present results from the fourth prespecified interim analysis, with a minimum follow-up of five years. PATIENTS AND METHODS: Eligible adults with ccRC…
Rank89.7
Preliminary study on the efficacy of pazopanib combined with toripalimab as first-line therapy for metastatic renal cell carcinoma: Real-world data from a single center.
Oncology letters · 2026 · PMID 42597921
The present study aimed to explore the clinical efficacy and safety of pazopanib combined with toripalimab as first-line therapy for metastatic renal cell carcinoma (mRCC), providing a reference for clinical decision-making. In the present study, clinical data from 22 patients with mRCC who received pazopanib combined with toripalimab treatment at Shanxi Province Cancer Hospital (Taiyuan, China) were retrospectively collected. The objective response rate (ORR), disease control rate (DCR), progression-free survival …
Rank85.0
Big Data Analytics in Urologic Oncology: A Comprehensive Review of Large-scale Database Research and Clinical Applications.
Current urology reports · 2026 · PMID 42579222
PURPOSE OF REVIEW: Large-scale databases have become an essential resource in urologic oncology, enabling the generation of real-world evidence across broad and diverse patient populations. This narrative review aims to summarize the contribution of population-based cancer registries, hospital-based clinical registries, and administrative healthcare databases to the understanding and management of prostate, bladder, renal, and other genitourinary malignancies. RECENT FINDINGS: Over the past decade, large database s…
Rank83.0
Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy in One Fraction (SMART ONE): A Multicenter, Single-Arm, Phase 2 Trial.
International journal of radiation oncology, biology, physics · 2025 · PMID 40158734
PURPOSE: Stereotactic body radiation therapy (SBRT) is an advanced technique that enables precise delivery of radiation directly to a tumor, typically in ≤5 fractions. Single-fraction SBRT for visceral tumors is uncommon, likely related to concerns about risks of geographic tumor miss because of suboptimal cone beam computed tomography scan quality on conventional linear accelerators (linacs). Magnetic resonance (MR) guided linacs are a novel technology offering superior imaging that might facilitate the safe deliv…
Rank81.5
Immune Checkpoint Inhibitor-Associated Uveitis: Insights From Comparative Analyses Across Malignancies and Drug Classes.
American journal of ophthalmology · 2026 · PMID 42229563
PURPOSE: Understanding how the risk of immune checkpoint inhibitor (ICI)-associated noninfectious uveitis (NIU) differs by malignancy and drug class may help understand its pathophysiology and guide targeted ophthalmic surveillance. This study aims to evaluate the comparative risk of ICI-associated NIU across different malignancies and drug classes. DESIGN: Retrospective, multicenter clinical cohort study. SUBJECTS: Adults with metastatic melanoma, lung cancer, renal cell carcinoma (RCC), urothelial carcinoma, hepa…
Rank80.4
External validation of the Meet-URO score in Japanese metastatic renal cell carcinoma patients receiving first-line immune-combinations.
International urology and nephrology · 2026 · PMID 42012775
PURPOSE: The Meet-URO score, incorporating IMDC classification, neutrophil-to-lymphocyte ratio (NLR), and bone metastases, was developed in European patients receiving second-line nivolumab; its applicability to Asian populations, particularly in real-world first-line immune checkpoint inhibitor (ICI)-based combination cohorts, remains uncertain. We externally validated the Meet-URO score in Japanese patients with metastatic renal cell carcinoma (mRCC) receiving first-line ICI-based combinations. METHODS: This retr…
Rank80.0
Efficacy of Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis Assessed by Modified MD Anderson Criteria: An Open-Label Phase 2 Study.
International journal of urology : official journal of the Japanese Urological Association · 2026 · PMID 42179010
OBJECTIVES: Cabozantinib treatment is associated with improved survival in renal cell carcinoma (RCC) patients with bone metastasis. We evaluated the direct effects of cabozantinib on bone metastasis in advanced RCC (aRCC). METHODS: In this multicenter, open-label study, adult Japanese aRCC patients with bone metastasis received oral cabozantinib 60 mg once daily until drug discontinuation/data cut-off. The primary endpoint was the objective response rate (ORR) of bone target lesions (modified MD Anderson criteria)…
Rank79.0
Four-Year Feasibility and Safety Results of a Phase 1/2 Single-Arm Prospective Clinical Trial of Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy for Metachronous Oligometastatic Abdominopelvic Lymph Node and Soft Tissue Metastases.
International journal of radiation oncology, biology, physics · 2026 · PMID 41529791
PURPOSE: Metachronous oligometastases may represent a favorable disease state for local therapy after prior curative treatment. Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy (SMART) provides precise targeting of nodal and soft tissue metastases. The primary objective was to assess the feasibility and safety of SMART for abdominopelvic metachronous oligometastases. Secondary objectives included assessing rates of toxicities and evaluating local control (LC). METHODS AND MATERIALS: Ten patients we…
Rank77.5
Efficacy, safety, and treatment feasibility of pembrolizumab plus lenvatinib in patients aged 75 years or older with advanced renal cell carcinoma: a Japanese multicenter retrospective study.
International journal of clinical oncology · 2026 · PMID 42377813
BACKGROUND: Pembrolizumab plus lenvatinib is a standard first-line treatment option for advanced renal cell carcinoma (RCC), but data focused on patients aged ≥ 75 years remain limited. We evaluated the efficacy, safety, and treatment feasibility of this regimen in a Japanese multicenter cohort. METHODS: We retrospectively analyzed 170 patients with metastatic or unresectable RCC treated with first-line pembrolizumab plus lenvatinib. We compared those aged ≥ 75 years (n = 31) with those aged < 75 years (n = 139), a…
Rank77.4
Pembrolizumab Plus Lenvatinib in Metastatic Renal Cell Carcinoma: Real-world Prognostic Factors.
Anticancer research · 2026 · PMID 42527074
BACKGROUND/AIM: Pembrolizumab plus lenvatinib is first-line treatment for metastatic renal cell carcinoma (mRCC) with favorable outcomes. However, clinicopathological factors associated with treatment outcomes are unclear. We evaluated the effectiveness and safety of pembrolizumab plus lenvatinib, and explored factors associated with progression-free survival (PFS) in a Japanese multicenter cohort. PATIENTS AND METHODS: We retrospectively analyzed 160 patients with mRCC who received first-line pembrolizumab plus le…
Rank77.0
High dose interleukin-2 in combination with anti-programmed cell death protein 1 to overcome immune checkpoint inhibitor resistance in metastatic melanoma and renal cell carcinoma.
Melanoma research · 2026 · PMID 42070986
To assess the combination of high dose interleukin 2 (HD IL2) and nivolumab in patients with checkpoint inhibitor-refractory melanoma or renal cell carcinoma (RCC), we performed a single-arm, Simon two-stage phase II trial for patients with unresectable stage III or IV melanoma or any histology RCC. The primary endpoint was overall response rate (ORR); secondary endpoints were adverse events and progression-free survival (PFS), defined as time to radiographic or clinical progression, whichever occurred first. Five …
Treatments That Failed Clinical Trials59 records
Rank99.3
Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024 · PMID 39255440
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Mesenchymal-epithelial transition (MET) signaling pathway plays a role in the pathogenesis of sele…
Rank99.0
The long-term impact of single intraoperative instillation of pirarubicin after radical nephroureterectomy on local and systemic cancer control: a prospective, multicenter, randomized trial.
World journal of urology · 2025 · PMID 40080123
PURPOSE: Although the preventive effect against intravesical recurrence (IVR) has been established for single instillation of chemotherapy during or after radical surgery of upper urinary tract urothelial carcinoma (UTUC), there has been no research on the long-term outcome. This study aims to investigate the IVR and long-term survival outcome of a single intraoperative instillation of pirarubicin during radical nephroureterectomy (RNU). METHODS: In this prospective, multicenter, randomized trial, 97 patients under…
Rank98.6
Suitability of the MP1000 system for robot-assisted partial nephrectomy: a multicenter randomized controlled noninferiority trial.
International journal of surgery (London, England) · 2024 · PMID 38349210
PURPOSE: This study aimed to compare the safety and effectiveness of the MP1000 surgical system with the da Vinci Si robot system in robot-assisted partial nephrectomy (RAPN) through a prospective, single-blinded, randomized controlled trial. MATERIALS AND METHODS: A total of 62 patients who were scheduled to undergo RAPN were randomly assigned to either the da Vinci Si robot or MP1000 group. A noninferiority test was conducted with a noninferior intermediate value of 10%. The study compared installation and operat…
Rank98.0
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 · PMID 42507969
PURPOSE: Bone metastases (BM) occur in approximately 30% of patients with metastatic renal cell carcinoma (mRCC) and are associated with poor survival and symptomatic skeletal events (SSEs). Radium-223, an alpha-emitting bone-seeking radioisotope, and cabozantinib, a tyrosine kinase inhibitor, have demonstrated activity in BM. RADICAL (Alliance A031801; ClinicalTrials.gov identifier: NCT04071223) evaluated cabozantinib ± radium-223 in mRCC with BM. METHODS: This phase II trial enrolled patients with mRCC of any his…
Rank97.9
Robot-assisted radical nephroureterectomy using the KangDuo Surgical Robot-01 System versus the da Vinci System: a multicenter prospective randomized controlled trial.
International braz j urol : official journal of the Brazilian Society of Urology · 2024 · PMID 39133792
INTRODUCTION: We aim to compare the safety and effectiveness of the KangDuo (KD)-Surgical Robot-01 (KD-SR-01) system and the da Vinci (DV) system for robot-assisted radical nephroureterectomy (RARNU). MATERIALS AND METHODS: This multicenter prospective randomized controlled trial was conducted between March 2022 and September 2023. Group 1 included 29 patients undergoing KD-RARNU. Group 2 included 29 patients undergoing DV-RARNU. Patient demographic and clinical characteristics, perioperative data, and follow-up ou…
Rank96.6
Randomized, Prospective Evaluation of Hemostatic Agents in Robotic-Assisted Laparoscopic Partial Nephrectomy.
The Journal of urology · 2026 · PMID 41360001
PURPOSE: Hemostatic agents (HAs) are typically used during robotic-assisted laparoscopic partial nephrectomy (RALPN) to minimize perioperative bleeding. However, high-quality evidence supporting their effectiveness is limited. We aimed to determine whether HAs reduce perioperative blood loss in patients undergoing RALPN. MATERIALS AND METHODS: We conducted a prospective, randomized controlled trial of patients undergoing RALPN. Patients were randomized to HA+, in which HAs were assigned, and HA-, no HA. The primary…
Rank96.6
Nephron Sparing Treatment (NEST) for Small Renal Masses: A Feasibility Cohort-embedded Randomised Controlled Trial Comparing Percutaneous Cryoablation and Robot-assisted Partial Nephrectomy.
European urology · 2024 · PMID 37684178
There is a paucity of high-level evidence on small renal mass (SRM) management, as previous classical randomised controlled trials (RCTs) failed to meet accrual targets. Our objective was to assess the feasibility of recruitment to a cohort-embedded RCT comparing cryoablation (CRA) to robotic partial nephrectomy (RPN). A total of 200 participants were recruited to the cohort, of whom 50 were enrolled in the RCT. In the CRA intervention arm, 84% consented (95% confidence interval [CI] 64-95%) and 76% (95% CI 55-91%)…
Rank96.4
Randomized controlled trial of the effect of general anesthetics on postoperative recovery after minimally invasive nephrectomy.
Korean journal of anesthesiology · 2024 · PMID 37232074
BACKGROUND: General anesthetic techniques can affect postoperative recovery. We compared the effect of propofol-based total intravenous anesthesia (TIVA) and desflurane anesthesia on postoperative recovery. METHODS: In this randomized trial, 150 patients undergoing robot-assisted or laparoscopic nephrectomy for renal cancer were randomly allocated to either the TIVA or desflurane anesthesia (DES) group. Postoperative recovery was evaluated using the Korean version of the Quality of Recovery-15 questionnaire (QoR-15…
Rank96.2
Transperitoneal vs retroperitoneal laparoscopic radical nephrectomy: a double-arm, parallel-group randomized clinical trial.
BMC urology · 2024 · PMID 38310213
OBJECTIVE: To compare the outcomes of patients undergoing Retroperitoneal laparoscopic Radical nephrectomy (RLRN) and Transperitoneal laparoscopic Radical nephrectomy (TLRN). METHODS: A total of 120 patients with localized renal cell carcinoma were randomized into either RLRN or TLRN group. Mainly by comparing the patient perioperative related data, surgical specimen integrity, pathological results and tumor results. RESULTS: Each group comprised 60 patients. The two group were equivalent in terms of perioperative …
Rank96.0
Checkpoint Inhibitors in Combination With Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors: The CHEERS Phase 2 Randomized Clinical Trial.
JAMA oncology · 2023 · PMID 37410476
IMPORTANCE: Although immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1) and PD-1 ligand 1 have improved the outcome for many cancer types, the majority of patients fails to respond to ICI monotherapy. Hypofractionated radiotherapy has the potential to improve the therapeutic ratio of ICIs. OBJECTIVE: To assess the addition of radiotherapy to ICIs compared with ICI monotherapy in patients with advanced solid tumors. DESIGN, SETTING, AND PARTICIPANTS: This open-label, multicenter, randomized…
Rank96.0
The efficacy and safety of duloxetine in treating refractory chronic cough: a randomized clinical trial.
BMC medicine · 2026 · PMID 41530764
BACKGROUND: Enhanced cough sensitivity is proposed as a potential cause for refractory chronic cough (RCC), and modulation of sensory nerve hyperresponsiveness is suggested as an effective treatment. However, the treatment of RCC has considerable potential for enhancement, particularly in terms of the targets and side effects. We aimed to investigate the efficacy and safety of duloxetine, a selective 5-HT and norepinephrine reuptake inhibitor, in patients with RCC. METHODS: This is a prospective, randomized, double…
Rank96.0
Intraoperative ultrasonography (IOUS)-guided vs conventional laparoscopic nephrectomy: a randomised control trial.
BJU international · 2024 · PMID 37470129
OBJECTIVES: To assess the efficacy of routine use of intraoperative ultrasonography (IOUS) in improving perioperative outcomes in patients undergoing IOUS-guided laparoscopic nephrectomy (IOUS-LN) and conventional laparoscopic nephrectomy (C-LN). PATIENTS AND METHODS: This was a parallel-arm, single-blinded, randomised controlled trial (CTRI/2021/12/038906). All patients undergoing LN, either for benign or malignant causes, were included. Patients undergoing partial/cytoreductive nephrectomy, with venous thrombus w…
Rank95.8
Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study.
The Lancet. Oncology · 2024 · PMID 38942046
BACKGROUND: The standard of care for patients with intermediate-to-high risk renal cell carcinoma is partial or radical nephrectomy followed by surveillance. We aimed to investigate use of nivolumab before nephrectomy followed by adjuvant nivolumab in patients with high-risk renal cell carcinoma to determine recurrence-free survival compared with surgery only. METHODS: In this open-label, randomised, phase 3 trial (PROSPER EA8143), patients were recruited from 183 community and academic sites across the USA and Can…
Rank95.8
Smart Continence Care for People With Profound Intellectual and Multiple Disabilities Within Dutch Residential Care Facilities: Economic Evaluation Alongside a Cluster Randomized Trial.
Journal of medical Internet research · 2025 · PMID 41071602
BACKGROUND: Persons with profound intellectual and multiple disabilities in residential care facilities may benefit from smart continence care (SCC), which is incontinence material (IM) with integrated sensors that notify caregivers when the IM is saturated and requires changing. SCC aims to reduce weekly leakages and improve the quality of life. OBJECTIVE: Given the growing demand for health care services and the decreasing workforce, it is essential to assess the cost-effectiveness and cost-utility of such techno…
Rank95.4
Quality-of-life outcomes of the ROBOtic-assisted versus Conventional Open Partial nephrectomy (ROBOCOP) II trial.
BJU international · 2024 · PMID 38816992
OBJECTIVES: To comprehensively compare quality-of-life (QoL) outcomes between open partial nephrectomy (OPN) and robot-assisted PN (RAPN) from the randomised ROBOtic-assisted versus Conventional Open Partial nephrectomy (ROBOCOP) II trial, as QoL data comparing OPN and RAPN are virtually non-existent, especially not from randomised controlled trials (RCTs). PATIENTS AND METHODS: The ROBOCOP II was a single-centre, open-label RCT between OPN and RAPN. The pre-planned analyses of QoL outcomes are presented. Data were…
Rank95.4
Two-year Follow-up for Oncological, Functional, and Quality-of-Life Outcomes in the Randomized ROBOCOP II Trial of Robot-assisted Versus Conventional Open Partial Nephrectomy.
European urology focus · 2026 · PMID 41760424
BACKGROUND AND OBJECTIVE: Robot-assisted partial nephrectomy (RAPN) is increasingly used to treat renal cell carcinoma (RCC), but randomized data comparing long-term outcomes to those after open partial nephrectomy (OPN) remain limited. Our aim was to compare oncological, renal function, and health-related quality of life (HRQOL) outcomes at 2 yr for patients who underwent RAPN versus OPN. METHODS: This single-center phase 2 randomized controlled trial included 50 patients with suspected localized RCC who were rand…
Rank95.3
Jetstream Atherectomy with Paclitaxel-Coated Balloons: Two-Year Outcome of the Prospective Randomized JET-RANGER Study.
Vascular health and risk management · 2023 · PMID 36936551
BACKGROUND: The JET-RANGER study (NCT03206762) was a multicenter (11 US centers) randomized trial, core lab adjudicated, designed to demonstrate the superiority of Jetstream + Paclitaxel coated balloon (JET+PCB) versus angioplasty (PTA) + PCB in treating femoropopliteal (FP) arterial disease. The one-year primary endpoint of JET-RANGER has been recently published. The 2-year outcome data are presented in this report. METHODS: There were 43 patients who completed the 1-year follow-up. Two were lost to follow-up and …
Rank95.0
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial.
Nature medicine · 2024 · PMID 38942995
Supplementation with CBM588, a bifidogenic live bacterial product, has been associated with improved clinical outcomes in persons with metastatic renal cell carcinoma (mRCC) receiving nivolumab and ipilimumab. However, its effect on those receiving tyrosine kinase inhibitor-based combinations is unknown. In this open-label, randomized, investigator-initiated, phase 1 study, 30 participants with locally advanced or mRCC with histological confirmation of clear cell, papillary or sarcomatoid component were randomized …
Rank94.9
A cluster randomized controlled trial of a train-the-trainer behavioral intervention delivered via respite care centers to improve nutritional outcomes and quality of life persons with dementia and their caregivers.
The journal of nutrition, health & aging · 2025 · PMID 41124731
OBJECTIVE: To evaluate a behavioral intervention, Partners at Meals (PAM), designed to empower caregivers (CGs) to improve caloric intake, weight, and quality of life (QOL) of persons with dementia (PWD), and to address dysfunctional behaviors during mealtime. The study also aimed to assess differences in caregiver psychosocial outcomes, including depression, burden, and QOL. DESIGN: A cluster randomized controlled experimental design was used, in which participating Respite Care Centers (RCCs) were randomized to e…
Rank94.9
Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma.
European urology · 2022 · PMID 35843776
BACKGROUND: In the phase 3 KEYNOTE-426 (NCT02853331) trial, pembrolizumab + axitinib demonstrated improvement in overall survival, progression-free survival, and objective response rate over sunitinib monotherapy for advanced renal cell carcinoma (RCC). OBJECTIVE: To evaluate health-related quality of life (HRQoL) in KEYNOTE-426. DESIGN, SETTING, AND PARTICIPANTS: A total of 861 patients were randomly assigned to receive pembrolizumab + axitinib (n = 432) or sunitinib (n = 429). HRQoL data were available for 429 pa…
Rank94.6
Selection and evaluation of preoperative systemic inflammatory response biomarkers model prior to cytoreductive nephrectomy using a machine-learning approach.
World journal of urology · 2022 · PMID 34671856
INTRODUCTION: This study aimed to determine the prognostic value of a panel of SIR-biomarkers, relative to standard clinicopathological variables, to improve mRCC patient selection for cytoreductive nephrectomy (CN). MATERIAL AND METHODS: A panel of preoperative SIR-biomarkers, including the albumin-globulin ratio (AGR), De Ritis ratio (DRR), and systemic immune-inflammation index (SII), was assessed in 613 patients treated with CN for mRCC. Patients were randomly divided into training and testing cohorts (65/35%).…
Rank94.2
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).
European journal of cancer (Oxford, England : 1990) · 2023 · PMID 36459768
BACKGROUND: Vorolanib is a highly potent tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor. This three-arm, randomised, registered study aimed to assess the combination of vorolanib and everolimus or vorolanib alone versus a control arm of everolimus as second-line treatment in patients with metastatic renal cell carcinoma (RCC). PATIENTS AND METHODS: Patients with advanced or metastatic RCC who had received one prior VEGFR-TKI …
Rank94.1
Molecular determinants of response to PD-L1 blockade across tumor types.
Nature communications · 2021 · PMID 34172722
Immune checkpoint inhibitors targeting the PD-1/PD-L1 axis lead to durable clinical responses in subsets of cancer patients across multiple indications, including non-small cell lung cancer (NSCLC), urothelial carcinoma (UC) and renal cell carcinoma (RCC). Herein, we complement PD-L1 immunohistochemistry (IHC) and tumor mutation burden (TMB) with RNA-seq in 366 patients to identify unifying and indication-specific molecular profiles that can predict response to checkpoint blockade across these tumor types. Multiple…
Rank94.0
CT Perfusion Blood Flow Provides an Early Response Marker for Progression-free Survival in a Prospective Randomized Clinical Trial of Metastatic Renal Cell Carcinoma.
Technology in cancer research & treatment · 2026 · PMID 42308169
IntroductionThere is currently no biomarker for progression-free survival (PFS) for patients undergoing treatment for metastatic renal cell carcinoma (RCC). The aim of our study was to evaluate computed tomography perfusion (CTp) blood flow as an early marker of PFS in patients with mRCC treated with targeted agents.MethodsAssociations between CTp blood flow and PFS were evaluated from prospective randomized evidence using univariable and multivariable Cox proportional hazards regression models with Harrell's conco…
Rank93.7
Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research · 2022 · PMID 35802667
PURPOSE: PD-L1 expression on tumor cells (TC) is associated with response to anti-PD-1-based therapies in some tumor types, but its significance in clear cell renal cell carcinoma (ccRCC) is uncertain. We leveraged tumor heterogeneity to identify molecular correlates of TC PD-L1 expression in ccRCC and assessed their role in predicting response to anti-PD-1 monotherapy. EXPERIMENTAL DESIGN: RNA sequencing was performed on paired TC PD-L1 positive and negative areas isolated from eight ccRCC tumors and transcriptomi…
i
Research information notice
Alexandria organizes PubMed-indexed literature. PubMed inclusion does not establish accuracy, endorsement, clinical applicability, or treatment suitability. Automated extraction can contain errors or omissions. This page is not medical advice.